

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/85, 5/10, C07K 14/705, 16/28, A61K 39/395		A1	(11) International Publication Number: WO 96/00289 (43) International Publication Date: 4 January 1996 (04.01.96)
(21) International Application Number: PCT/US95/08071 (22) International Filing Date: 26 June 1995 (26.06.95)		(81) Designated States: AU, BR, CA, CN, CZ, FI, HU, JP, MX, NO, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/268,161 27 June 1994 (27.06.94) US		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: DOHENY EYE INSTITUTE [US/US]; 1450 San Pablo Street, Los Angeles, CA 90033 (US). (72) Inventor: SUZUKI, Shintaro; 5501 Arvada Street, Torrance, CA 90505 (US). (74) Agent: NOLAND, Greta, E.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).			
(54) Title: PROTOCADHERIN PROTEINS AND THEIR USES			
(57) Abstract			
<p>Polynucleotide sequences encoding cadherin-like polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Protocadherin proteins and their uses

This application is a continuation-in-part of International Patent Application No. PCT/US93/12588 filed December 23, 1993 which is in turn a continuation-in-part of U.S. Patent Application Serial No. 07/998,003 which was filed on December 29, 1992.

5

FIELD OF THE INVENTION

The present invention relates, in general, to materials and methods relevant to cell-cell adhesion. More particularly, the invention relates to novel adhesion proteins, designated protocadherins, and to polynucleotide sequences encoding the protocadherins. The invention also relates to methods for inhibiting binding of the protocadherins to their natural ligands/antiligands.

10

10

BACKGROUND

15

In vivo, intercellular adhesion plays an important role in a wide range of events including morphogenesis and organ formation, leukocyte extravasation, tumor metastasis and invasion, and the formation of cell junctions. Additionally, cell-cell adhesion is crucial for the maintenance of tissue integrity.

20

Intercellular adhesion is mediated by specific cell surface adhesion molecules. Cell adhesion molecules have been classified into at least four families including the immunoglobulin superfamily, the integrin superfamily, the selectin family and the cadherin superfamily. All cell types that form solid tissues express some members of the cadherin superfamily suggesting that cadherins are involved in selective adhesion of most cell types.

25

Cadherins have been generally described as glycosylated integral membrane proteins that have an N-terminal extracellular domain (the N-terminal 113 amino acids of the domain appear to be directly involved in binding) consisting of five subdomains characterized by sequences unique to cadherins, a hydrophobic membrane-spanning domain and a C-terminal cytoplasmic domain that interacts with the cytoskeleton through catenins and other cytoskeleton-

- 2 -

associated proteins. Some cadherins lack a cytoplasmic domain, however, and appear to function in cell-cell adhesion by a different mechanism than cadherins having a cytoplasmic domain. The cytoplasmic domain is required for the adhesive function of the extracellular domain in cadherins that do have an cytoplasmic domain. Binding between members of the cadherin family expressed on different cells is homophilic (*i.e.*, a member of the cadherin family binds to cadherins of its own or a closely related subclass) and Ca^{2+} -dependent. For recent reviews on cadherins, see Takeichi, *Annu. Rev. Biochem.*, 59: 237-252 (1990) and Takeichi, *Science*, 251: 1451-1455 (1991).

The first cadherins to be described (E-cadherin in mouse epithelial cells, L-CAM in avian liver, uvomorulin in the mouse blastocyst, and CAM 120/80 in human epithelial cells) were identified by their involvement in Ca^{2+} -dependent cell adhesion and their unique immunological characteristics and tissue localization. With the later immunological identification of N-cadherin, which was found to have a different tissue distribution than E-cadherin, it became apparent that a new family of Ca^{2+} -dependent cell-cell adhesion molecules had been discovered.

The molecular cloning of the genes encoding E-cadherin [see Nagafuchi *et al.*, *Nature*, 329: 341-343 (1987)], N-cadherin [Hatta *et al.*, *J. Cell. Biol.*, 106: 873-881 (1988)], and P-cadherin [Nose *et al.*, *EMBO J.*, 6: 3655-3661 (1987)] provided structural evidence that the cadherins comprised a family of cell adhesion molecules. Cloning of L-CAM [Gallin *et al.*, *Proc. Natl. Acad. Sci. USA*, 84: 2808-2812 (1987)] and uvomorulin [Ringwald *et al.*, *EMBO J.*, 6: 3647-3653 (1986)] revealed that they were identical to E-cadherin. Comparisons of the amino acid sequences of E-, N-, and P-cadherins showed a level of amino acid similarity of about 45%-58% among the three subclasses. Liaw *et al.*, *EMBO J.*, 9: 2701-2708 (1990) describes the use of PCR with degenerate oligonucleotides based on conserved regions of the E-, N- and P-cadherins to amplify N- and P-cadherin from a bovine microvascular endothelial cell cDNA.

- 3 -

The isolation by PCR of eight additional cadherins was reported in Suzuki *et al.*, *Cell Regulation*, 2: 261-270 (1991). Subsequently, several other cadherins were described including R-cadherin [Inuzuka *et al.*, *Neuron*, 7: 69-79 (1991)], M-cadherin [Donalies, *Proc. Natl. Acad. Sci. USA*, 88: 8024-8028 (1991)], B-cadherin [Napolitano, *J. Cell. Biol.*, 113: 893-905 (1991)] and T-cadherin [Ranscht, *Neuron*, 7: 391-402 (1991)].

Additionally, proteins distantly related to cadherins such as desmoglein [Goodwin *et al.*, *Biochem. Biophys. Res. Commun.*, 173: 1224-1230 (1990) and Koch *et al.*, *Eur. J. Cell Biol.*, 53: 1-12 (1990)] and the desmocollins [Holton *et al.*, *J. Cell Science*, 97: 239-246 (1990)] have been described. The extracellular domains of these molecules are structurally related to the extracellular domains of typical cadherins, but each has a unique cytoplasmic domain. Mahoney *et al.*, *Cell*, 67: 853-868 (1991) describes a tumor suppressor gene of *Drosophila*, called *fat*, that also encodes a cadherin-related protein. The *fat* tumor suppressor comprises 34 cadherin-like subdomains followed by four EGF-like repeats, a transmembrane domain, and a novel cytoplasmic domain. The identification of these cadherin-related proteins is evidence that a large superfamily characterized by a cadherin extracellular domain motif exists.

Studies of the tissue expression of the various cadherin-related proteins reveal that each subclass of molecule has a unique tissue distribution pattern. For example, E-cadherin is found in epithelial cells while N-cadherin is found in neural and muscle cells. Expression of cadherin-related proteins also appears to be spatially and temporally regulated during development because individual proteins appear to be expressed by specific cells and tissues at specific developmental stages [for review see Takeichi (1991), *supra*]. Both the ectopic expression of cadherin-related proteins and the inhibition of native expression of cadherin-related proteins hinders the formation of normal tissue structure [Detrick *et al.*, *Neuron*, 4: 493-506 (1990); Fujimori *et al.*, *Development*, 110: 97-104 (1990); Kintner, *Cell*, 69: 225-236 (1992)].

- 4 -

The unique temporal and tissue expression pattern of the different cadherins and cadherin-related proteins is particularly significant when the role each subclass of proteins may play *in vivo* in normal events (e.g., the maintenance of the intestinal epithelial barrier) and in abnormal events (e.g., tumor metastasis or inflammation) is considered. Different subclasses or combinations of subclasses of cadherin-related proteins are likely to be responsible for different cell-cell adhesion events in which therapeutic detection and/or intervention may be desirable. For example, auto-antibodies from patients with pemphigus vulgaris, an autoimmune skin disease characterized by blister formation caused by loss of cell adhesion, react with a cadherin-related protein offering direct support for adhesion function of cadherins *in vivo* [Amagai *et al.*, *Cell*, 67: 869-877 (1991)]. Studies have also suggested that cadherins and cadherin-related proteins may have regulatory functions in addition to adhesive activity. Matsunaga *et al.*, *Nature*, 334: 62-64 (1988) reports that N-cadherin has neurite outgrowth promoting activity. The *Drosophila fat* tumor suppressor gene appears to regulate cell growth and suppress tumor invasion as does mammalian E-cadherin [see Mahoney *et al.*, *supra*; Frixen *et al.*, *J. Cell. Biol.*, 113:173-185 (1991); Chen *et al.*, *J. Cell. Biol.*, 114:319-327 (1991); and Vleminckx *et al.*, *Cell*, 66:107-119 (1991)]. Thus, therapeutic intervention in the regulatory activities of cadherin-related proteins expressed in specific tissues may be desirable.

There thus continues to exist a need in the art for the identification and characterization of additional cadherin-related proteins which participate in cell-cell adhesion and/or regulatory events. Moreover, to the extent that cadherin-related proteins might form the basis for the development of therapeutic and diagnostic agents, it is essential that the genes encoding the proteins be cloned. Information about the DNA sequences and amino acid sequences encoding the cadherin-related proteins would provide for the large scale production of the proteins by recombinant techniques and for the identification of the tissues/cells naturally producing the proteins. Such sequence information would also permit

- 5 -

the preparation of antibody substances or other novel binding molecules specifically reactive with the cadherin-related proteins that may be useful in modulating the natural ligand/antiligand binding reactions in which the proteins are involved.

5

SUMMARY OF THE INVENTION

The present invention provides cadherin-related materials and methods that are relevant to cell-cell adhesion. In one of its aspects, the present invention provides purified and isolated polynucleotides (*e.g.*, DNA and RNA, both sense and antisense strands) encoding the novel cell adhesion molecules designated herein as protocadherins, including protocadherin-42, protocadherin-10 43, protocadherin pc3, protocadherin pc4 and protocadherin pc5. Preferred polynucleotide sequences of the invention include genomic and cDNA sequences as well as wholly or partially synthesized DNA sequences, and biological replicas thereof (*i.e.*, copies of the sequences made *in vitro*). Biologically active vectors 15 comprising the polynucleotide sequences are also contemplated.

Specifically illustrating protocadherin polynucleotide sequences of the present invention are the inserts in the plasmids pRC/RSV-pc42 and pRC/RSV-pc43 which were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 on December 16, 20 1992 and were assigned ATCC Accession Nos. 69162 and 69163, respectively.

The scientific value of the information contributed through the disclosures of the DNA and amino acid sequences of the present invention is manifest. For example, knowledge of the sequence of a partial or complete DNA 25 encoding a protocadherin makes possible the isolation by standard DNA/DNA hybridization or PCR techniques of full length cDNA or genomic DNA sequences that encode the protein (or variants thereof) and, in the case of genomic DNA sequences, that specify protocadherin-specific regulatory sequences such as promoters, enhancers and the like. Alternatively, DNA sequences of the present invention may be chemically synthesized by conventional techniques.

- 6 -

Hybridization and PCR techniques also allow the isolation of DNAs encoding heterologous species proteins homologous to the protocadherins specifically illustrated herein.

According to another aspect of the invention, host cells, especially
5 eucaryotic and procaryotic cells, are stably transformed or transfected with the polynucleotide sequences of the invention in a manner allowing the expression of protocadherin polypeptides in the cells. Host cells expressing protocadherin polypeptide products, when grown in a suitable culture medium, are particularly useful for the large scale production of protocadherin polypeptides, fragments and
10 variants thereby enabling the isolation of the desired polypeptide products from the cells or from the medium in which the cells are grown.

The novel protocadherin protein products of the invention may be obtained as isolates from natural tissue sources, but are preferably produced by recombinant procedures involving the host cells of the invention. The products
15 may be obtained in fully or partially glycosylated, partially or wholly de-glycosylated, or non-glycosylated forms depending on the host cell selected or recombinant production and/or post-isolation processing.

Protocadherin variants according to the invention may comprise polypeptide analogs wherein one or more of the specified amino acids is deleted or replaced or wherein one or more non-naturally encoded amino acids are added:
20 (1) without loss, and preferably with enhancement, of one or more of the biological activities or immunological characteristics specific for a protocadherin; or (2) with specific disablement of a particular ligand/antiligand binding function. Also contemplated by the present invention are antibody substances (e.g.,
25 monoclonal and polyclonal antibodies, chimeric and humanized antibodies, antibody domains including Fab, Fab', F(ab')₂, Fv or single variable domains, and single chain antibodies) which are specific for the protocadherins of the invention. Antibody substances can be developed using isolated natural, recombinant or synthetic protocadherin polypeptide products or host cells

- 7 -

expressing such products on their surfaces. The antibody substances may be utilized for purifying protocadherin polypeptides of the invention, for determining tissue expression of polypeptides and as antagonists of the ligand/antiligand binding activities of the protocadherins. Specifically illustrating monoclonal antibodies of the present invention are the protocadherin-43 specific monoclonal antibodies produced by the hybridoma cell line designated 38I2C which was deposited with the ATCC on December 2, 1992 and was assigned ATCC Accession No. HB 11207.

Numerous other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description, reference being made to the drawing wherein FIGURE 1A-C is an alignment of protocadherin amino acid sequences of the invention with the amino acid sequences of N-cadherin and of the *Drosophila fat* tumor suppressor.

DETAILED DESCRIPTION

The present invention is illustrated by the following examples wherein Examples 1, 2 and 3 describe the isolation by PCR of protocadherin polynucleotide sequences. Example 3 also describes the chromosome localization of several protocadherin genes of the invention. Example 4 describes the isolation by DNA/DNA hybridization of additional protocadherin polynucleotide sequences of the present invention. Example 5 presents the construction of expression plasmids including polynucleotides encoding protocadherin-42 or protocadherin-43 and the transfection of L cells with the plasmids. The generation of antibodies to protocadherin-42 and protocadherin-43 is described in Example 6. Example 7 presents the results of immunoassays of transfected L cells for the expression of protocadherin-42 or protocadherin-43. Example 8 describes the cell aggregation properties of L cells transfected with protocadherin-42, protocadherin-43 or a chimeric protocadherin-43/E-cadherin molecule. The calcium-binding properties of pc43 are described in Example 9. The results of assays of various tissues and cell lines for the expression of protocadherin-42 and protocadherin-43

- 8 -

by Northern blot, Western blot and *in situ* hybridization are respectively presented in Examples 10, 11 and 12. Example 13 describes immunoprecipitation experiments identifying a 120 kDa protein that coprecipitates with protocadherin-43.

5

Example 1

The polymerase chain reaction (PCR) was used to isolate novel rat cDNA fragments encoding cadherin-related polypeptides.

Design of PCR Primers

Two regions of conserved amino acid sequence, one from the middle of the third cadherin extracellular subdomain (EC-3) and the other from the C-terminus of the fourth extracellular subdomain (EC-4), were identified by comparison of the published amino acid sequences for L-CAM (Gallin *et al.*, *supra*), E-cadherin (Nagafuchi *et al.*, *supra*), mouse P-cadherin (Nose *et al.*, *supra*), uvomorulin (Ringwald *et al.*, *supra*), chicken N-cadherin (Hatta *et al.*, *supra*), mouse N-cadherin [Miyatani *et al.*, *Science*, 245:631-635 (1989)] and human P-cadherin [Shimoyama *et al.*, *J. Cell. Biol.*, 109:1787-1794 (1989)], and the corresponding degenerate oligonucleotides respectively set out below in IUPAC-IUB Biochemical nomenclature were designed for use as PCR primers.

Primer 1 (SEQ ID NO: 1)
20 5' AARSSNNTNGAYTRYGA 3'
Primer 2 (SEQ ID NO: 2)
25 3' TTRCTRTTTRCGNGGNNN 5'

The degenerate oligonucleotides were synthesized using an Applied Biosystems model 380B DNA synthesizer (Foster City, California).

Cloning of cDNA Sequences by PCR

PCR was carried out in a manner similar to that described in Suzuki *et al.*, *Cell Regulation*, 2: 261-270 (1991) on a rat brain cDNA preparation. Total RNA was prepared from rat brain by the guanidium

- 9 -

isothiocyanate/cesium chloride method described in Maniatis *et al.*, pp. 196 in *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1982). Brain poly(A)⁺ RNAs were then isolated using a FastTrack® kit (Invitrogen, San Diego, California) and cDNA was prepared using a cDNA synthesis kit (Boehringer Mannheim Biochemicals, Indianapolis, Indiana). The PCR reaction was initiated by adding 2.5 units of Taq DNA polymerase (Boehringer Mannheim Biochemicals) to 100 ng template cDNA and 10 µg of each primer, after which 35 reaction cycles of denaturation at 94 °C for 1.5 minutes, annealing at 45 °C for 2 minutes, and polymerization at 72 °C for 3 minutes were carried out. Two major bands of about 450 base pairs (bp) and 130 bp in size were found when the products of the PCR reaction were subjected to agarose gel electrophoresis. The 450 bp band corresponded to the expected length between the two primer sites corresponding to the middle of the third cadherin extracellular subdomain (EC-3) and the carboxyl terminus of the fourth cadherin extracellular subdomain (EC-4), but the 130 bp band could not be predicted from any of the previously identified cadherin sequences. The 450 bp and 130 bp bands were extracted by a freezing and thawing method. The resulting fragments were phosphorylated at the 5' end with T4 polynucleotide kinase and subcloned by a blunt-end ligation into the Sma I site of M13mp18 (Boehringer Mannheim Biochemicals) in a blunt end ligation for sequence analysis. Sequencing of the fragments was carried out by the dideoxynucleotide chain termination method using a Sequenase kit (United States Biochemicals, Cleveland, Ohio). DNA and amino acid sequence were analyzed using the Beckman Microgenie program (Fullerton, California).

25 Analysis of cDNA Sequences

Nineteen novel partial cDNA clones were isolated. The DNA and deduced amino acid sequences of the clones (including sequences corresponding to the PCR primers) are set out as follows: RAT-123 (SEQ ID NOS: 3 and 4, respectively), RAT-212 (SEQ ID NOS: 5 and 6), RAT-214 (SEQ ID NOS: 7 and

- 10 -

8), RAT-216 (SEQ ID NOs: 9 and 10), RAT-218 (SEQ ID NOs: 11 and 12), RAT-224 (SEQ ID NOs: 13 and 14), RAT-312 (SEQ ID NOs: 15 and 16), RAT-313 (SEQ ID NOs: 17 and 18), RAT-314 (SEQ ID NOs: 19 and 20), RAT-315 (SEQ ID NOs: 21 and 22), RAT-316 (SEQ ID NOs: 23 and 24), RAT-317 (SEQ 5 ID NOs: 25 and 26), RAT-321 (SEQ ID NOs: 27 and 28), RAT-323 (SEQ ID NOs: 29 and 30), RAT-336 (SEQ ID NOs: 31 and 32), RAT-352 (SEQ ID NOs: 33 and 34), RAT-411 (SEQ ID NOs: 35 and 36), RAT-413 (SEQ ID NOs: 37 and 38), and RAT-551 (SEQ ID NOs: 39 and 40).

The deduced amino acid sequences of the cDNA clones are 10 homologous to, but distinct from the known cadherins. The cadherins described thus far have highly conserved, short amino acid sequences in the third extracellular subdomain (EC-3) including the consensus sequence D-Y-E or D-F-E located at the middle region of the subdomain and the consensus sequence D-X-N-E-X-P-X-F (SEQ ID NO: 41) or D-X-D-E-X-P-X-F (SEQ ID NO: 42) at 15 its end (Hatta et al., *supra*), while the corresponding sequences of other subdomains, except for the fifth extracellular subdomain (EC-5), are D-R-E and D-X-N-D-N-X-P-X-F (SEQ ID NO: 43), respectively. In contrast, the deduced amino acid sequences of the new clones that correspond to cadherin extracellular 20 subdomains include the sequence D-Y-E or D-F-E at one end, but have the sequence D-X-N-D-N-X-P-X-F instead of D-X-N-E-X-P-X-F or D-X-D-E-X-P-X-F, at the other end. The polypeptides encoded by the partial clones are homologous to previously identified cadherins but did not show significant homology to any other sequences in Genbank. Therefore, the partial cDNAs appear to comprise a new subclass of cadherin-related molecules.

25

Example 2

Various cDNA fragments structurally similar to the rat cDNAs described in Example 1 were isolated from human, mouse, and Xenopus brain cDNA preparations and from *Drosophila* and *C. elegans* whole body cDNA

- 11 -

preparations by PCR using Primers 1 and 2 as described in Example 1. The DNA and deduced amino acid sequences of the resulting PCR fragments (including sequences corresponding to the PCR primers) are set out as follows:

5 MOUSE-321 (SEQ ID NOs: 44 and 45), MOUSE-322 (SEQ ID NOs: 46 and 47),
MOUSE-324 (SEQ ID NOs: 48 and 49), MOUSE-326 (SEQ ID NOs: 50 and 51),
HUMAN-11 (SEQ ID NOs: 52 and 53), HUMAN-13 (SEQ ID NOs: 54 and 55),
HUMAN-21 (SEQ ID NOs: 56 and 57), HUMAN-24 (SEQ ID NOs: 58 and 59),
HUMAN-32 (SEQ ID NOs: 60 and 61), HUMAN-42 (SEQ ID NOs: 62 and 63),
HUMAN-43 (SEQ ID NOs: 64 and 65), HUMAN-212 (SEQ ID NOs: 66 and
10 67), HUMAN-213 (SEQ ID NOs: 68 and 69), HUMAN-215 (SEQ ID NOs: 70
and 71), HUMAN-223 (SEQ ID NOs: 72 and 73), HUMAN-410 (SEQ ID NOs:
74 and 75), HUMAN-443 (SEQ ID NOs: 76 and 77), XENOPUS-21 (SEQ ID
NOs: 78 and 79), XENOPUS-23 (SEQ ID NOs: 80 and 81), XENOPUS-25 (SEQ
ID NOs: 82 and 83), XENOPUS-31 (SEQ ID NOs: 84 and 85), DROSOPHILA-
15 12 (SEQ ID NOs: 86 and 87), DROSOPHILA-13 (SEQ ID NOs: 88 and 89),
DROSOPHILA-14 (SEQ ID NOs: 90 and 91) and C.ELEGANS-41 (SEQ ID
NOs: 92 and 93). Comparison of the deduced amino acid sequences indicates
significant similarity between sets of these clones. In particular, there are three
sets of clones that appear to be cross-species homologues: RAT-218, MOUSE-322
20 and HUMAN-43; RAT-314, MOUSE-321 and HUMAN-11; and MOUSE-326
and HUMAN-42.

Example 3

To ascertain the complete structure of the new proteins defined by
the PCR products, two full length human cDNAs corresponding to the partial
25 cDNAs HUMAN-42 and HUMAN-43 were isolated.

Isolation of Full-length Human cDNAs

A human fetal brain cDNA library (Stratagene, La Jolla,
California) in the λZapII vector was screened by the plaque hybridization method

- 12 -

[described in Ausubel *et al.*, Eds., *Current Protocols in Molecular Biology*, Sections 6.1.1 to 6.1.4 and 6.2.1 to 6.2.3, John Wiley & Sons, New York (1987)] with ^{32}P -labelled HUMAN-42 and HUMAN-43 DNA fragments. The positive clones were plaque-purified and, using a helper virus, the inserts were cut out by an *in vivo* excision method in the form of a Bluescript SK(+) plasmid. The insert sequences were then subcloned into the M13 vector (Boehringer Mannheim, Biochemicals) for sequencing. Several overlapping cDNA clones were isolated with each probe including two cDNAs which contained the putative entire coding sequences of two novel proteins designated protocadherin-42 (pc42) and protocadherin-43 (pc43). The DNA and deduced amino acid sequences of pc42 are set out in SEQ ID NOs: 94 and 95, respectively, while the DNA and deduced amino acid sequences of pc43 are set out in SEQ ID NOs: 96 and 97, respectively.

A description of the cloning of protocadherin sequences of the invention was published in Sano *et al.*, *The EMBO Journal*, 12(6): 2249-2256 (1993) after filing of the priority application hereto. The deduced amino acid sequence of pc43 was previously presented at the December 9, 1991 meeting of the American Society for Cell Biology. An abstract of the presentation is published as Suzuki *et al.*, *J. Cell. Biol.*, 115: 72a (Abstract 416) (December 9, 1991).

Analysis of Full-length Human Clones

Comparison of the full length cDNA sequences of pc42 and pc43 to the sequences of the various DNA fragments originally obtained by PCR reveals that MOUSE-326 and HUMAN-42 correspond to a portion of the fourth extracellular subdomain (EC-4) of pc42, and RAT-314, MOUSE-321, and HUMAN-11 correspond to a portion of the third extracellular subdomain (EC-3) of pc43 and RAT-218, MOUSE-322 and HUMAN-43 correspond to a portion of the fifth extracellular domain (EC-5) of pc43.

- 13 -

The overall structures of pc42 and pc43 are similar to that of typical cadherins but the new molecules also have distinct features. Both protocadherin cDNA sequences contain putative translation initiation sites and translated amino acid sequences start with typical signal sequences, but the clones
5 lack the prosequences that are present in all known cadherin precursors. The cDNAs encode proteins having a large N-terminal extracellular domain and a relatively short C-terminal cytoplasmic domain connected by a transmembrane sequence. The extracellular domains of pc42 and pc43 are different in length and
10 pc42 contains seven subdomains that closely resemble the typical cadherin extracellular subdomain while pc43 has six such subdomains. The sizes of the protocadherin cytoplasmic domains are similar to those of typical cadherins, but the sequences do not show any significant homology with those of known cadherins or cadherin-related proteins.

Amino acid identity determinations between extracellular
15 subdomains of human pc42 and pc43, and of mouse N-cadherin (SEQ ID NO: 98) (presented as an example of a "typical" cadherin) and the eighteenth extracellular subdomain of *Drosophila fat* tumor suppressor (EC-18, SEQ ID NO: 99) (the eighteenth extracellular subdomain of *fat* is a prototypical *fat* subdomain) are presented in Table 1 below, wherein, for example, "N-EC-1 x pc42" indicates
20 that the first extracellular subdomain of N-cadherin was compared to the extracellular subdomain of pc42 indicated on the horizontal axis.

- 14 -

Table 1

		<u>EC-1</u>	<u>EC-2</u>	<u>EC-3</u>	<u>EC-4</u>	<u>EC-5</u>	<u>EC-6</u>	<u>EC-7</u>
5	N-EC-1 x pc42	20	27	26	26	31	29	17
	N-EC-1 x pc43	31	23	23	26	31	24	
	N-EC-2 x pc42	28	30	32	30	37	31	19
	N-EC-2 x pc43	30	28	30	36	29	30	
	N-EC-3 x pc42	21	26	30	29	31	30	22
	N-EC-3 x pc43	25	18	26	28	28	25	
	N-EC-4 x pc42	28	28	26	25	29	27	17
	N-EC-4 x pc43	21	25	28	28	29	24	
	N-EC-5 x pc42	24	21	25	24	24	19	12
	N-EC-5 x pc43	15	21	20	20	25	16	
10	fat EC-18 x pc42	22	35	32	34	42	35	19
	fat EC-18 x pc43	32	30	36	36	33	29	

15 The amino acid identity values between the extracellular subdomains of pc42 and pc43, and N-cadherin EC-1 through EC-5 and *Drosophila* fat EC-18 are mostly less than 40%. These identity values are comparable to the values between the subdomains of other cadherin subclasses. However, higher identity values indicate that pc42 and pc43 are more closely related to *fat* than to N-cadherin.

20 Amino acid identity determinations between extracellular subdomains of human pc42 and pc43 are presented in Table 2 below.

- 15 -

Table 2

pc42

<u>pc43</u>	<u>EC-1</u>	<u>EC-2</u>	<u>EC-3</u>	<u>EC-4</u>	<u>EC-5</u>	<u>EC-6</u>	<u>EC-7</u>
5	EC-1	33	27	29	26	25	26
	EC-2	26	38	29	33	34	28
	EC-3	26	32	41	30	32	31
	EC-4	25	34	30	41	39	31
	EC-5	23	32	29	27	36	34
	EC-6	25	25	26	25	28	23

10 The identity values between respective EC-1, EC-2, EC-3, EC-4, EC-5 subdomains and the last subdomains of pc42 and pc43 are generally higher values than values obtained for comparisons of the protocadherins to N-cadherin. These results suggest that pc42 and pc43 are more closely related to one another than they are to classic cadherins.

15 FIGURE 1A-C presents an alignment of the deduced amino acid sequences of the extracellular subdomains of pc42 (EC-1 through EC-7), pc43 (EC-1 through EC-6), mouse N-cadherin (EC-1 through EC-5) and *Drosophila fat* EC-18. A sequence on a line in FIGURE 1A continues on the same line in FIGURES 1B and 1C. Gaps were introduced to maximize homology. The amino acid residues described by capital letters in the "motif" line are present in more than half of the subdomains of N-cadherin, pc42, pc43 and *Drosophila fat*. The amino acid residues described by small letters in the motif line are less well conserved in human pc42, pc43, and *Drosophila fat*. FIGURE 1A-C shows that many amino acids characteristic of other cadherin extracellular domain repeats are conserved in the pc42 and pc43 sequences, including the cadherin sequence motifs DXD, DRE and DXNDNXPXF (SEQ ID NO: 43), two glycine residues, and one glutamic acid residue. Additionally, pc42 and pc43 share unique features in comparison to N-cadherin. More amino acids at specific sites are conserved

- 16 -

between pc42 and pc43, such as the DXDXGXN (SEQ ID NO: 100) protocadherin sequence motif near the amino terminus of the pc42 and pc43 subdomains and the AXDXGXP (SEQ ID NO: 101) sequence motif near the carboxyl terminus of the subdomains. Additionally, both protocadherins share regions that do not show significant homology with the typical cadherin motif (of N-cadherin) near the carboxyl terminus of EC-1, in the middle of EC-2 and EC-4, and at the carboxyl terminus of the last repeat. A cysteine residue is located at a similar position in the middle of EC-4 of pc42 and pc43. In general, the extracellular subdomains of pc42 and pc43 are more similar to EC-18 of *fat* than the extracellular subdomains of N-cadherin.

Possible Alternative Splicing

Sequence analysis of various overlapping protocadherin cDNA clones revealed that some clones contained unique sequences at the 3' end, although the 5' end sequences were identical to other clones. The sequences forming the boundaries of the 3' end regions are consistent with the consensus sequence of mRNA splicing, suggesting that these clones may correspond to alternatively spliced mRNAs. The DNA and deduced amino acid sequences of one possible product of alternative splicing of pc42 mRNA are set out in SEQ ID NOs: 102 and 103. The DNA and deduced amino acid sequences of two possible products of alternative splicing of pc43 mRNA are respectively presented in SEQ ID NO: 104 and 105, and SEQ ID NOs: 106 and 107.

Chromosome Localization

The chromosomal location of the protocadherin 413 gene (SEQ ID NO: 37) and of the pc42 and pc43 genes was determined by conventional methods.

Briefly, C3H/HeJ-*gld* and *Mus spreitus* (Spain) mice and [(C3H/HeJ-*gld* x *Mus spreitus*) F₁ x C3H/HeJ-*gld*] interspecies backcross mice were bred and maintained as previously described in Seldin, *et al.*, *J. Exp. Med.*, 167: 688-693 (1988). *Mus spreitus* was chosen as the second parent in the cross

- 17 -

because of the relative ease of detection of informative restriction fragment length variants (RFLVs) in comparison with crosses using conventional inbred laboratory strains. Gene linkage was determined by segregation analysis.

Genomic DNA isolated from mouse organs by standard techniques
5 was digested with restriction endonucleases and 10 μ g samples were electrophoresed in 0.9% agarose gels. DNA was transferred to Nytran membranes (Schleicher & Schull, Inc., Keene, NH), hybridized with the appropriate probe at 65°C and washed under stringent conditions, all as previously described in Maniatis *et al.*, *supra*). To localize the pc42 gene, a
10 mouse sequence probe corresponding to nucleotides 1419 to 1906 of SEQ ID NO: 94 was used and for pc43 a rat sequence probe corresponding to nucleotides 1060 to 1811 of SEQ ID NO: 96 was used. To localize the protocadherin 413 gene, a probe including the sequence set out in SEQ ID NO: 37 was used. Other clones used as probes in the current study and RFLVs used to detect anonymous DNA
15 loci were all previously described [Chromosome 7, DNA segment, Washington 12 (*D7Was12*); the parathyroid hormone (*Pth*); calcitonin (*Calc*); hemoglobin, β chain (*Hbb*); metallothionein-I (*Mt-1*); adenine phosphoribosyltransferase (*Aprt*); growth hormone receptor (*Ghr*); prostaglandin E receptor EP2 subtype (*Ptgerep2*); dihydrofolate reductase-2 (*Dhfr2*); fibroblast growth factor a (*Fgfa*);
20 and glucocorticoid receptor-1 (*Grl-1*)].

Comparison of the haplotype distribution of protocadherin genes with those determined for loci throughout the mouse genome allowed each to be mapped to specific regions of mouse chromosomes. The probability for linkage was >99% and indicated assignment of both the pc42 gene and the pc43 gene was chromosome 18. The assignment of the protocadherin 413 gene was chromosome 7. The region of chromosome 18 to which the pc42 and pc43 genes were mapped corresponds to the ataxia (*ax*) loci [Burt, *Anat. Rec.*, 196: 61-69 (1980) and Lyon, *J. Hered.*, 46: 77-80 (1955)] and twirler (*Tw*) loci [Lyon, *J. Embryol. Exp. Morphol.*, 6: 105-116 (1958)], while the region of chromosome
25

- 18 -

7 to which the protocadherin 413 gene was mapped corresponds to the shaker (*sh-1*) locus [Kikuchi *et al.*, *Acta Oto-Laryngol.*, 60: 287-303 (1965) and Lord *et al.*, *Am. Nat.*, 63: 453-442 (1929)]. These loci have been implicated as involved in hereditary neural disease in the mouse. This result is consistent with *in situ* hybridization results (see Example 12) showing that pc42 and pc43 are strongly expressed in the brain and particularly in the cerebellum.
5

Example 4

Two additional novel human protocadherin cDNAs and one additional novel rat protocadherin cDNA were isolated using rat protocadherin
10 fragments described in Example 1 as probes.

Initially, the rat clone RAT-214 (SEQ ID NO: 7) was used as a probe to screen a rat brain cDNA library (Stratagene, La Jolla, CA). The final washing step was performed twice at 50°C in 0.1X SSC with 0.1% SDS for 15 minutes. Various clones were identified which contained partial cDNA inserts
15 encoding related protocadherin amino acid sequences. The nucleotide sequence of one novel rat clone designated #6-2 is set out in SEQ ID NO: 108. The first fifteen nucleotides of SEQ ID NO: 108 are the sequence of a linker and are not part of the rat #6-2 clone.

A human fetal brain cDNA library obtained from Stratagene was screened with the 0.7 kbp PstI fragment of clone #6-2. The fragment appears to encode the EC-2 and EC-3 of the rat protocadherin. After screening about 2x10⁶ phages, eleven positive clones were isolated. Sequencing of the clones identified a novel full length human protocadherin cDNA designated human pc3. The nucleotide and deduced amino acid sequence of human pc3 are set out in SEQ ID
20 NOs: 109 and 110.

The 0.7 kbp PstI fragment of rat clone #6-2 was also used to rescreen the Stratagene rat brain cDNA library for full length rat cDNA clones. A clone containing an insert encoding a full length novel protocadherin cDNA

- 19 -

was isolated. The DNA and deduced amino acid sequence of the insert are set out in SEQ ID NO: 111 and 112. The full length rat cDNA was named pc5 because it does not appear to be the homolog of the human pc3 clone based upon a comparison of the sequences.

5 Concurrently, the 0.8 kbp Eco RI-Pst I fragment of partial rat cDNA designated #43 (SEQ ID NO: 113), which was obtained by screening the Stratagene rat brain cDNA library with a probe corresponding to the human pc43 cytoplasmic domain, was used to probe the Stratagene human cDNA library for full length human protocadherin cDNAs. The fragment appears to encode EC-3
10 through the beginning of EC-6 of clone #43. One partial clone identified encodes a novel human protocadherin named human pc4. The nucleotide sequence and deduced amino acid sequences of the human pc4 clone are set out in SEQ ID NOs: 114 and 115. The amino acid sequence encoded by the pc4 clone appears to begin in the middle of EC-2 of pc4 and continues through the cytoplasmic tail
15 of the protocadherin.

Example 5

The full length human cDNAs encoding pc42 and pc43 were expressed in L cells (ATCC CCL 1) using the pRC/RSV expression vector (Invitrogen, San Diego, California). The cDNAs were isolated from the Bluescript SK(+) clones described in Example 2 by digestion with SspI followed by blunt-ending with DNA polymerase and digestion with XbaI (for pc42), or by double digestion with SpeI and EcoRV (for pc43). The pRC/RSV expression vector was digested with HindIII, followed by blunt-ending and re-digestion with XbaI for insertion of pc42 sequences, or by digested with XbaI followed by blunt-ending and re-digestion with SpeI for insertion of pc43 sequences. The isolated protocadherin DNAs were ligated into the linearized pRC/RSV vector. The resulting pc42 expression plasmid designated pRC/RSV-pc42 (ATCC 69162) and pc43 expression plasmid designated pRC/RSV-pc43 (ATCC 69163) were

- 20 -

purified by CsCl gradient centrifugation and transfected into L cells by a Ca-phosphate method.

The pc42 and pc43 transfectants were morphologically similar to the parental cells. Northern blot analysis of L cells transfected with pc42 or pc43 5 DNA sequences showed that the transfected cells expressed mRNAs of a size expected to encode the particular protocadherin.

Example 6

Rabbit polyclonal antibodies specific for pc42 and pc43 were generated as well as a mouse monoclonal antibody specific for pc43.

Preparation of Polyclonal Antibodies Specific for pc42 and pc43

DNA sequences encoding portions of the extracellular domain of pc42 and pc43 were each fused to a maltose binding protein-encoding sequence and expressed in bacteria. Specifically, DNAs corresponding to EC-4 through EC-7 of pc42 and EC-3 through EC-5 of pc43 were prepared by PCR and 15 subcloned in the correct reading frame into the multicloning site of the pMAL expression vector (New England Biolabs, Beverly, Massachusetts) which contains sequences encoding maltose binding protein immediately upstream of the multicloning site. The resulting plasmids were then introduced into *E. coli* NM522 cells (Invitrogen, San Diego, California) by a single step transformation 20 method. Expression of the fusion proteins was induced by the addition of IPTG and the fusion proteins were purified from cell extracts by amylose resin affinity chromatography (New England Biolabs) as described by the manufacturer. The fusion proteins were used for the immunization of rabbits without further purification.

25 Polyclonal antibodies were prepared in rabbits by immunization at four subcutaneous sites with 500 μ g of purified fusion protein in Freund's complete adjuvant. Subsequent immunizations with 100 μ g of the fusion protein were in Freund's incomplete adjuvant. Immune sera was passed through

- 21 -

5 sepharose coupled to maltose binding protein (New England Biolabs) and polyclonal antibodies were purified from immune sera using Sepharose affinity columns prepared by reaction of the purified fusion protein with CNBr Sepharose (Pharmacia). Reactivity of the polyclonal sera with purified pc42 fusion protein and pc42 transfected cell extracts (described in Example 5) was confirmed.

Preparation of Monoclonal Antibodies Specific for pc43

10 The pc43 fusion protein (containing the EC-3 through EC-5 subdomains of pc43) was used to generate monoclonal antibodies in mice according to the method of Kennett, *Methods in Enzymol.*, 58:345-359 (1978). Briefly, mice were immunized with the pc43 fusion protein (100 μ g) at two subcutaneous sites. The spleen from the highest titer mouse was fused to the NS1 myeloma cell line. The resulting hybridoma supernatants were screened in a ELISA assay for reactivity with the pc43 fusion protein and with maltose binding protein. The fusion wells with the highest reactivity to the pc43 extracellular 15 domains were subcloned. The hybridoma cell line designated 38I2C (ATCC HB 11207) produced a IgG₁ subtype monoclonal antibody specific for pc43. Reactivity of the monoclonal antibody produced by hybridoma cell line 38I2C to pc43 was confirmed by immunoblotting the pc43 L cell transfectants described in Example 5. The 38I2C monoclonal antibody is specific for human pc43.

20

Example 7

L cells transfected with DNA sequences encoding pc42 and pc43 as prepared in Example 5 were assayed for expression of the protocadherins by immunoblot and by immunofluorescence microscopy.

Immunoblot Analysis

25

Cell extracts of pc42 and pc43 transfectants were subjected to SDS-PAGE and then blotted electrophoretically onto a PVDF membrane (Millipore, Bedford, Massachusetts). The membranes were incubated with 5% skim milk in Tris-buffered saline (TBS) for two hours and then respectively with

- 22 -

either pc42 polyclonal sera or pc43 monoclonal antibody for one hour. The membranes were washed three times (for 5 minutes each wash) with TBS containing 0.05% Tween 20 and respectively incubated with alkaline phosphatase-conjugated anti-rabbit IgG antibody or anti-mouse IgG antibody (Promega, Madison, Wisconsin) in the same buffer for one hour. After washing the membranes with TBS containing 0.05% Tween 20, reactive bands were visualized by using Western Blue solution (Promega).

Anti-pc42 polyclonal antibodies stained a band of about 170 kDa molecular weight in pc42 transfected cells, but not parental L cells. The pc43-specific monoclonal antibody (38I2C) and polyclonal antibodies stained two adjacent bands of about 150 kDa molecular weight in pc43 transfected cells. The pc43 antibodies did not stain bands in parental L-cells. The molecular weights indicated by the staining of bands by the pc42 and pc43 antibodies are significantly larger than the molecular weights predicted from the deduced amino acid sequences. This discrepancy in molecular weight is common among various cadherin-related proteins and may be attributable to the glycosylation and/or cadherin specific structural properties. The pc42 antibody also stained smaller bands, which may be proteolytic degradation products.

When transfected cells were trypsinized and cell extracts were prepared, run on SDS/PAGE and immunoblotted with the appropriate antibody, the pc42 and pc43 polypeptides expressed by the transfected cells were found to be highly sensitive to proteolysis and were easily digested by 0.01% trypsin treatment. In contrast to the classic cadherins, however, these proteins were not protected from the digestion in the presence of 1-5mM Ca²⁺.

Immunofluorescence Microscopy

Transfected cells were grown on a cover slip precoated with fibronectin and were fixed with 4% paraformaldehyde for 5 minutes at room temperature or with cold methanol on ice for 10 minutes followed by 4% paraformaldehyde fixation. After washing with TBS, the cells were incubated with

- 23 -

TBS containing 1% BSA for 30 minutes and then with anti-pc42 polyclonal antibody or anti-pc43 monoclonal antibody in TBS containing 1% BSA for 1 hour at room temperature. Cover slips were then washed with TBS containing 0.01% BSA and respectively incubated with FITC-conjugated anti-rabbit antibody or 5 anti-mouse antibody (Cappel, Durham, North Carolina) for 60 minutes at room temperature. The cells were washed again with TBS containing 0.01% BSA and subjected to fluorescence microscopy. Both pc42-specific and pc43-specific polyclonal antibodies stained the cell periphery of transfected cells expressing the protocadherin proteins, mainly at the cell-cell contact sites. The antibodies did 10 not stain the parent L cells, nor did rabbit preimmune sera stain the pc42 and pc43 transfectants.

Example 8

The cell aggregation properties of the transfected L cells expressing protocadherin proteins were examined. Transfected L cells were cultured in 15 Dulbecco's Modified Eagles Medium (DMEM) (Gibco, Grand Island, New York) supplemented with 10% fetal bovine serum at 37°C in 5% CO₂. Cells grown near confluence were treated with 0.01% trypsin in the presence of 1 mM EGTA for 25 minutes on a rotary shaker at 37°C and collected by centrifugation. The cells were washed three times with Ca²⁺ free HEPES-buffered saline (HBS) after 20 adding soybean trypsin inhibitor, and were resuspended in HBS containing 1% BSA. The cell aggregation assay [Urushihara *et al.*, *Dev. Biol.*, 70: 206-216 (1979)] was performed by incubating the resuspended cells in a 1:1 mixture of DMEM and HBS containing 1% BSA, 2 mM CaCl₂ and 20 µg/ml of deoxyribonuclease on a rotary shaker at 37°C for 30 minutes to 6 hours.

25 The pc42 and pc43 transfectants did not show any significant cell aggregation activity during periods of incubation less than 1 hour. This is in contrast to the cell aggregation that occurs with classic cadherins in similar experiments (Nagafuchi *et al.*, *supra*, and Hatta *et al.*, *supra*). However,

- 24 -

prolonged incubation of transfected cells (more than 1-2 hours) resulted in gradual re-aggregation of the cells into small aggregates. Similar results were obtained when single cell suspensions of transfected cells were prepared by trypsin treatment in the presence of Ca^{2+} . No re-aggregation was observed under the
5 same conditions when untransfected L cells or L cells transfected with pRC/RSV vector alone were tested. When pc43 transfectants labelled with DiO (Molecular Probes, Eugene, OR) were incubated with unlabelled pc42 transfectants in the cell aggregation assay, aggregation of labelled and unlabelled cells was almost mutually exclusive indicating that protocadherin binding is homophilic.

10 In view of the fact that the protocadherin cytoplasmic domains exhibit no apparent homology to cadherin domains, experiments were performed to determine if the difference in cytoplasmic domains could account for the difference in cell aggregation activity observed in cadherin and protocadherin transfectants. The cytoplasmic domain of pc43 was replaced with the cytoplasmic
15 domain of E-cadherin and aggregation of cells transfected with the chimeric construct was analyzed.

The Bluescript SK(+) clone described in Example 2 which contained the entire coding sequence for pc43 was digested with EcoRV and then partially digested with XbaI to remove the sequence corresponding to the
20 cytoplasmic domain, and the plasmid DNA was purified by agarose gel electrophoresis. The cDNA corresponding to the cytoplasmic domain of mouse E-cadherin was synthesized by PCR using mouse cDNA made from mouse lung mRNA as a template and specific primers corresponding to a region near the N-terminus of the cytoplasmic domain sequence or the region containing the stop codon of mouse E-cadherin (Nagafuchi *et al.*, *supra*). A XbaI sequence was included to the 5' end of the upstream primer. The E-cadherin cytoplasmic domain cDNA was then subcloned into the linearized pc43 Bluescript clone. The
25 DNA containing the entire resulting chimeric sequence was cut out with SpeI and EcoRV and was subcloned into the SpeI-blunted XbaI site of the expression vector pRc/RSV vector. Finally, L cells were transfected with the resultant construct by
30

- 25 -

a calcium phosphate method. After screening with G418 for about 10 days, the transfectants were stained with FITC-labeled 38I2C anti-pc43 antibody and subjected to FACS analysis. A portion of highly labeled cells were isolated and cloned. Transfectants showed a morphology similar to that of parental L cells and the expressed protein was localized at the cell periphery using pc43 antibody for immunofluorescence microscopy.

Cell aggregation activity of the chimeric transfectants was analyzed as follows. The chimeric pc43 transfectants were labeled with DiO for 20 minutes at room temperature. The resultant cells were trypsinized in the presence of 1mM EGTA and single cell suspension was made. Then, the cells were mixed with unlabeled other type of transfectants and incubated on a rotary shaker for two hours. The results were examined with a fluorescence and a phase contrast microscope apparatus. Antibody inhibition of cell aggregation was examined by incubation of the transfectants in the presence of polyclonal anti-pc43 antibody (100 ng/ml) in the standard assay medium.

In the cell aggregation assay, the chimeric pc43 transfectants showed clear Ca^{2+} -dependent cell aggregation within forty minutes of incubation. Cell aggregation was inhibited by the addition of pc43-specific polyclonal antibody.

20

Example 9

The procedures of Maruyama *et al.*, *J. Biochem.*, 95: 511-519 (1984) were used to determine the calcium binding properties of pc43 by Western blot analysis in the presence or absence of calcium-45. The pc43 fusion protein described in Example 6 containing pc43 subdomains EC-3 through EC-5 was compared to the calcium binding protein calmodulin. Samples of purified pc43 fusion protein were run on SDS/PAGE and electrophoretically transferred to PVDF membrane. Binding of the $^{45}\text{Ca}^{2+}$ to the pc43 fusion protein was detected by autoradiography and was determined to be nearly as efficient as binding of $^{45}\text{Ca}^{2+}$ to calmodulin. In contrast, there was no binding of calcium to purified

- 26 -

maltose binding protein lacking the pc43 extracellular domain. The pc43 subdomains EC-3 through EC-5 contain sequences highly homologous to the putative $\text{Ca}^{2\pm}$ binding motifs found in E-cadherin. [See, Ringwald *et al.*, *EMBO J.*, 6: 3647-3653 (1987).]

5

Example 10

The expression of mRNA encoding pc42 and pc43 was assayed in various tissues and cell lines by Northern blot.

Total RNAs were prepared by the guanidium isothiocyanate method and poly(A)+ RNAs were isolated using a FastTrack kit (Invitrogen). RNA preparations were electrophoresed in a 0.8% agarose gel under denaturing conditions and transferred onto a nitrocellulose filter using a capillary method. Northern blot analyses were performed according to the method of Thomas, *Proc. Natl. Acad. Sci. USA*, 77: 5201-5205 (1980). The final wash was in 0.2X standard saline citrate containing 0.1% sodium dodecyl sulfate at 65°C for 10 minutes.

15

Protocadherin mRNA Expression in Adult Rat Tissues

20

Total mRNA preparations of rat tissues including brain, heart, liver, lung, skin, kidney and muscle were separated electrophoretically under denaturing conditions (10 μg mRNA/lane) and transferred onto nitrocellulose filters. The filters were hybridized with ^{32}P -labelled cDNA fragments MOUSE-326 (which corresponds to EC-4 of human pc42) and RAT-218 (which corresponds to EC-5 of human pc43). The mRNAs of both protocadherins were highly expressed in brain. The pc42 probe detected a major band of 7 kb and a minor band of 4 kb in size, possibly representing the products of alternative splicing. The pc43 probe hybridized to a major band of 5 kb in size and with minor bands of smaller sizes.

25

Developmental Expression of Protocadherin mRNA in Rat Brain

To examine the developmental regulation of mRNA expression of the protocadherins, brain mRNA from rats at embryonic days 17 and 20, neonatal

- 27 -

days 5 and 11 and from adult rats was prepared and subjected to Northern blot analysis as described above for other rat tissues. β -actin was used as an internal standard. mRNA levels for pc42 and pc43 proteins increased during embryonic development of the brain as compared with β -actin expression.

5 Protocadherin mRNA Expression in Human Cell Lines

Several neuronal and glial cell lines (including human SK-N-SH neuroblastoma, human U251 glioma, and mouse Neuro-2a neuroblastoma cell lines) were assayed by Northern blot using 32 P-labelled for expression of pc42 and pc43 mRNA. Human cell lines were probed with HUMAN-42 (which corresponds to EC-4 of human pc42) and HUMAN-43 (which corresponds to EC-5 of human pc43) cDNA fragments while the mouse cell line was probed with MOUSE-326 (which corresponds to EC-4 of human pc42) and RAT-322 (which corresponds to EC-5 of human pc43) cDNA fragments. SK-N-SH human neuroblastoma cells and U251 human glioma cells were found to express pc43 mRNA and Neuro-2a mouse neuroblastoma cells were found to express pc42 mRNA.

10 Example 11

Expression of pc43 protein in various tissues, extracts and cells was assayed by Western blot and immunofluorescence microscopy.

15 Expression in Rat Cardiac Muscle Extracts

A rat heart non-ionic detergent extract was prepared by freezing a heart in liquid nitrogen after removal, powdering in a mortar and pestle, grinding briefly in a polytron in 0.5% Nonidet P40 in [10 mM PIPES (pH 6.8), 50 mM NaCl, 250 mM NH₄SO₄, 300 mM sucrose, 3 mM MgCl₂] and microfuging for 15 minutes. Samples were separated by SDS/PAGE and electrophoretically transferred to nitrocellulose (Towbin *et al.*, *PNAS* 76:4350-4354, 1979). Two pc43 protein bands with molecular weights of 150 KDa and 140 KDa were

- 28 -

detected with rabbit polyclonal antibodies to pc43 by the immunoblot method described in Example 7.

Expression in Tissue Sections and Cells

To determine the localization of the protocadherins in various tissues, human and rat adult tissues were removed, incubated in 30% sucrose in PBS for 30 minutes at 4°C, embedded in OCT compound (Tissue-Tek, Elkhart, Indiana) in cryomolds and quickly frozen. Six micron sections were cut and placed on glass slides. The slides were washed with PBS and fixed in 3% p-formaldehyde for 5 minutes. To permeabilize the tissue sections, the slides were immersed in -20°C acetone for 10 minutes and air dried. The sections were blocked with 2% goat serum and 1% BSA in PBS for 30 minutes and then incubated with the rabbit anti-pc43 polyclonal antisera for 1 hour at room temperature. The sections were rinsed 3 times in PBS containing 0.1% BSA and incubated with a biotinylated anti-rabbit (Vector Laboratories, Burlingame, California) in 1% BSA in PBS for 30 minutes. After rinsing 3 times, streptavidin-conjugated with FITC (Vector Laboratories) was added for 30 minutes and again washed 3 times. For co-localization studies, an appropriate primary antibody was used with a TRITC-conjugated secondary antibody.

A. Muscle

Immunolocalization of pc43 in rat cardiac muscle shows that pc43 is localized in a repeating pattern which is consistent with pc43 being associated with the sarcomeres. Sarcomeres are repetitive contractile units between the *fascia adherens* in skeletal and cardiac muscle. Co-localization with cytoskeletal proteins shows that pc43 is present at the ends of the sarcomeres in the Z lines which are associated with desmin and the actin-binding protein vinculin, and alpha-actinin. The thin microfilaments of F-actin are associated with the thick myosin filaments between the Z lines. In contrast, N-cadherin is localized at the ends of cardiac myocytes at the *fascia adherens* junctions at sites of myocyte:myocyte contact. The localization of pc43 in cardiac muscle suggests

- 29 -

that pc43 may play a role in muscle contraction in the anchoring of the contractile apparatus to the plasma membrane.

Similar localization for pc43 was observed in rat skeletal muscle. Ultrastructural studies have shown that dystrophin, the gene product lacking in 5 Duchenne muscular dystrophy, is a component of the sarcolemma [Porter *et al.*, *J. Cell. Biol.*, 117:997-1005 (1992)]. The sarcolemma is connected to the contractile apparatus at the M and Z lines where pc43 is localized.

B. Brain

Reactivity of anti-pc43 polyclonal antibody and monoclonal 10 antibody 38I2C on frozen sections of rat and human cerebellum, respectively, shows that the major sites of pc43 expression are located in Purkinje cells and the granule cell layer which contains numerous small neurons.

C. Placenta

Strong reactivity of monoclonal antibody 38I2C with human 15 syncytiotrophoblasts was also observed in development of the placenta at an early state (5-7 weeks of gestation). Expression appeared to gradually decrease as the stage progressed indicating that pc43 may be involved in the implantation of fertilized eggs into the placenta.

D. Neuroblastoma and Astrocytoma Cells

Immunocytochemical localization of pc43 in Sk-N-SH 20 neuroblastoma cells and UW28 astrocytoma cells using anti-pc43 antibodies reveals a punctate cell surface distribution of pc43 and in some cells there is a localization at the tips of extensions of neuronal foot processes. At sites of cell-cell contact of UW28 astrocytoma cells, pc43 is organized in a series of parallel 25 lines. The lines start at the contact site and extend approximately 5 micron. F-actin microfilaments were identified with rhodamine-phalloidin (Molecular Probes, Eugene, Oregon, as described by the manufacturer) showing that the microfilaments in the cell appear to end in the pc43 linear structures which extend from the edge of the cell at sites of cell contact.

- 30 -

Immunoblotting studies with pc43 specific antibodies show that a protein with a molecular weight of 140 kDa is recognized in human Sk-N-SH neuroblastoma cells and in UW28 astrocytoma cells.

E. Osteoblasts

5 Immunocytochemical localization of pc43 using monoclonal antibody 38I2C in tow human osteogenic sarcoma cell lines [SaOS (ATCC HTB 85) and MG-63 (ATCC CRL 1427)] and in cultures of normal human trabecular osteoblasts [culture system described in Civitelli *et al.*, *J. Clin. Invest.*, 91: 1888-1896 (1993)] showed that pc43 is expressed in osteoblasts in a pattern similar to
10 that seen in UW28 astrocytoma cells. At sites of cell-cell contact, pc43 is organized in a series of parallel lines that appear to correspond to the actin stress fibers. In addition, in some cells, pc43 appears to localize at the tips of contacting cell processes. Northern blot analysis provides additional evidence that
15 pc43 is expressed in normal human trabecular osteoblasts. A pc43 specific DNA probe hybridized to a major band of 5 kb in samples of poly-A mRNA isolated from normal human trabecular osteoblasts.

Example 12

In situ hybridization experiments using protocadherin specific RNA probes were performed on cryosections of rat tissue.

20 Sense and antisense 35 S-riboprobes were made using the standard procedure described by Promega (Madison, Wisconsin). An approximately 400 bp EcoRI-XbaI fragment of the MOUSE-326 cDNA clone was used as a pc42 specific probe. This fragment encodes the middle of EC-3 to the end of EC-4 of pc42. An approximately 700 bp SmaI fragment of the RAT-218 cDNA clone was
25 used as a pc43 specific probe. The fragment encodes the end of EC-3 to the end of EC-5 of pc43.

Rat adult tissues were harvested and immediately embedded with OCT Compound (Tissue-Tek) in cryomolds and quickly frozen in a bath of 95% ethanol/dry ice. The frozen blocks were stored at -80°C until cut. Six micron

- 31 -

tissue sections were cut using a cryostat (Reichert-Jung, Model #2800 Frigocut N, Leica, Inc., Gilroy, California). Cut tissue sections were stored at -80°C.

The *in situ* protocol used was a variation of that described by Angerer *et al.*, *Methods in Enzymology*, 152: 649-660, (1987). All solutions were treated with diethylpyrocarbonate (DEPC, Sigma, St. Louis, Missouri) to remove RNase contamination. The tissue sections were first fixed in 4% paraformaldehyde at 4°C for 20 minutes. To remove excess paraformaldehyde and stop the tissue fixation, the slides were washed in PBS (phosphate buffered saline), denatured in a graded series of alcohols (70, 95, 100%) and then dried. To prevent the tissue from detaching from the glass slide during the *in situ* procedure, the tissue sections were treated in a poly-L-lysine solution (Sigma) at room temperature for 10 minutes. To denature all RNA in the tissue, the sections were placed in a solution of 70% formamide/2x SSC (0.15 M NaCl/0.3 M Na citrate, pH 7.0) at 70°C for 2 minutes after which they were rinsed in chilled 2x SSC, dehydrated in a graded series of alcohols and then dried. Once dried, the sections were prehybridized in hybridization buffer [50% formamide/50 mM DTT (dithiothreitol)/0.3M NaCl/20 mM Tris, pH 8.0/5 mM EDTA/1X Denhardt's (0.02% Ficoll Type 400/0.02% polyvinylpyrrolidone/0.02% BSA)/10% Dextran Sulfate] at the final hybridization temperature for approximately 4 hours. After prehybridization, approximately 1 X 10⁶ cpm of the appropriate riboprobe was added to each section. The sections were generally hybridized at 45°C overnight (12-16 hours). To insure that the hybridization seen was specific, in some experiments the hybridization stringency was increased by raising the hybridization temperature to 50°C. As both the 45°C and 50°C experiments gave comparable results, the standard hybridization temperature used was 45°C.

To remove excess, nonhybridized probe, the sections were put through a series of washes. The sections were first rinsed in 4X SSC to remove the bulk of the hybridization solution and probe. Next a 15 minute wash in 4X SSC/50 mM DTT was carried out at room temperature. Washes at increased

- 32 -

stringencies were also utilized. A 40 minute wash in 50% formamide/2X SSC/50 mM DTT was performed at 60°C. Four final room temperature washes were carried out for 10 minutes each: two in 2X SSC and two in 0.1X SSC. The washed slides were dehydrated in a graded series of alcohols and dried.

5 To visualize the hybridized probe, the slides were dipped in Kodak NTB2 nuclear emulsion (International Biotechnology, New Haven, Connecticut) which had been diluted 1:1 in dH₂O. Once dry, the slides were stored at 4°C in light-tight boxes for the appropriate exposure time. The *in situ* slides were independently viewed by two persons and scored positive or negative for
10 hybridization signal.

All *in situ* hybridization studies were performed on rat tissue. Because results from Northern blot experiments (see Example 9) indicated that both pc42 and pc43 are expressed in adult brain, *in situ* hybridization studies were carried out to localize the expression of these molecules to specific brain cell types. Hybridization seen in the normal adult rat brain was specific (no background hybridization was seen with the sense probes) and was localized to specific regions in the brain. The overall pattern of expression seen for pc42 and pc43 was very similar, with the major difference being in the level of expression. pc43 appears to be expressed at a lower level than pc42. Both molecules are expressed in the germinal and pyramidal cells of the hippocampus, Purkinje cells of the cerebellum and neurons in grey matter. In addition, pc42 is expressed in glial cells in the white matter but, in contrast to the expression of pc43 in glioma cell lines (as described in Example 9), expression of pc43 in normal glial cells was not observed. In the spinal chord, both protocadherins are expressed in the motor neurons in the gray matter and pc42 is expressed in the glial cells in the white matter.
15
20
25

When expression of both protocadherin molecules was analyzed in brains and spinal chords from rats having EAE (experimental allergic encephalomyelitis) [Vandenbark et al., *Cell. Immunol.*, 12: 85-93 (1974)], the same structures as described above were found to be positive. In addition,
30

- 33 -

expression of pc42 was observed in the leukocytic infiltrates in the EAE tissues. Expression of pc42 in leukocytes was confirmed by *in situ* hybridization analysis of two leukocytic cell lines, RBL-1 and y3.

5 Expression of both protocadherin-42 and -43 was observed in the developing brain of rat embryos at all embryological days tested (E15-E19). In addition protocadherin-43 was observed in the developing rat heart at all embryological days tested (E13-E19). This finding is consistent with the immunohistochemistry results showing protocadherin-43 expression in adult heart.

10 To determine possible roles of protocadherins in the development of the nervous system, expression profiles of protocadherin members in developing rat brain and adult rat brain were also examined by *in situ* hybridization. A series of coronal, sagittal and horizontal sections of rat brains at postnatal days 0, 6, 14, 30 (P0 through P30) and at 3 months (young adult) were hybridized with labelled cRNA probes corresponding to various 15 protocadherins of the invention including pc42, pc43, RAT-212, RAT-411, and RAT-418. In developing brain, RAT-411 was expressed at high levels in neurons of the olfactory bulb, *i.e.*, mitral cells and periglomerular cells. The expression of RAT-411 mRNA was transient; expression appeared at P0, peaked at P6, diminished by P14, and was undetectable at P30 and in adult brain. In the adult, 20 pc43 mRNA was found to be expressed predominantly in Purkinje cells in the cerebellum. The expression of pc43 mRNA in Purkinje cells was observed from the beginning of Purkinje cell differentiation at around P6. Other protocadherin members were expressed at very low levels in various areas of developing and adult brains. These results indicate that protocadherin members are differentially expressed during the development of the central nervous system, and suggest that 25 RAT-411 and pc43 have specific roles during the development of olfactory bulb neurons and Purkinje cells, respectively.

- 34 -

Example 13

Conventional immunoprecipitations using pc43-specific polyclonal antibodies and monoclonal antibody 38I2C were performed to identify proteins that interacted with pc43 in L cell transfectants.

5 The pc43 and chimeric pc43 transfectants were metabolically labeled by incubating the cells in Dulbecco's modified Eagle's medium containing [³⁵S] methionine (50 uCi/ml) overnight. After washing, the transfectants were lysed with PBS containing Triton X 100 and incubated with anti-pc43 antibody. The immunocomplexes were then collected using protein A-Sepharose beads. The 10 resulting beads were washed five times with a washing buffer (50mM Tris-HCl, pH 8.0, containing 0.5M NaCl, 0.1% ovalbumin, 0.5% NP-40, 0.5% Triton X 100 and 1mM EDTA) at room temperature. Protein was separated by SDS-PAGE and subjected to autoradiography.

15 The chimeric pc43 co-precipitated with 105 kDa and a 95 kDa bands that are likely to correspond to α - and β -catenins, respectively, because anti- α -catenin and anti- β -catenin antibodies stained comparable bands. Pc43, on the other hand, co-precipitated with a 120 kDa band.

20 While the present invention has been described in terms of specific methods and compositions, it is understood that variations and modifications will occur to those skilled in the art. Therefore, only such limitations as appear in the claims should be placed on the invention.

- 35 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Suzuki, Shintaro
- (ii) TITLE OF INVENTION: Protocadherin Materials and Methods
- (iii) NUMBER OF SEQUENCES: 115
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray, & Borun
 - (B) STREET: 6300 Sears Tower, 233 S. Wacker Drive
 - (C) CITY: Chicago
 - (D) STATE: Illinois
 - (E) COUNTRY: USA
 - (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA
 - (A) APPLICATION NUMBER: PCT/US93/12588
 - (B) FILING DATE: 23 DEC 1993
- (viii) PRIOR APPLICATION DATA
 - (A) APPLICATION NUMBER: US 07/998,003
 - (B) FILING DATE: 29 DEC 1992
- (ix) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Noland, Greta E.
 - (B) REGISTRATION NUMBER: 35,302
 - (C) REFERENCE/DOCKET NUMBER: 32149
- (x) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 312/474-6300
 - (B) TELEFAX: 312/474-0448
 - (C) TELEX: 25-3856

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

- 36 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AARSSNNNTNG ATRYGA

17

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTRCTRTRRC GNGGNNN

17

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 131 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGGGAGTGG ACTTGAGGA GCAGCCTGAG CTTAGTCTCA TCCTCACGGC TTTGGATGGA

60

GGGACTCCAT CCAGGTCTGG GACTGCATTG GTTCAAGTGG AAGTCATAGA TGCCAATGAC

120

AACGCACCGT A

131

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Lys	Gly	Val	Asp	Phe	Glu	Glu	Gln	Pro	Glu	Leu	Ser	Leu	Ile	Leu	Thr
1				5					10				15		

Ala	Leu	Asp	Gly	Gly	Thr	Pro	Ser	Arg	Ser	Gly	Thr	Ala	Leu	Val	Gln
			20				25					30			

Val	Glu	Val	Ile	Asp	Ala	Asn	Asp	Asn	Ala	Pro					
			35				40								

- 37 -

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAACGCATGG ATTCGAGGA GTCTCCTCC TACCAAGATCT ATGTGCAAGC TACTGACCGG	60
GGACCAGTAC CCATGGCGGG TCATTGCAAG GTGTTGGTGG ACATTATAGA TGTGAACGAC	120
AACGCACCTA A	131

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Lys Ala Met Asp Phe Glu Glu Ser Ser Ser Tyr Gln Ile Tyr Val Gln	
1 5 10 15	
Ala Thr Asp Arg Gly Pro Val Pro Met Ala Gly His Cys Lys Val Leu	
20 25 30	
Val Asp Ile Ile Asp Val Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGCGACTGG ACTTGAGAC CCTGCAGACC TTCAAGTTCA GCGTGGGTGC CACAGACCAT	60
GGCTCCCCCT CGCTCCGCAG TCAGGCTCTG GTGCGCGTGG TGGTGCTGGA CCACAATGAC	120

- 38 -

AATGCCCTCA A

131

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Lys	Arg	Leu	Asp	Phe	Glu	Thr	Leu	Gln	Thr	Phe	Glu	Phe	Ser	Val	Gly
1				5				10						15	

Ala	Thr	Asp	His	Gly	Ser	Pro	Ser	Leu	Arg	Ser	Gln	Ala	Leu	Val	Arg
				20				25					30		

Val	Val	Val	Leu	Asp	His	Asn	Asp	Asn	Ala	Pro					
				35			40								

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAGGGCCTGG	ATTACGAGGC	ACTGCAGTCC	TTCGAGTTCT	ACGTGGGCCG	TACAGATGGA	60
------------	------------	------------	------------	------------	------------	----

GGCTCACCCG	CGCTCAGCAG	CCAGACTCTG	GTGCGGATGG	TGGTGCTGGA	TGACAACGAC	120
------------	------------	------------	------------	------------	------------	-----

AACGCCCTCA A		131
--------------	--	-----

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Lys	Gly	Leu	Asp	Tyr	Glu	Ala	Leu	Gln	Ser	Phe	Glu	Phe	Tyr	Val	Gly
1				5				10					15		

- 39 -

Ala Thr Asp Gly Gly Ser Pro Ala Leu Ser Ser Gln Thr Leu Val Arg
20 25 30

Met Val Val Leu Asp Asp Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AAGGCCTTG ATTTGAGGA TCAGAGAGAG TTCCAGCTAA CCGCTCATAT AAACGACGGA	60
GGTACCCCGG TTTGGCCAC CAACATCAGC GTAACATAT TTGTTACTGA CCGCAATGAC	120
AACGCCCGC A	131

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys Ala Phe Asp Phe Glu Asp Gln Arg Glu Phe Gln Leu Thr Ala His	
1 5 10 15	
Ile Asn Asp Gly Gly Thr Pro Val Leu Ala Thr Asn Ile Ser Val Asn	
20 25 30	
Ile Phe Val Thr Asp Arg Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 40 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAGGCGGTGG ATTACGAAAT CACCAAGTCC TATGAGATAG ATGTTCAAGC CCAAGATCTG	60
GGTCCAATT CTATTCCCTGC TCATTGAAA ATTATAATTA AGGTCGTGGA TGTCAACGAC	120
AACGCTCCCA A	131

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Ala Val Asp Tyr Glu Ile Thr Lys Ser Tyr Glu Ile Asp Val Gln	
1 5 10 15	
Ala Gln Asp Leu Gly Pro Asn Ser Ile Pro Ala His Cys Lys Ile Ile	
20 25 30	
Ile Lys Val Val Asp Val Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 135 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TATGACCATG ATTACGAGAC AACCAAAGAA TATACACTGC GGATCCGGGC CCAGGATGGT	60
GGCCGGACTC CACTTCCAA CGTCTCCGGT CTAGTAACCG TGCAGGTCCCT AGACATCAAC	120
GACAATGCCA CCCCA	135

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 41 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Tyr Asp His Asp Tyr Glu Thr Thr Lys Glu Tyr Thr Leu Arg Ile Arg
1 5 10 15
Ala Gln Asp Gly Gly Arg Thr Pro Leu Ser Asn Val Ser Gly Leu Val
20 25 30
Thr Val Gln Val Leu Asp Ile Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 129 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGGGGGTCGA TTACGAGGAG AACGGCATGT TAGAGATCGA CGTGCAGGCC AGAGACCTAG 60
GACCTAACCC AATTCCAGCC CATTGCAAGG TCACAGTCAA GCTCATCGAC CGCAATGATA 120
ACGCCCCCA 129

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Arg Gly Val Asp Tyr Glu Glu Asn Gly Met Leu Glu Ile Asp Val Gln
1 5 10 15
Ala Arg Asp Leu Gly Pro Asn Pro Ile Pro Ala His Cys Lys Val Thr
20 25 30
Val Lys Leu Ile Asp Arg Asn Asp Asn Ala Pro
35 40

- 42 -

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAGGGGTTGG ACTACGAAGA CACCAAAC	TC CATGAGATTT ACATCCAGGC CAAAGACAAA	60
GGTGCCAATC CGGAAGGAGC GCATTGCAA	AA GTACTGGTAG AGGTTGTGGA CGTTAACGAC	120
AATGCCCTC A		131

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Lys	Gly	Leu	Asp	Tyr	Glu	Asp	Thr	Lys	Leu	His	Glu	Ile	Tyr	Ile	Gln
1				5				10					15		
Ala	Lys	Asp	Lys	Gly	Ala	Asn	Pro	Glu	Gly	Ala	His	Cys	Lys	Val	Leu
	20					25						30			
Val	Glu	Val	Val	Asp	Val	Asn	Asp	Asn	Ala	Pro					
			35			40									

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAGGGTTTGG ACTTGAGCA AGTAGATGTC TACAAAATCC GCGTTGACGC GACGGACAAA	60
GGACACCCCTC CGATGGCAGG CCATTGCACT GTTTAGTGA GGGTATTGGA TGAAAACGAC	120

- 43 -

AATGCGCCCTC T

131

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Lys Gly Leu Asp Phe Glu Gln Val Asp Val Tyr Lys Ile Arg Val Asp
1 5 10 15

Ala Thr Asp Lys Gly His Pro Pro Met Ala Gly His Cys Thr Val Leu
20 25 30

Val Arg Val Leu Asp Glu Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 134 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AAGGGTATAG ACTTCGAGCA GATCAAGGAC TTCAGCTTTC AAGTCAAAGC CCGGGACGCC 60

GGCACTCCCC AGGCGCTGTC CGGCAACTGC ACTGTCAACA TCTTGATAGT GGATCAGAAC 120

GACAAACGCCCTAA 134

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 44 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Lys Gly Ile Asp Phe Glu Gln Ile Lys Asp Phe Ser Phe Gln Val Glu
1 5 10 15

- 44 -

Ala Arg Asp Ala Gly Ser Pro Gln Ala Leu Ala Gly Asn Thr Thr Val
20 25 30

Asn Ile Leu Ile Val Asp Gln Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 134 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AAGCCGTTCG ACTATGAGCA AACCGCCAAC ACGCTGGCAC AGATTGACGC CGTGCTGGAA	60
AAACAGGGCA GCAATAAAC GAGCATTCTG GATGCCACCA TTTTCCTGGC CGATAAAAAC	120
GACAATGCGC CAGA	134

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Lys Pro Phe Asp Tyr Glu Gln Thr Ala Asn Thr Leu Ala Gln Ile Asp	
1 5 10 15	
Ala Val Leu Glu Lys Gln Gly Ser Asn Lys Ser Ser Ile Leu Asp Ala	
20 25 30	
Thr Ile Phe Leu Ala Asp Lys Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 45 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AAGCGGCTGG ATTCGAACA GTTCCAGCAG CACAAAGCTGC TCGTAAGGGC TGTTGATGGA	60
GGAATGCCGC CACTGAGCAG CGATGTGGTC GTCACTGTGG ATGTCACCGA CCTCAACGAT	120
AACGCGCCCT A	131

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Lys Arg Leu Asp Phe Glu Gln Phe Gln Gln His Lys Leu Leu Val Arg	
1 5 10 15	
Ala Val Asp Gly Gly Met Pro Pro Leu Ser Ser Asp Val Val Val Thr	
20 25 30	
Val Asp Val Thr Asp Leu Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

AAGGGGATAG ACTTGAGAG TGAGAATTAC TATGAATTG ATGTGCGGGC TCGCGATGGG	60
GGTTCTCCAG CCATGGAGCA ACATTGCAGC CTTCGAGTGG ATCTGCTGGA CGTAAATGAC	120
AACGCCCCAC T	131

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 46 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Lys Gly Ile Asp Phe Glu Ser Glu Asn Tyr Tyr Glu Phe Asp Val Arg
1 5 10 15
Ala Arg Asp Gly Gly Ser Pro Ala Met Glu Gln His Cys Ser Leu Arg
20 25 30
Val Asp Leu Leu Asp Val Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

AAGGCATTGG ACTTTGAGGC CCGGCGACTG TATTCGCTGA CAGTTCAAGGC CACGGACCGA 60
GGCGTGCCT CGCTCACCGG GCGTGCCGAA GCGCTTATCC AGCTGCTAGA TGTCAACGAC 120
AACGCACCCA T 131

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Lys Ala Leu Asp Phe Glu Ala Arg Arg Leu Tyr Ser Leu Thr Val Gln
1 5 10 15
Ala Thr Asp Arg Gly Val Pro Ser Leu Thr Gly Arg Ala Glu Ala Leu
20 25 30
Ile Gln Leu Leu Asp Val Asn Asp Asn Ala Pro
35 40

- 47 -

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 125 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

AAGCCAATTG ATTACGAGGC AACTCCATAC TATAACATGG AAATTGTAGC CACAGACAGC	60
GGAGGTCTTT CGGGAAAATG CACTGTGTCT ATACAGGTGG TGGATGTGAA CGACAACGCC	120
CCCAA	125

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Lys Pro Ile Asp Tyr Glu Ala Thr Pro Tyr Tyr Asn Met Glu Ile Val	
1 5 10 15	
Ala Thr Asp Ser Gly Gly Leu Ser Gly Lys Cys Thr Val Ser Ile Gln	
20 25 30	
Val Val Asp Val Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 446 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AAGCGGGTAG ACTTCGAAAT GTGCAAAAGA TTTTACCTTG TGGTGGAAAGC TAAAGACGGA	60
GGCACCCAG CCCTCAGCAC GGCAAGCCACT GTCAGCATCG ACCTCACAGA TGTGAATGAT	120

- 48 -

AACCCCTCCTC GGTTCAAGCCA AGATGTCTAC AGTGCTGTCA TCAGTGAGGA TGCCTTAGAG	180
GGGGACTCTG TCATTCTGCT GATAGCAGAA GATGTGGATA GCAAGCCTAA TGGACAGATT	240
CGGTTTCCA TCGTGGGTGG AGATAGGGAC AATGAATTTG CTGTCGATCC AATCTGGGA	300
CTTGTGAAAG TTAAGAAGAA ACTGGACCGG GAGCGGGTGT CAGGATACTC CCTGCTCATC	360
CAGGCAGTAG ATAGTGGCAT TCCTGCAATG TCCTCAACGA CAACTGTCAA CATTGATATT	420
TCTGATGTGA ACGACAACGC CCCCCT	446

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 148 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Lys Arg Val Asp Phe Glu Met Cys Lys Arg Phe Tyr Leu Val Val Glu	
1 5 10 15	
Ala Lys Asp Gly Gly Thr Pro Ala Leu Ser Thr Ala Ala Thr Val Ser	
20 25 30	
Ile Asp Leu Thr Asp Val Asn Asp Asn Pro Pro Arg Phe Ser Gln Asp	
35 40 45	
Val Tyr Asp Ala Val Ile Ser Glu Asp Ala Leu Glu Gly Asp Ser Val	
50 55 60	
Ile Leu Leu Ile Ala Glu Asp Val Asp Ser Lys Pro Asn Gly Gln Ile	
65 70 75 80	
Arg Phe Ser Ile Val Gly Gly Asp Arg Asp Asn Glu Phe Ala Val Asp	
85 90 95	
Pro Ile Leu Gly Leu Val Lys Val Lys Lys Leu Asp Arg Glu Arg	
100 105 110	
Val Ser Gly Tyr Ser Leu Leu Ile Gln Ala Val Asp Ser Gly Ile Pro	
115 120 125	
Ala Met Ser Ser Thr Thr Val Asn Ile Asp Ile Ser Asp Val Asn	
130 135 140	
Asp Asn Ala Pro	
145	

- 49 -

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 440 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

AAGGGGGTTG ATTATGAGAC AAACCCACGG CTACGACTGG TGCTACAGGC AGAGAGTGGA	60
GGAGGCCCTTG CTTTCTCGGT GCTGACCCCTG ACCCTTCAAG ATGCCAATGA CAATGCTCCC	120
CGTTTCCTGC AGCCTCACTA CGTGGCTTTC CTGCCAGAGT CCCGACCCTT GGAAGGGCCC	180
CTGCTGCAGG TCCAAGCAGA CGACCTGGAT CAAGGCTCTG GAGGACAGAT CTCCCTACAGT	240
CTGGCTGCAT CCCAGCCAGC ACGGGGCTTG TTCCATGTAG ACCCAGCCAC AGGCACATATC	300
ACTACCCACAG CCATCCTGGA CCGGGAAATC TGGGCTGAAA CACGGCTGGT ACTGATGGCC	360
ACAGACAGAG GAAGCCCAGC ATTGGTGGGC TCAGCTACCC TGACAGTGAT GGTCATCGAT	420
ACCAACGACA ATGCTCCCCCT	440

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 146 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Lys	Gly	Val	Asp	Tyr	Glu	Thr	Asn	Pro	Arg	Leu	Arg	Leu	Val	Leu	Gln
1				5					10						15
Ala	Glu	Ser	Gly	Gly	Ala	Phe	Ala	Phe	Ser	Val	Leu	Thr	Leu	Thr	Leu
									20			25		30	
Gln	Asp	Ala	Asn	Asp	Asn	Ala	Pro	Arg	Phe	Leu	Gln	Pro	His	Tyr	Val
									35			40		45	
Ala	Phe	Leu	Pro	Glu	Ser	Arg	Pro	Leu	Glu	Gly	Pro	Leu	Leu	Gln	Val
								50		55				60	
Glu	Ala	Asn	Asp	Leu	Asp	Gln	Gly	Ser	Gly	Gly	Gln	Ile	Ser	Tyr	Ser
								65		70		75		80	
Leu	Ala	Ala	Ser	Gln	Pro	Ala	Arg	Gly	Leu	Phe	His	Val	Asp	Pro	Ala
								85		90				95	

- 50 -

Thr Gly Thr Ile Thr Thr Ala Ile Leu Asp Arg Glu Ile Trp Ala
 100 105 110

Glu Thr Arg Leu Val Leu Met Ala Thr Asp Arg Gly Ser Pro Ala Leu
 115 120 125

Val Gly Ser Ala Thr Leu Thr Val Met Val Ile Asp Thr Asn Asp Asn
 130 135 140

Ala Pro
 145

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 124 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

AAGGTCTCGA TTATGAGGCA ACTCCATATT ATAACGTGGA AATTGTAGCC ACAGATGGTG 60
GGGGCCTTTC AGGAAAATGC ACTGTGGCTA TAGAAGTGGT GGATGTGAAC GACGGCGCTC 120
CAAT 124

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Lys Gly Leu Asp Tyr Glu Ala Thr Pro Tyr Tyr Asn Val Glu Ile Val
 1 5 10 15
 Ala Thr Asp Gly Gly Ala Phe Asp Glu Asn Cys Thr Val Ala Ile Glu
 20 25 30
 Val Val Asp Val Asn Asp Asn Ala Pro
 35 40

- 51 -

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Asp Xaa Asn Glu Xaa Pro Xaa Phe
1 5

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Asp Xaa Asp Glu Xaa Pro Xaa Phe
1 5

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Asp Xaa Asn Asp Asn Xaa Pro Xaa Phe
1 5

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 52 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

AAGCGGATGG ATTTGAAGA CACCAAACTC CATGAGATT ACATCCAGGC CAAAGACAAA	60
GGTGCCAATC CCGAAGGAGC GCATTGAAA GTACTTGTAG AGGTTGTAGA CGTAAACGAC	120
AACGCCCAAG T	131

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Leu Arg Met Asp Phe Glu Asp Thr Lys Leu His Glu Ile Tyr Ile Gln														
1	5	10	15	Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys Val Leu		20	25	30		Val Glu Val Val Asp Val Asn Asp Asn Ala Pro		35	40	
10	15													
Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys Val Leu														
20	25	30		Val Glu Val Val Asp Val Asn Asp Asn Ala Pro		35	40							
30														
Val Glu Val Val Asp Val Asn Asp Asn Ala Pro														
35	40													

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

AAGGCTTGG ATTACGAGGA TCAGAGAGAG TTCCAACTAA CAGCTCATAT AAACGACGGA	60
GGTACCCCAAG TCTTAGCCAC CAACATCAGC GTGAACGTAT TTGTTACTGA CCGCAATGAT	120
AACGCCCAAG A	131

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 53 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Lys Ala Leu Asp Tyr Glu Asp Gln Arg Glu Phe Gln Leu Thr Ala His
1 5 10 15
Ile Asn Asp Gly Gly Thr Pro Val Leu Ala Thr Asn Ile Ser Val Asn
20 25 30
Val Phe Val Thr Asp Arg Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 131 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

AAGCGCTTGG ACTACGAGGA GAGTAACAAT TATGAAATTACGTGGATGC TACAGATAAA 60
GGATACCCAC CTATGGTTGC TCACTGCACC GTACTCGTGG GAATCTTGGA TGAAAATGAC 120
AACGCACCCA T 131

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Lys Arg Leu Asp Tyr Glu Glu Ser Asn Asn Tyr Glu Ile His Val Asp
1 5 10 15
Ala Thr Asp Lys Gly Tyr Pro Pro Met Val Ala His Cys Thr Val Leu
20 25 30
Val Gly Ile Leu Asp Glu Asn Asp Asn Ala Pro
35 40

- 54 -

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

AAACCGGTGG ACTACGAGAA AGTCAAAGAC TATACCATCG AGATCGTGGC TGTGGATTCC	60
GGCAACCCCTC CACTCTCTAG CACCAACTCC CTCAAGGTGC AGGTGGTAGA CGTCAACGAT	120
AACGCCCTC T	131

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Lys Pro Val Asp Tyr Glu Lys Val Lys Asp Tyr Thr Ile Glu Ile Val	
1 5 10 15	
Ala Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys	
20 25 30	
Val Gln Val Val Asp Val Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

AAGCCTTTG ATTCGAGGA CACCAAACTC CATGAGATT ACATCCAGGC CAAAGACAAG	60
GGCGCCAATC CGGAAGGAGC ACATTGCAAA GTGTTGGTGG AGGTTGTGGA TGTGAACGAC	120

- 55 -

AATGCCCTC A

131

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Lys	Pro	Phe	Asp	Phe	Glu	Asp	Thr	Lys	Leu	His	Glu	Ile	Tyr	Ile	Gln
1				5					10				15		

Ala	Lys	Asp	Lys	Gly	Ala	Asn	Pro	Glu	Gly	Ala	His	Cys	Lys	Val	Leu
	20						25				30				

Val	Glu	Val	Val	Asp	Val	Asn	Asp	Asn	Ala	Pro					
	35				40										

(2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 122 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

AAAGGTGTCG	ATTACGAGGT	GAGTCCACGG	CTGCGACTGG	TGCTGCAGGC	AGAGAGTCGA	60
------------	------------	------------	------------	------------	------------	----

GGAGCCTTG	CCTTCACTGT	GCTGACCCTG	ACCCCTGCAAG	ATGCCAACGA	CAACGCCCG	120
-----------	------------	------------	-------------	------------	-----------	-----

AG						122
----	--	--	--	--	--	-----

(2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Lys	Gly	Val	Asp	Tyr	Glu	Val	Ser	Pro	Arg	Leu	Arg	Leu	Val	Leu	Gln
1				5					10				15		

- 56 -

Ala Glu Ser Arg Gly Ala Phe Ala Phe Thr Val Leu Thr Leu
20 25 30

Gln Asp Ala Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

AAAGGGATTG ATTACGAGCA GTTGAGAGAC CTACAGCTGT GGGTGACAGC CAGCGACAGC	60
GGGGACCCGC CTCTTAGCAG CAACGTGTCA CTGAGCCTGT TTGTGCTGGA CCAGAACGAC	120
AACGCCCCCC T	131

(2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Lys Gly Ile Asp Tyr Glu Gln Leu Arg Asp Leu Gln Leu Trp Val Thr	
1 5 10 15	
Ala Ser Asp Ser Gly Asp Pro Pro Leu Ser Ser Asn Val Ser Leu Ser	
20 25 30	
Leu Phe Val Leu Asp Gln Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 125 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- 57 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

AAGGCGGTCTG ATTTGAGCG CACATCCTCT TATCAACTCA TCATTCAAGGC CACCAATATG	60
GCAGGAATGG CTTCCAATGC TACAGTCAAT ATTCAAGATTG TTGATGAAAA CGACAACGCC	120
CCCCA	125

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Lys Ala Val Asp Phe Glu Arg Thr Ser Ser Tyr Gln Leu Ile Ile Gln													
1	5	10	15	Ala Thr Asn Met Ala Gly Met Ala Ser Asn Ala Thr Val Asn Ile Gln		20	25	30		Ile Val Asp Glu Asn Asp Asn Ala Pro		35	40
10	15												
Ala Thr Asn Met Ala Gly Met Ala Ser Asn Ala Thr Val Asn Ile Gln													
20	25	30		Ile Val Asp Glu Asn Asp Asn Ala Pro		35	40						
30													
Ile Val Asp Glu Asn Asp Asn Ala Pro													
35	40												

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

AAACGGCTAG ACTTGAAAAA GATACAAAAA TATGTTGTAT GGATAGAGGC CAGAGATGGT	60
GGTTTCCCTC CTTTCTCCTC TTACGAGAAA CTTGATATAA CAGTATTAGA TGTCAACGAT	120
AACGCGCCTA A	131

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 58 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Lys Arg Leu Asp Phe Glu Lys Ile Gln Lys Tyr Val Val Trp Ile Glu
1 5 10 15

Ala Arg Asp Gly Gly Phe Pro Pro Phe Ser Ser Tyr Glu Lys Leu Asp
20 25 30

Ile Thr Val Leu Asp Val Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

AAGGGGATCG ATTATGAGAA GGTCAAAGAC TACACCATTG AGATTGTGGC TGTGGACTCT 60
GGCAACCCCC CACTCTCCAG CACTAACTCC CTCAAGGTGC AGGTGGTGGA CGTCAATGAC 120
AACGCACCGT G 131

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Lys Gly Ile Asp Tyr Glu Lys Val Lys Asp Tyr Thr Ile Glu Ile Val
1 5 10 15

Ala Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys
20 25 30

Val Gln Val Val Asp Val Asn Asp Asn Ala Pro
35 40

- 59 -

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

AAGGGACTCG ACTACGAGGA TCGGCAGGAA TTTGAATTAA CAGCTCATAT CAGCGATGGG	60
GGCACCCCGG TCCTAGCCAC CAACATCAGC GTGAACATAT TTGTCACTGA TCGAACGAT	120
AATGCCCGG T	131

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Lys Gly Leu Asp Tyr Glu Asp Arg Arg Glu Phe Glu Leu Thr Ala His	
1 5 10 15	
Ile Ser Asp Gly Gly Thr Pro Val Leu Ala Thr Asn Ile Ser Val Asn	
20 25 30	
Ile Phe Val Thr Asp Arg Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 470 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

AAGGGTTTGG ACTACGAGAC CACACAGGCC TACCAAGCTCA CGGTCAACGC CACAGATCAA	60
GACAACACCA GGCCTCTGTC CACCCTGGCC AACTTGGCCA TCATCATCAC AGATGTCCAG	120

- 60 -

GACATGGACC CCATCTTCAT CAACCTGCCT TACAGCACCA ACATCTACGA GCATTCTCCT	180
CCGGGCACGA CGGTGCGCAT CATCACCGCC ATAGACCAGG ATCAAGGACG TCCCCGGGGC	240
ATTGGCTACA CCATCGTTTC AGGGAATACC AACAGCATCT TTGCCCTGGA CTACATCAGC	300
GGAGTGCTGA CCTTGAATGG CCTGCTGGAC CGGGAGAACCC CCGTGTACAG CCATGGCTTC	360
ATCCTGACTG TGAAGGGCAC GGAGCTGAAC GATGACCGCA CCCCATCTGA CGCTACAGTC	420
ACCACGACCT TCAATATCCT GGTTATTGAC ATCAACGACA ACGCCCCACT	470

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 156 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Lys Gly Leu Asp Tyr Glu Thr Thr Gln Ala Tyr Gln Leu Thr Val Asn																																																									
1	5	10	15	Ala Thr Asp Gln Asp Asn Thr Arg Pro Leu Ser Thr Leu Ala Asn Leu		20	25	30		Ala Ile Ile Ile Thr Asp Val Gln Asp Met Asp Pro Ile Phe Ile Asn		35	40	45		Leu Pro Tyr Ser Thr Asn Ile Tyr Glu His Ser Pro Pro Gly Thr Thr		50	55	60		Val Arg Ile Ile Thr Ala Ile Asp Gln Asp Gln Gly Arg Pro Arg Gly		65	70	75	80	Ile Gly Tyr Thr Ile Val Ser Gly Asn Thr Asn Ser Ile Phe Ala Leu		85	90	95		Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu		100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155	
10	15																																																								
Ala Thr Asp Gln Asp Asn Thr Arg Pro Leu Ser Thr Leu Ala Asn Leu																																																									
20	25	30		Ala Ile Ile Ile Thr Asp Val Gln Asp Met Asp Pro Ile Phe Ile Asn		35	40	45		Leu Pro Tyr Ser Thr Asn Ile Tyr Glu His Ser Pro Pro Gly Thr Thr		50	55	60		Val Arg Ile Ile Thr Ala Ile Asp Gln Asp Gln Gly Arg Pro Arg Gly		65	70	75	80	Ile Gly Tyr Thr Ile Val Ser Gly Asn Thr Asn Ser Ile Phe Ala Leu		85	90	95		Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu		100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155							
30																																																									
Ala Ile Ile Ile Thr Asp Val Gln Asp Met Asp Pro Ile Phe Ile Asn																																																									
35	40	45		Leu Pro Tyr Ser Thr Asn Ile Tyr Glu His Ser Pro Pro Gly Thr Thr		50	55	60		Val Arg Ile Ile Thr Ala Ile Asp Gln Asp Gln Gly Arg Pro Arg Gly		65	70	75	80	Ile Gly Tyr Thr Ile Val Ser Gly Asn Thr Asn Ser Ile Phe Ala Leu		85	90	95		Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu		100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155													
45																																																									
Leu Pro Tyr Ser Thr Asn Ile Tyr Glu His Ser Pro Pro Gly Thr Thr																																																									
50	55	60		Val Arg Ile Ile Thr Ala Ile Asp Gln Asp Gln Gly Arg Pro Arg Gly		65	70	75	80	Ile Gly Tyr Thr Ile Val Ser Gly Asn Thr Asn Ser Ile Phe Ala Leu		85	90	95		Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu		100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155																			
60																																																									
Val Arg Ile Ile Thr Ala Ile Asp Gln Asp Gln Gly Arg Pro Arg Gly																																																									
65	70	75	80	Ile Gly Tyr Thr Ile Val Ser Gly Asn Thr Asn Ser Ile Phe Ala Leu		85	90	95		Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu		100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155																									
75	80																																																								
Ile Gly Tyr Thr Ile Val Ser Gly Asn Thr Asn Ser Ile Phe Ala Leu																																																									
85	90	95		Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu		100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155																															
95																																																									
Asp Tyr Ile Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu																																																									
100	105	110		Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu		115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155																																					
110																																																									
Asn Pro Leu Tyr Ser Gly Gly Phe Ile Leu Thr Val Lys Gly Thr Glu																																																									
115	120	125		Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe		130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155																																											
125																																																									
Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Phe																																																									
130	135	140		Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro		145	150	155																																																	
140																																																									
Asn Ile Leu Val Ile Asp Ile Asn Asp Asn Ala Pro																																																									
145	150	155																																																							
155																																																									

- 61 -

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

AAGGGGGTCT ATTACGAGGT ACTACAGGCC TTTGAGTTCC ACGTGAGCGC CACAGACCGA	60
GGCTCACCGG GGCTCAGCAG CCAGGCTCTG GTGCCGCTGG TGGTGCTGGA CGACAATGAC	120
AACGCTCCCG T	131

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Lys Gly Val Asp Tyr Glu Val Leu Gln Ala Phe Glu Phe His Val Ser	
1 5 10 15	
Ala Thr Asp Arg Gly Ser Pro Gly Leu Ser Ser Gln Ala Leu Val Arg	
20 25 30	
Val Val Val Leu Asp Asp Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

AAGGGGCTGG ATTATGAGCA GTTCCAGACC CTACAACCTGG GAGTGACCGC TAGTGACAGT	60
GGAAACCCAC CATTAAGAAG CAATATTCA CTGACCCCTT TCGTGCTGGA CCAGAATGAT	120

- 62 -

AACGCCCCAA A

131

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Lys	Gly	Leu	Asp	Tyr	Glu	Gln	Phe	Gln	Thr	Leu	Gln	Leu	Gly	Val	Thr
1				5					10				15		
Ala	Ser	Asp	Ser	Gly	Asn	Pro	Pro	Leu	Arg	Ser	Asn	Ile	Ser	Leu	Thr
						20			25				30		
Leu	Phe	Val	Leu	Asp	Gln	Asn	Asp	Asn	Ala	Pro					
						35			40						

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

AAGCGGGTTG ATTACGAGGA TGTCCAGAAA TACTCGCTGA GCATTAAGGC CCAGGATGGG	60
CGGCCCGCCGC TCATCAATTTC TTCAGGGGTG GTGTCTGTGC AGGTGCTGGA TGTCAACGAC	120
AATGCCCGG A	131

(2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Lys	Arg	Val	Asp	Tyr	Glu	Asp	Val	Gln	Lys	Tyr	Ser	Leu	Ser	Ile	Lys
1				5					10				15		

- 63 -

Ala Gln Asp Gly Arg Pro Pro Leu Ile Asn Ser Ser Gly Val Val Ser
20 25 30

Val Gln Val Leu Asp Val Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 125 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

AAACCGGTAG ACTTTGAGCT ACAGCAGTTC TATGAAGTAG CTGTGGTGGC TTGGAACTCT 60
GAGGGATTTC ATGTCAAAAG GGTCATTAAA GTGCAACTTT TAGATGACAA CGACAATGCC 120
CCGAT 125

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Lys Pro Val Asp Phe Glu Leu Gln Gln Phe Tyr Glu Val Ala Val Val
1 5 10 15
Ala Trp Asn Ser Glu Gly Phe His Val Lys Arg Val Ile Lys Val Gln
20 25 30
Leu Leu Asp Asp Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 125 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 64 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

AAGGGATTAG ATTTGAAAC TTTGCCATT TACACATTGA TAATACAAGG AACTAACATG	60
GCTGGTTTGT CCACTAATAC AACGGTTCTA GTTCACTTGC AGGATGAGAA TGATAACGCC	120
CCAAA	125

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Lys Gly Leu Asp Phe Glu Thr Leu Pro Ile Tyr Thr Leu Ile Ile Gln			
1	5	10	15
Gly Thr Asn Met Ala Gly Leu Ser Thr Asn Thr Thr Val Leu Val His			
20	25	30	
Leu Gln Asp Glu Asn Asp Asn Ala Pro			
35	40		

(2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 134 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

AAGCGGGCGG ATTCGAGGC GATCCGGGAG TACAGTCTGA GGATCAAAGC GCAGGACGGG	60
GGGCGGGCCTC CCCTCAGCAA CACCACGGGC ATGGTCACAG TGCAGGTCGT GGACGTCAAT	120
GACAACGCCAC CCCT	134

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 65 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Lys Arg Ala Asp Phe Glu Ala Ile Arg Glu Tyr Ser Leu Arg Ile Lys
1 5 10 15
Ala Gln Asp Gly Gly Arg Pro Pro Leu Ser Asn Thr Thr Gly Met Val
20 25 30
Thr Val Gln Val Val Asp Val Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 131 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

AAGCGGTTGG ATTACGAAAA GGCATCGGAA TATGAAATCT ATGTTCAAGC CGCTGACAAA 60
GGCGCTGTCC CTATGGCTGG CCATTGCAAA GTGTTGCTGG AGATCGTGGAG TGTCAACGAC 120
AACGCCCCCT T 131

(2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Lys Arg Leu Asp Tyr Glu Lys Ala Ser Glu Tyr Glu Ile Tyr Val Gln
1 5 10 15
Ala Ala Asp Lys Gly Ala Val Pro Met Ala Gly His Cys Lys Val Leu
20 25 30
Leu Glu Ile Val Asp Val Asn Asp Asn Ala Pro
35 40

- 66 -

(2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

AAGGGGATCG ATTATGAGGA TCAGGTCTCT TACACATTAG CAGTAACAGC ACATGACTAT	60
GGCATCCCTC AAAAATCAGA CACTACCTAT TTGGAAATCT TAGTAATTGA TGTTAACGAC	120
AACGCGCCCC A	131

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Lys Gly Ile Asp Tyr Glu Asp Gln Val Ser Tyr Thr Leu Ala Val Thr	
1 5 10 15	
Ala His Asp Tyr Gly Ile Pro Gln Lys Ser Asp Thr Thr Tyr Leu Glu	
20 25 30	
Ile Leu Val Ile Asp Val Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

AAAGGGTTAG ATTCGAGGG CACTAAAGAT TCAGCGTTA AAATAGTGGC AGCTGACACA	60
GGGAAGCCCA GCCTCAACCA GACAGCCCTG GTGAGAGTAG AGCTGGAGGA TGAGAACGAC	120

- 67 -

AACGCCCAA T

131

(2) INFORMATION FOR SEQ ID NO:85:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Lys	Gly	Leu	Asp	Phe	Glu	Gly	Thr	Lys	Asp	Ser	Ala	Phe	Lys	Ile	Val
1				5				10					15		

Ala	Ala	Asp	Thr	Gly	Lys	Pro	Ser	Leu	Asn	Gln	Thr	Ala	Leu	Val	Arg
				20				25				30			

Val	Glu	Leu	Glu	Asp	Glu	Asn	Asp	Asn	Ala	Pro					
	35				40										

(2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 130 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

AAGGGTGTGG	ATTTGAAAG	TGTGCGTAGC	TACAGGCTGG	TTATTCGTGC	TCAAGATGGA	60
------------	-----------	------------	------------	------------	------------	----

GGCAGCCCT	CCAGAACGAA	CACCACCCAG	CTCTGGTCA	ACGTCATCGA	TCGAATGACA	120
-----------	------------	------------	-----------	------------	------------	-----

ATGCGCCGCT						130
------------	--	--	--	--	--	-----

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Lys	Gly	Val	Asp	Phe	Glu	Ser	Val	Arg	Ser	Tyr	Arg	Leu	Val	Ile	Arg
1				5				10				15			

- 68 -

Ala Gln Asp Gly Gly Ser Pro Ser Arg Ser Asn Thr Thr Gln Leu Leu
20 25 30

Val Asn Val Ile Asp Val Asn Asp Asn Ala Pro
35 40

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

AAGGGTGTGG ACTTCGAGCT GACACATCTG TATGAGATTT GGATTGAGGC TGCCGATGGA	60
GACACGCCAA GTCTGCGTAG TGTAACTCTT ATAACGCTCA ACGTAACGGA TGCCAATGAC	120
AATGCTCCC A	131

(2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Lys Gly Val Asp Phe Glu Leu Thr His Leu Tyr Glu Ile Trp Ile Glu	
1 5 10 15	
Ala Ala Asp Gly Asp Thr Pro Ser Leu Arg Ser Val Thr Leu Ile Thr	
20 25 30	
Leu Asn Val Thr Asp Ala Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 441 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 69 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

CAAGGCGTTT GATTTGAAG AGACAAGTAG ATATGTGTTG AGTGTGGAAG CTAAGGATGG	60
AGGAGTACAC ACAGCTCACT GTAATGTTCA AATAGAAATT GTTGACGAGA ATGACAATGC	120
CCCAGAGGTG ACATTCATGT CCTTCTCTAA CCAGATTCCA GAGGATTCA GAGGATTCA ACCTTGGAAC	180
TGTAATAGCC CTCATAAAAAG TCGGAGACAA GGATTCTGGG CAAAATGGCA TGGTGACATG	240
CTATACTCAG GAAGAAGTTC CTTTCAAATT AGAATCCACC TCGAAGAATT ATTACAAGCT	300
GGTGATTGCT GGAGCCCTAA ACCGGGAGCA GACAGCAGAC TACAACGTCA CAATCATAGC	360
CACCGACAAG GGCAAACCAAG CCCTTCCTC CAGGACAAGC ATCACCCCTGC ACATCTCCGA	420
CATCAACGAT AATGCCCG T	441

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 146 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Lys Ala Phe Asp Phe Glu Glu Thr Ser Arg Tyr Val Leu Ser Val Glu			
1	5	10	15
Ala Lys Asp Gly Gly Val His Thr Ala His Cys Asn Val Gln Ile Glu			
20	25	30	
Ile Val Asp Glu Asn Asp Asn Ala Pro Glu Val Thr Phe Met Ser Phe			
35	40	45	
Ser Asn Gln Ile Pro Glu Asp Ser Asp Leu Gly Thr Val Ile Ala Leu			
50	55	60	
Ile Lys Val Arg Asp Lys Asp Ser Gly Gln Asn Gly Met Val Thr Cys			
65	70	75	80
Tyr Thr Gln Glu Val Pro Phe Lys Leu Glu Ser Thr Ser Lys Asn			
85	90	95	
Tyr Tyr Lys Leu Val Ile Ala Gly Ala Leu Asn Arg Glu Gln Thr Ala			
100	105	110	
Asp Tyr Asn Val Thr Ile Ile Ala Thr Asp Lys Gly Lys Pro Ala Leu			
115	120	125	
Ser Ser Arg Thr Ser Ile Thr Leu His Ile Ser Asp Ile Asn Asp Asn			
130	135	140	
Ala Pro			
145			

- 70 -

(2) INFORMATION FOR SEQ ID NO:92:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

AAGCGAGTGG ATTACGAGGC CACTCGGAAT TATAAGCTGA GAGTTAAGGC TACTGATCTT	60
GGGATTCCAC CGAGATCTTC TAACATGACA CTGTCATTGATGTTAACGAC	120
AACGCTCCCT T	131

(2) INFORMATION FOR SEQ ID NO:93:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Lys Arg Val Asp Tyr Glu Ala Thr Arg Asn Tyr Lys Leu Arg Val Lys	
1 5 10 15	
Ala Thr Asp Leu Gly Ile Pro Pro Arg Ser Ser Asn Met Thr Leu Phe	
20 25 30	
Ile His Val Leu Asp Val Asn Asp Asn Ala Pro	
35 40	

(2) INFORMATION FOR SEQ ID NO:94:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4104 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 495..3572

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

- 71 -

CCTCTATTCTG ACATTCTCTT TGGATTGTT TGCTATAACT TGAAATTTGG GATGTCACAA	60
ACGAAACTGT CATCTGTTTC CGCCAAACTG TGGTTCTGCT AATCTCCCAG GCTGGCAGCA	120
TTGGAGACTT GCTGACTTCT TTCATCCCCC ACTCTTTCA CCTGAAATTC CTTTCCTTGG	180
TTTGCTCTA AGTCCTATGC TTCAGTCAGG GGCCAACCAA ATCTCACTGC CTCCTTTTA	240
TCATGAAGCC TTTGATCACT GATAGTTCTT TTTATATCTT GAAAAATCAC CCTTCCCAGT	300
ACAGTTAATA TTTAGTATCT CTACTCATCT TGGCACTTAC TCACAGCTCC ATAATTCACT	360
CGTTTCGTA CCTCTTCATG GTGATGGGGA GCCCTTGGA GGTGGTACT GTGCTTTATA	420
CTCCTCATGA TGCTTCACAT GTGGCAGGCG TGGAGTGCC GGAGGCGGCC CTCCTGATTC	480
TGGGGCCTCC CAGG ATG GAG CCC CTG AGG CAC AGC CCA GGC CCT GGG GGG	530
Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly	
1 5 10	
CAA CGG CTA CTG CTG CCC TCC ATG CTG CTA GCA CTG CTG CTC CTG CTG	578
Gln Arg Leu Leu Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu	
15 20 25	
GCT CCA TCC CCA GGC CAC GCC ACT CGG GTA GTG TAC AAG GTG CCG GAG	626
Ala Pro Ser Pro Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu	
30 35 40	
GAA CAG CCA CCC AAC ACC CTC ATT GGG AGC CTC GCA GCC GAC TAT GGT	674
Glu Gln Pro Pro Asn Thr Leu Ile Gly Ser Leu Ala Ala Asp Tyr Gly	
45 50 55 60	
TTT CCA GAT GTG GGG CAC CTG TAC AAG CTA GAG GTG GGT GCC CCG TAC	722
Phe Pro Asp Val Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr	
65 70 75	
CTT CGC GTG GAT GGC AAG ACA GGT GAC ATT TTC ACC ACC GAG ACC TCC	770
Leu Arg Val Asp Gly Lys Thr Gly Asp Ile Phe Thr Thr Glu Thr Ser	
80 85 90	
ATC GAC CGT GAG GGG CTC CGT GAA TGC CAG AAC CAG CTC CCT GGT GAT	818
Ile Asp Arg Glu Gly Leu Arg Glu Cys Gln Asn Gln Leu Pro Gly Asp	
95 100 105	
CCC TGC ATC CTG GAG TTT GAG GTA TCT ATC ACA GAC CTC GTG CAG AAT	866
Pro Cys Ile Leu Glu Phe Glu Val Ser Ile Thr Asp Leu Val Gln Asn	
110 115 120	
GCG AGC CCC CGG CTG CTA GAG GGC CAG ATA GAA GTA CAA GAC ATC AAT	914
Ala Ser Pro Arg Leu Leu Glu Gly Gln Ile Glu Val Gln Asp Ile Asn	
125 130 135 140	
GAC AAC ACA CCC AAC TTC GCC TCA CCA GTC ATC ACT CTG GCC ATC CCT	962
Asp Asn Thr Pro Asn Phe Ala Ser Pro Val Ile Thr Leu Ala Ile Pro	
145 150 155	
GAG AAC ACC AAC ATC GGC TCA CTC TTC CCC ATC CCG CTG GCT TCA GAC	1010
Glu Asn Thr Asn Ile Gly Ser Leu Phe Pro Ile Pro Leu Ala Ser Asp	
160 165 170	

- 72 -

CGT GAT GCT GGT CCC AAC GGT GTG GCA TCC TAT GAG CTG CAG GTG GCA Arg Asp Ala Gly Pro Asn Gly Val Ala Ser Tyr Glu Leu Gln Val Ala 175 180 185	1058
GAG GAC CAG GAG GAG AAG CAA CCA CAG CTC ATT GTG ATG GGC AAC CTG Glu Asp Gln Glu Glu Lys Gln Pro Gln Leu Ile Val Met Gly Asn Leu 190 195 200	1106
GAC CGT GAG CGC TGG GAC TCC TAT GAC CTC ACC ATC AAG GTG CAG GAT Asp Arg Glu Arg Trp Asp Ser Tyr Asp Leu Thr Ile Lys Val Gln Asp 205 210 215 220	1154
GGC GGC AGC CCC CCA CGC GCC ACG AGT GCC CTG CTG CGT GTC ACC GTG Gly Gly Ser Pro Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val 225 230 235	1202
CTT GAC ACC AAT GAC AAC GCC CCC AAG TTT GAG CGG CCC TCC TAT GAG Leu Asp Thr Asn Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu 240 245 250	1250
GCC GAA CTA TCT GAG AAT AGC CCC ATA GGC CAC TCG GTC ATC CAG GTG Ala Glu Leu Ser Glu Asn Ser Pro Ile Gly His Ser Val Ile Gln Val 255 260 265	1298
AAG GCC AAT GAC TCA GAC CAA GGT GCC AAT GCA GAA ATC GAA TAC ACA Lys Ala Asn Asp Ser Asp Gln Gly Ala Asn Ala Glu Ile Glu Tyr Thr 270 275 280	1346
TTC CAC CAG GCG CCC GAA GTT GTG AGG CGT CTT CTT CGA CTG GAC AGG Phe His Gln Ala Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg 285 290 295 300	1394
AAC ACT GGA CTT ATC ACT GTT CAG GGC CCG GTG GAC CGT GAG GAC CTA Asn Thr Gly Leu Ile Thr Val Gln Gly Pro Val Asp Arg Glu Asp Leu 305 310 315	1442
AGC ACC CTG CGC TTC TCA GTG CTT GCT AAG GAC CGA GGC ACC AAC CCC Ser Thr Leu Arg Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro 320 325 330	1490
AAG AGT GCC CGT GCC CAG GTG GTT GTG ACC GTG AAG GAC ATG AAT GAC Lys Ser Ala Arg Ala Gln Val Val Val Thr Val Lys Asp Met Asn Asp 335 340 345	1538
AAT GCC CCC ACC ATT GAG ATC CGG GGC ATA GGG CTA GTG ACT CAT CAA Asn Ala Pro Thr Ile Glu Ile Arg Gly Ile Gly Leu Val Thr His Gln 350 355 360	1586
GAT GGG ATG GCT AAC ATC TCA GAG GAT GTG GCA GAG GAG ACA GCT GTG Asp Gly Met Ala Asn Ile Ser Glu Asp Val Ala Glu Glu Thr Ala Val 365 370 375 380	1634
GCC CTG GTG CAG GTG TCT GAC CGA GAT GAG GGA GAG AAT GCA GCT GTC Ala Leu Val Gln Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val 385 390 395	1682
ACC TGT GTG GTG GCA GGT GAT GTG CCC TTC CAG CTG CGC CAG GCC AGT Thr Cys Val Val Ala Gly Asp Val Pro Phe Gln Leu Arg Gln Ala Ser 400 405 410	1730

- 73 -

GAG ACA GGC AGT GAC AGC AAG AAG AAG TAT TTC CTG CAG ACT ACC ACC Glu Thr Gly Ser Asp Ser Lys Lys Lys Tyr Phe Leu Gln Thr Thr Thr 415 420 425	1778
CCG CTA GAC TAC GAG AAG GTC AAA GAC TAC ACC ATT GAG ATT GTG GCT Pro Leu Asp Tyr Glu Lys Val Lys Asp Tyr Thr Ile Glu Ile Val Ala 430 435 440	1826
GTG GAC TCT GGC AAC CCC CCA CTC TCC AGC ACT AAC TCC CTC AAG GTG Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val 445 450 455 460	1874
CAG GTG GTG GAC GTC AAT GAC AAC GCA CCT GTC TTC ACT CAG AGT GTC Gln Val Val Asp Val Asn Asp Asn Ala Pro Val Phe Thr Gln Ser Val 465 470 475	1922
ACT GAG GTC GCC TTC CCG GAA AAC AAC AAG CCT GGT GAA GTG ATT GCT Thr Glu Val Ala Phe Pro Glu Asn Asn Lys Pro Gly Glu Val Ile Ala 480 485 490	1970
GAG ATC ACT GCC AGT GAT GCT GAC TCT GGC TCT AAT GCT GAG CTG GTT Glu Ile Thr Ala Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val 495 500 505	2018
TAC TCT CTG GAG CCT GAG CCG GCT GCT AAG GGC CTC TTC ACC ATC TCA Tyr Ser Leu Glu Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr Ile Ser 510 515 520	2066
CCC GAG ACT GGA GAG ATC CAG GTG AAG ACA TCT CTG GAT CGG GAA CAG Pro Glu Thr Gly Glu Ile Gln Val Lys Thr Ser Leu Asp Arg Glu Gln 525 530 535 540	2114
CGG GAG AGC TAT GAG TTG AAG GTG GTG GCA GCT GAC CGG GGC AGT CCT Arg Glu Ser Tyr Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro 545 550 555	2162
AGC CTC CAG GGC ACA GCC ACT GTC CTT GTC AAT GTG CTG GAC TGC AAT Ser Leu Gln Gly Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn 560 565 570	2210
GAC AAT GAC CCC AAA TTT ATG CTG AGT GGC TAC AAC TTC TCA GTG ATG Asp Asn Asp Pro Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met 575 580 585	2258
GAG AAC ATG CCA GCA CTG AGT CCA GTG GGC ATG GTG ACT GTC ATT GAT Glu Asn Met Pro Ala Leu Ser Pro Val Gly Met Val Thr Val Ile Asp 590 595 600	2306
GGA GAC AAG GGG GAG AAT GCC CAG GTG CAG CTC TCA GTG GAG CAG GAC Gly Asp Lys Gly Glu Asn Ala Gln Val Gln Leu Ser Val Glu Gln Asp 605 610 615 620	2354
AAC GGT GAC TTT GTT ATC CAG AAT GGC ACA GGC ACC ATC CTA TCC AGC Asn Gly Asp Phe Val Ile Gln Asn Gly Thr Gly Thr Ile Leu Ser Ser 625 630 635	2402
CTG AGC TTT GAT CGA GAG CAA CAA AGC ACC TAC ACC TTC CAG CTG AAG Leu Ser Phe Asp Arg Glu Gln Gln Ser Thr Tyr Thr Phe Gln Leu Lys 640 645 650	2450

- 74 -

GCA GTG GAT GGT GGC GTC CCA CCT CGC TCA GCT TAC GTT GGT GTC ACC Ala Val Asp Gly Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr 655 660 665	2498
ATC AAT GTG CTG GAC GAG AAT GAC AAC GCA CCC TAT ATC ACT GCC CCT Ile Asn Val Leu Asp Glu Asn Asn Ala Pro Tyr Ile Thr Ala Pro 670 675 680	2546
TCT AAC ACC TCT CAC AAG CTG CTG ACC CCC CAG ACA CGT CTT GGT GAG Ser Asn Thr Ser His Lys Leu Leu Thr Pro Gln Thr Arg Leu Gly Glu 685 690 695 700	2594
ACG GTC AGC CAG GTG GCA GCC GAG GAC TTT GAC TCT GGT GTC AAT GCC Thr Val Ser Gln Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala 705 710 715	2642
GAG CTG ATC TAC AGC ATT GCA GGT GGC AAC CCT TAT GGA CTC TTC CAG Glu Leu Ile Tyr Ser Ile Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gln 720 725 730	2690
ATT GGG TCA CAT TCA GGT GCC ATC ACC CTG GAG AAG GAG ATT GAG CGG Ile Gly Ser His Ser Gly Ala Ile Thr Leu Glu Lys Glu Ile Glu Arg 735 740 745	2738
CGC CAC CAT GGG CTA CAC CGC CTG GTG GTG AAG GTC AGT GAC CGC GGC Arg His His Gly Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly 750 755 760	2786
AAG CCC CCA CGC TAT GGC ACA GCC TTG GTC CAT CTT TAT GTC AAT GAG Lys Pro Pro Arg Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu 765 770 775 780	2834
ACT CTG GCC AAC CGC ACG CTG CTG GAG ACC CTC CTG GGC CAC AGC CTG Thr Leu Ala Asn Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu 785 790 795	2882
GAC ACG CCG CTG GAT ATT GAC ATT GCT GGG GAT CCA GAA TAT GAG CGC Asp Thr Pro Leu Asp Ile Ala Gly Asp Pro Glu Tyr Glu Arg 800 805 810	2930
TCC AAG CAG CGT GGC AAC ATT CTC TTT GGT GTG GTG GCT GGT GTG GTG Ser Lys Gln Arg Gly Asn Ile Leu Phe Gly Val Val Ala Gly Val Val 815 820 825	2978
GCC GTG GCC TTG CTC ATC GCC CTG GCG GTT CTT GTG CGC TAC TGC AGA Ala Val Ala Leu Leu Ile Ala Leu Ala Val Leu Val Arg Tyr Cys Arg 830 835 840	3026
CAG CGG GAG GCC AAA AGT GGT TAC CAG GCT GGT AAG AAG GAG ACC AAG Gln Arg Glu Ala Lys Ser Gly Tyr Gln Ala Gly Lys Lys Glu Thr Lys 845 850 855 860	3074
GAC CTG TAT GCC CCC AAG CCC AGT GGC AAG GCC TCC AAG GGA AAC AAA Asp Leu Tyr Ala Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys 865 870 875	3122
AGC AAA GGC AAG AAG AGC AAG TCC CCA AAG CCC GTG AAG CCA GTG GAG Ser Lys Gly Lys Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu 880 885 890	3170

- 75 -

GAC GAG GAT GAG GCC GGG CTG CAG AAG TCC CTC AAG TTC AAC CTG ATG Asp Glu Asp Glu Ala Gly Leu Gln Lys Ser Leu Lys Phe Asn Leu Met 895 900 905	3218
AGC GAT GCC CCT GGG GAC AGT CCC CGC ATC CAC CTG CCC CTC AAC TAC Ser Asp Ala Pro Gly Asp Ser Pro Arg Ile His Leu Pro Leu Asn Tyr 910 915 920	3266
CCA CCA GGC AGC CCT GAC CTG GGC CGC CAC TAT CGC TCT AAC TCC CCA Pro Pro Gly Ser Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro 925 930 935 940	3314
CTG CCT TCC ATC CAG CTG CAG CCC CAG TCA CCC TCA GCC TCC AAG AAG Leu Pro Ser Ile Gln Leu Gln Pro Gln Ser Pro Ser Ala Ser Lys Lys 945 950 955	3362
CAC CAG GTG GTA CAG GAC CTG CCA CCT GCA AAC ACA TTC GTG GGC ACC His Gln Val Val Gln Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr 960 965 970	3410
GGG GAC ACC ACG TCC ACG GGC TCT GAG CAG TAC TCC GAC TAC AGC TAC Gly Asp Thr Thr Ser Thr Gly Ser Glu Gln Tyr Ser Asp Tyr Ser Tyr 975 980 985	3458
CGC ACC AAC CCC CCC AAA TAC CCC AGC AAG CAG GTA GGC CAG CCC TTT Arg Thr Asn Pro Pro Lys Tyr Pro Ser Lys Gln Val Gly Gln Pro Phe 990 995 1000	3506
CAG CTC AGC ACA CCC CAG CCC CTA CCC CAC CCC TAC CAC GGA GCC ATC Gln Leu Ser Thr Pro Gln Pro Leu Pro His Pro Tyr His Gly Ala Ile 1005 1010 1015 1020	3554
TGG ACC GAG GTG TGG GAG TGATGGAGCA GGTTTACTGT GCCTGCCCGT Trp Thr Glu Val Trp Glu 1025	3602
GTTGGGGGCC AGCCTGAGCC AGCAGTGGGA GGTGGGGCCT TAGTGCTCA CCGGGCACAC	3662
GGATTAGGCT GAGTGAAGAT TAAGGGAGGG TGTGCTCTGT GGTCTCCTCC CTGCCCTCTC	3722
CCC ACTGGGG AGAGACCTGT GATTTGCCAA GTCCCTGGAC CCTGGACCAG CTACTGGGCC	3782
TTATGGGTTG GGGGTGGTAG GCAGGTGAGC GTAAGTGGGG AGGGAAATGG GTAAGAAGTC	3842
TACTCCAAAC CTAGGTCTCT ATGTCAGACC AGACCTAGGT GCTTCTCTAG GAGGGAAACA	3902
GGGAGACCTG GGGCCTGTG GATAACTGAG TGGGGAGTCT GCCAGGGAG GGCACCTTCC	3962
CATTGTGCCT TCTGTGTGTA TTGTGCATTA ACCTCTTCCT CACCACTAGG CTTCTGGGC	4022
TGGGTCCCCAC ATGCCCTTGA CCCTGACAAT AAAGTTCTCT ATTTTTGGAA AAAAAAAA	4082
AAAAAAAAA AAAAAAAA AA	4104

- 76 -

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1026 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly Gln Arg Leu Leu
1 5 10 15

Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Ala Pro Ser Pro
20 25 30

Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu Glu Gln Pro Pro
35 40 45

Asn Thr Leu Ile Gly Ser Leu Ala Ala Asp Tyr Gly Phe Pro Asp Val
50 55 60

Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr Leu Arg Val Asp
65 70 75 80

Gly Lys Thr Gly Asp Ile Phe Thr Thr Glu Thr Ser Ile Asp Arg Glu
85 90 95

Gly Leu Arg Glu Cys Gln Asn Gln Leu Pro Gly Asp Pro Cys Ile Leu
100 105 110

Glu Phe Glu Val Ser Ile Thr Asp Leu Val Gln Asn Ala Ser Pro Arg
115 120 125

Leu Leu Glu Gly Gln Ile Glu Val Gln Asp Ile Asn Asp Asn Thr Pro
130 135 140

Asn Phe Ala Ser Pro Val Ile Thr Leu Ala Ile Pro Glu Asn Thr Asn
145 150 155 160

Ile Gly Ser Leu Phe Pro Ile Pro Leu Ala Ser Asp Arg Asp Ala Gly
165 170 175

Pro Asn Gly Val Ala Ser Tyr Glu Leu Gln Val Ala Glu Asp Gln Glu
180 185 190

Glu Lys Gln Pro Gln Leu Ile Val Met Gly Asn Leu Asp Arg Glu Arg
195 200 205

Trp Asp Ser Tyr Asp Leu Thr Ile Lys Val Gln Asp Gly Gly Ser Pro
210 215 220

Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val Leu Asp Thr Asn
225 230 235 240

Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu Ala Glu Leu Ser
245 250 255

Glu Asn Ser Pro Ile Gly His Ser Val Ile Gln Val Lys Ala Asn Asp
260 265 270

- 77 -

Ser Asp Gln Gly Ala Asn Ala Glu Ile Glu Tyr Thr Phe His Gln Ala
275 280 285

Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg Asn Thr Gly Leu
290 295 300

Ile Thr Val Gln Gly Pro Val Asp Arg Glu Asp Leu Ser Thr Leu Arg
305 310 315 320

Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro Lys Ser Ala Arg
325 330 335

Ala Gln Val Val Val Thr Val Lys Asp Met Asn Asp Asn Ala Pro Thr
340 345 350

Ile Glu Ile Arg Gly Ile Gly Leu Val Thr His Gln Asp Gly Met Ala
355 360 365

Asn Ile Ser Glu Asp Val Ala Glu Glu Thr Ala Val Ala Leu Val Gln
370 375 380

Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val Thr Cys Val Val
385 390 395 400

Ala Gly Asp Val Pro Phe Gln Leu Arg Gln Ala Ser Glu Thr Gly Ser
405 410 415

Asp Ser Lys Lys Tyr Phe Leu Gln Thr Thr Pro Leu Asp Tyr
420 425 430

Glu Lys Val Lys Asp Tyr Thr Ile Glu Ile Val Ala Val Asp Ser Gly
435 440 445

Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val Gln Val Val Asp
450 455 460

Val Asn Asp Asn Ala Pro Val Phe Thr Gln Ser Val Thr Glu Val Ala
465 470 475 480

Phe Pro Glu Asn Asn Lys Pro Gly Glu Val Ile Ala Glu Ile Thr Ala
485 490 495

Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val Tyr Ser Leu Glu
500 505 510

Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr Ile Ser Pro Glu Thr Gly
515 520 525

Glu Ile Gln Val Lys Thr Ser Leu Asp Arg Glu Gln Arg Glu Ser Tyr
530 535 540

Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro Ser Leu Gln Gly
545 550 555 560

Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn Asp Asn Asp Pro
565 570 575

Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met Glu Asn Met Pro
580 585 590

- 78 -

Ala Leu Ser Pro Val Gly Met Val Thr Val Ile Asp Gly Asp Lys Gly
595 600 605

Glu Asn Ala Gln Val Gln Leu Ser Val Glu Gln Asp Asn Gly Asp Phe
610 615 620

Val Ile Gln Asn Gly Thr Gly Thr Ile Leu Ser Ser Leu Ser Phe Asp
625 630 635 640

Arg Glu Gln Gln Ser Thr Tyr Thr Phe Gln Leu Lys Ala Val Asp Gly
645 650 655

Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr Ile Asn Val Leu
660 665 670

Asp Glu Asn Asp Asn Ala Pro Tyr Ile Thr Ala Pro Ser Asn Thr Ser
675 680 685

His Lys Leu Leu Thr Pro Gln Thr Arg Leu Gly Glu Thr Val Ser Gln
690 695 700

Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala Glu Leu Ile Tyr
705 710 715 720

Ser Ile Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gln Ile Gly Ser His
725 730 735

Ser Gly Ala Ile Thr Leu Glu Lys Glu Ile Glu Arg Arg His His Gly
740 745 750

Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly Lys Pro Pro Arg
755 760 765

Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu Thr Leu Ala Asn
770 775 780

Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu Asp Thr Pro Leu
785 790 795 800

Asp Ile Asp Ile Ala Gly Asp Pro Glu Tyr Glu Arg Ser Lys Gln Arg
805 810 815

Gly Asn Ile Leu Phe Gly Val Val Ala Gly Val Val Ala Val Ala Leu
820 825 830

Leu Ile Ala Leu Ala Val Leu Val Arg Tyr Cys Arg Gln Arg Glu Ala
835 840 845

Lys Ser Gly Tyr Gln Ala Gly Lys Lys Glu Thr Lys Asp Leu Tyr Ala
850 855 860

Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys Ser Lys Gly Lys
865 870 875 880

Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu Asp Glu Asp Glu
885 890 895

Ala Gly Leu Gln Lys Ser Leu Lys Phe Asn Leu Met Ser Asp Ala Pro
900 905 910

- 79 -

Gly	Asp	Ser	Pro	Arg	Ile	His	Leu	Pro	Leu	Asn	Tyr	Pro	Pro	Gly	Ser
915							920					925			
Pro	Asp	Leu	Gly	Arg	His	Tyr	Arg	Ser	Asn	Ser	Pro	Leu	Pro	Ser	Ile
930							935					940			
Gln	Leu	Gln	Pro	Gln	Ser	Pro	Ser	Ala	Ser	Lys	Lys	His	Gln	Val	Val
945							950			955		960			
Gln	Asp	Leu	Pro	Pro	Ala	Asn	Thr	Phe	Val	Gly	Thr	Gly	Asp	Thr	Thr
							965		970			975			
Ser	Thr	Gly	Ser	Glu	Gln	Tyr	Ser	Asp	Tyr	Ser	Tyr	Arg	Thr	Asn	Pro
							980		985			990			
Pro	Lys	Tyr	Pro	Ser	Lys	Gln	Val	Gly	Gln	Pro	Phe	Gln	Leu	Ser	Thr
							995		1000			1005			
Pro	Gln	Pro	Leu	Pro	His	Pro	Tyr	His	Gly	Ala	Ile	Trp	Thr	Glu	Val
							1010		1015			1020			
Trp	Glu														
							1025								

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4705 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 115..2827

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

CGAAAGCCAT	GTCCGGACTCG	TCGCCCAGCG	CCCAAGCGCT	AACCCGCTGA	AAGTTTCTCA	60										
GCGAAATCTC	AGGGACGATC	TGGACCCCGC	TGAGAGGAAC	TGCTTTGAG	TGAG ATG	117										
					Met											
					1											
GTC	CCA	GAG	GCC	TGG	AGG	AGC	GGA	CTG	GTA	AGC	ACC	GGG	AGG	GTA	GTG	165
Val	Pro	Glu	Ala	Trp	Arg	Ser	Gly	Leu	Val	Ser	Thr	Gly	Arg	Val	Val	
								5		10			15			
GGA	GTT	TTG	CTT	CTG	CTT	GGT	GCC	TTG	AAC	AAG	GCT	TCC	ACG	GTC	ATT	213
Gly	Val	Leu	Leu	Leu	Gly	Ala	Leu	Asn	Lys	Ala	Ser	Thr	Val	Ile		
								20		25			30			
CAC	TAT	GAG	ATC	CCG	GAG	GAA	AGA	GAG	AAG	GGT	TTC	GCT	GTG	GGC	AAC	261
His	Tyr	Glu	Ile	Pro	Glu	Glu	Arg	Glu	Lys	Gly	Phe	Ala	Val	Gly	Asn	
									35		40			45		

- 80 -

GTG GTC GCG AAC CTT GGT TTG GAT CTC GGT AGC CTC TCA GCC CGC AGG Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg Arg 50 55 60 65	309
TTC CCG GTG GTG TCT GGA GCT AGC CGA AGA TTC TTT GAG GTG AAC CGG Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn Arg 70 75 80	357
GAG ACC GGA GAG ATG TTT GTG AAC GAC CGT CTG GAT CGA GAG GAG CTG Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu Leu 85 90 95	405
TGT GGG ACA CTG CCC TCT TGC ACT GTA ACT CTG GAG TTG GTA GTG GAG Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val Glu 100 105 110	453
AAC CCG CTG GAG CTG TTC AGC GTG GAA GTG GTG ATC CAG GAC ATC AAC Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val Ile Gln Asp Ile Asn 115 120 125	501
GAC AAC AAT CCT GCT TTC CCT ACC CAG GAA ATG AAA TTG GAG ATT AGC Asp Asn Asn Pro Ala Phe Pro Thr Gln Glu Met Lys Leu Glu Ile Ser 130 135 140 145	549
GAG GCC GTG GCT CCG GGG ACG CGC TTT CCG CTC GAG AGC GCG CAC GAT Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His Asp 150 155 160	597
CCC GAT CTG GGA AGC AAC TCT TTA CAA ACC TAT GAG CTG AGC CGA AAT Pro Asp Leu Gly Ser Asn Ser Leu Gln Thr Tyr Glu Leu Ser Arg Asn 165 170 175	645
GAA TAC TTT GCG CTT CGC GTG CAG ACG CGG GAG GAC AGC ACC AAG TAC Glu Tyr Phe Ala Leu Arg Val Gln Thr Arg Glu Asp Ser Thr Lys Tyr 180 185 190	693
GCG GAG CTG GTG TTG GAG CGC GCC CTG GAC CGA GAA CGG GAG CCT AGT Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro Ser 195 200 205	741
CTC CAG TTA GTG CTG ACG GCG TTG GAC GGA GGG ACC CCA GCT CTC TCC Leu Gln Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu Ser 210 215 220 225	789
GCC AGC CTG CCT ATT CAC ATC AAG GTG CTG GAC GCG AAT GAC AAT GCG Ala Ser Leu Pro Ile His Ile Lys Val Leu Asp Ala Asn Asp Asn Ala 230 235 240	837
CCT GTC TTC AAC CAG TCC TTG TAC CGG GCG CGC GTT CCT GGA GGA TGC Pro Val Phe Asn Gln Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly Cys 245 250 255	885
ACC TCC GGC ACG CGC GTG GTA CAA GTC CTT GCA ACG GAT CTG GAT GAA Thr Ser Gly Thr Arg Val Val Gln Val Leu Ala Thr Asp Leu Asp Glu 260 265 270	933
GGC CCC AAC GGT GAA ATT ATT TAC TCC TTC GGC AGC CAC AAC CGC GCC Gly Pro Asn Gly Glu Ile Ile Tyr Ser Phe Gly Ser His Asn Arg Ala 275 280 285	981

- 81 -

GGC GTG CGG CAA CTA TTC GCC TTA GAC CTT GTA ACC GGG ATG CTG ACA Gly Val Arg Gln Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu Thr 290 295 300 305	1029
ATC AAG GGT CGG CTG GAC TTC GAG GAC ACC AAA CTC CAT GAG ATT TAC Ile Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu Ile Tyr 310 315 320	1077
ATC CAG GCC AAA GAC AAG GGC GCC AAT CCC GAA GGA GCA CAT TGC AAA Ile Gln Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys 325 330 335	1125
GTC TTG GTG GAG GTT GTG GAT GTG AAT GAC AAC GCC CCG GAG ATC ACA Val Leu Val Val Asp Val Asn Asp Asn Ala Pro Glu Ile Thr 340 345 350	1173
GTC ACC TCC GTG TAC AGC CCA GTA CCC GAG GAT GCC TCT GGG ACT GTC Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr Val 355 360 365	1221
ATC GCT TTG CTC AGT GTG ACT GAC CTG GAT GCT GGC GAG AAC GGG CTG Ile Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly Leu 370 375 380 385	1269
GTC ACC TGC GAA GTT CCA CCG GGT CTC CCT TTC AGC CTT ACT TCT TCC Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser Ser 390 395 400	1317
CTC AAG AAT TAC TTC ACT TTG AAA ACC AGT GCA GAC CTG GAT CGG GAG Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg Glu 405 410 415	1365
ACT GTG CCA GAA TAC AAC CTC AGC ATC ACC GCC CGA GAC GCC GGA ACC Thr Val Pro Glu Tyr Asn Leu Ser Ile Thr Ala Arg Asp Ala Gly Thr 420 425 430	1413
CCT TCC CTC TCA GCC CTT ACA ATA GTG CGT GTT CAA GTG TCC GAC ATC Pro Ser Leu Ser Ala Leu Thr Ile Val Arg Val Gln Val Ser Asp Ile 435 440 445	1461
AAT GAC AAC CCT CCA CAA TCT TCT CAA TCT TCC TAC GAC GTT TAC ATT Asn Asp Asn Pro Pro Gln Ser Ser Gln Ser Tyr Asp Val Tyr Ile 450 455 460 465	1509
GAA GAA AAC AAC CTC CCC GGG GCT CCA ATA CTA AAC CTA AGT GTC TGG Glu Glu Asn Asn Leu Pro Gly Ala Pro Ile Leu Asn Leu Ser Val Trp 470 475 480	1557
GAC CCC GAC GCC CCG CAG AAT GCT CGG CTT TCT TTC TTT CTC TTG GAG Asp Pro Asp Ala Pro Gln Asn Ala Arg Leu Ser Phe Phe Leu Leu Glu 485 490 495	1605
CAA GGA GCT GAA ACC GGG CTA GTG GGT CGC TAT TTC ACA ATA AAT CGT Gln Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr Ile Asn Arg 500 505 510	1653
GAC AAT GGC ATA GTG TCA TCC TTA GTG CCC CTA GAC TAT GAG GAT CGG Asp Asn Gly Ile Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp Arg 515 520 525	1701

- 82 -

CGG GAA TTT GAA TTA ACA GCT CAT ATC AGC GAT GGG GGC ACC CCG GTC Arg Glu Phe Glu Leu Thr Ala His Ile Ser Asp Gly Gly Thr Pro Val 530 535 540 545	1749
CTA GCC ACC AAC ATC AGC GTG AAC ATA TTT GTC ACT GAT CGC AAT GAC Leu Ala Thr Asn Ile Ser Val Asn Ile Phe Val Thr Asp Arg Asn Asp 550 555 560	1797
AAT GCC CCC CAG GTC CTA TAT CCT CGG CCA GGT GGG AGC TCG GTG GAG Asn Ala Pro Gln Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val Glu 565 570 575	1845
ATG CTG CCT CGA GGT ACC TCA GCT GGC CAC CTA GTG TCA CGG GTG GTA Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val Val 580 585 590	1893
GCG TGG GAC GCG GAT GCA GGG CAC AAT GCC TGG CTC TCC TAC AGT CTC Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser Leu 595 600 605	1941
TTT GGA TCC CCT AAC CAG AGC CTT TTT GCC ATA GGG CTG CAC ACT GGT Phe Gly Ser Pro Asn Gln Ser Leu Phe Ala Ile Gly Leu His Thr Gly 610 615 620 625	1989
CAA ATC AGT ACT GCC CGT CCA GTC CAA GAC ACA GAT TCA CCC AGG CAG Gln Ile Ser Thr Ala Arg Pro Val Gln Asp Thr Asp Ser Pro Arg Gln 630 635 640	2037
ACT CTC ACT GTC TTG ATC AAA GAC AAT GGG GAG CCT TCG CTC TCC ACC Thr Leu Thr Val Leu Ile Lys Asp Asn Gly Glu Pro Ser Leu Ser Thr 645 650 655	2085
ACT GCT ACC CTC ACT GTG TCA GTA ACC GAG GAC TCT CCT GAA GCC CGA Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala Arg 660 665 670	2133
GCC GAG TTC CCC TCT GGC TCT GCC CCC CGG GAG CAG AAA AAA AAT CTC Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gln Lys Lys Asn Leu 675 680 685	2181
ACC TTT TAT CTA CTT CTT TCT CTA ATC CTG GTT TCT GTG GGC TTC GTG Thr Phe Tyr Leu Leu Ser Leu Ile Leu Val Ser Val Gly Phe Val 690 695 700 705	2229
GTC ACA GTG TTC GGA GTA ATC ATA TTC AAA GTT TAC AAG TGG AAG CAG Val Thr Val Phe Gly Val Ile Ile Phe Lys Val Tyr Lys Trp Lys Gln 710 715 720	2277
TCT AGA GAC CTA TAC CGA GCC CCG GTG AGC TCA CTG TAC CGA ACA CCA Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr Pro 725 730 735	2325
GGG CCC TCC TTG CAC GCG GAC GCC GTG CGG GGA GGC CTG ATG TCG CCG Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser Pro 740 745 750	2373
CAC CTT TAC CAT CAG GTG TAT CTC ACC ACG GAC TCC CGC CGC AGC GAC His Leu Tyr His Gln Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser Asp 755 760 765	2421

- 83 -

CCG CTG CTG AAG AAA CCT GGT GCA GCC AGT CCA CTG GCC AGC CGC CAG Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg Gln 770 775 780 785	2469
AAC ACG CTG CGG AGC TGT GAT CCG GTG TTC TAT AGG CAG GTG TTG GGT Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gln Val Leu Gly 790 795 800	2517
GCA GAG AGC GCC CCT CCC GGA CAG CAA GCC CCG CCC AAC ACG GAC TGG Ala Glu Ser Ala Pro Pro Gly Gln Gln Ala Pro Pro Asn Thr Asp Trp 805 810 815	2565
CGT TTC TCT CAG GCC CAG AGA CCC GGC ACC AGC GGC TCC CAA AAT GGC Arg Phe Ser Gln Ala Gln Arg Pro Gly Thr Ser Gly Ser Gln Asn Gly 820 825 830	2613
GAT GAC ACC GGC ACC TGG CCC AAC AAC CAG TTT GAC ACA GAG ATG CTG Asp Asp Thr Gly Thr Trp Pro Asn Asn Gln Phe Asp Thr Glu Met Leu 835 840 845	2661
CAA GCC ATG ATC TTG GCG TCC GCC AGT GAA GCT GCT GAT GGG AGC TCC Gln Ala Met Ile Leu Ala Ser Ala Ser Glu Ala Ala Asp Gly Ser Ser 850 855 860 865	2709
ACC CTG GGA GGG GGT GCC GGC ACC ATG GGA TTG AGC GCC CGC TAC GGA Thr Leu Gly Gly Ala Gly Thr Met Gly Leu Ser Ala Arg Tyr Gly 870 875 880	2757
CCC CAG TTC ACC CTG CAG CAC GTG CCC GAC TAC CGC CAG AAT GTC TAC Pro Gln Phe Thr Leu Gln His Val Pro Asp Tyr Arg Gln Asn Val Tyr 885 890 895	2805
ATC CCA GGC AGC AAT GCA CAC T GACCAACGCA GCTGGCAAGC GGATGGCAAG Ile Pro Gly Ser Asn Ala His 900	2857
GCCCCAGCAGG TGGCAATGGC AACAAAGAAGA AGTCGGCAAG AAGGAGAAGA AGTAACATGG	2917
AGGCCAGGCC AAGAGCCACA GGGCAGCCTC TCCCCGAACC AGCCCAGCTT CTCCTTACCT	2977
GCACCCAGGC CTCAGAGTTT CAGGGCTAAC CCCCCAGAATA CTGGTAGGGG CCAAGGCATC	3037
TCCCTTGGAA ACAGAAACAA GTGCCATCAC ACCATCCCTT CCCCAGGTGT AATATCCAAA	3097
GCAGTTCCGC TGGGAACCCC ATCCAATCAG TGGCTGTACC CATTGGGTA GTGGGGTTCA	3157
TGTAGACACC AAGAACATT TGCCACACCC CGTTTAGTTA CAGCTGAACC CTCCATCTTC	3217
CAAATCAATC AGGCCCATCC ATCCCATGCC TCCCTCCTCC CCACCCCCACT CCAACAGTTC	3277
CTCTTTCCCG AGTAAGGTGG TTGGGGTGT GAAGTACCAA GTAACCTACA AGCCTCCTAG	3337
TTCTGAAAAG TTGGAAGGGC ATCATGACCT CTTGGCCTCT CCTTTGATTC TCAATCTCC	3397
CCCAAAGCAT GGTTTGGTGC CAGCCCCCTC ACCTCCTTCC AGAGCCCAAG ATCAATGCTC	3457
AAGTTTGGA GGACATGATC ACCATCCCCA TGGTACTGAT GCTTGCTGGA TTTAGGGAGG	3517
GCATTTGCT ACCAAGCCTC TTCCCAACGC CCTGGGACCA GTCTTCTGTT TTGTTTTCA	3577
TTGTTTGAGC TTTCCACTGC ATGCCTTGAC TTCCCCCACC TCCTCCTCAA ACAAGAGACT	3637

- 84 -

CCACTGCATG TTCCAAGACA GTATGGGTG GTAAGATAAG GAAGGGAAGT GTGTGGATGT	3697
GGATGGTGGG GGCATGGACA AAGCTTGACA CATCAAGTTA TCAAGGCCTT GGAGGAGGCT	3757
CTGTATGTCC TCAGGGACT GACAACATCC TCCAGATTCC AGCCATAAAC CAATAACTAG	3817
GCTGGACCCT TCCCAC TACA TAATAGGGCT CAGCCAGGCA GCCAGCTTG GGCTGAGCTA	3877
ACAGGACCAA TGGATTA ACT GGCATTCAG TCCAAGGAAG CTCGAAGCAG GTTTAGGACC	3937
AGGTCCCCCTT GAGAGGTCAG AGGGGCCTCT GTGGGTGCTG GGTACTCCAG AGGTGCCACT	3997
GGTGGAAAGGG TCAGCGGAGC CCCAGCAGGA AGGGTGGGCC AGCCAGGCCA TTCTTAGTCC	4057
CTGGGTTGGG GAGGCAGGGA GCTAGGGCAG GGACCAAATG AACAGAAAGT CTCAGCCCAG	4117
GATGGGGCTT CTTCAACAGG CCCCTGCCCT CCTGAAGCCT CAGTCCTTCA CCTTGCCAGG	4177
TGCCGTTTCT CTTCCGTGAA GGCCACTGCC CAGGTCCCCA GTGCGCCCC TAGTGGCCAT	4237
AGCCTGGTTA AAGTCCCCA GTGCCTCCTT GTGATA GACC TTCTTCTCCC ACCCCCCTCT	4297
GCCCCCTGGGT CCCCGGCCAT CCAGCGGGC TGCCAGAGAA CCCCAGACCT GCCCTTACAG	4357
TAGTGTAGCG CCCCCCTCCCT CTTCGGCTG GTGTAGAATA GCCAGTAGTG TAGTGCAGTG	4417
TGCTTTTACG TGATGGCGGG TGGGCAGCGG CGGGCGCGT CCGCGCAGCC GTCTGTCCTT	4477
GATCTGCCCG CGGCGGCCCG TGTTGTGTT TGTGCTGTGT CCAGCGCTAA GGCGACCCCC	4537
TCCCCCGTAC TGACTTCTCC TATAAGCGCT TCTCTCGCA TAGTCACGTA GCTCCCACCC	4597
CACCCCTCTTC CTGTGTCTCA CGCAAGTTT ATACTCTAAT ATTTATATGG CTTTTTTCT	4657
TCGACAAAAA AATAATAAAA CGTTTCTTCT GAAAAAAA AAAAAAAA	4705

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 904 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Met Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val	
1 5 10 15	
Val Gly Val Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val	
20 25 30	
Ile His Tyr Glu Ile Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly	
35 40 45	
Asn Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg	
50 55 60	

- 85 -

Arg Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn
65 70 75 80

Arg Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu
85 90 95

Leu Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val
100 105 110

Glu Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val Ile Gln Asp Ile
115 120 125

Asn Asp Asn Asn Pro Ala Phe Pro Thr Gln Glu Met Lys Leu Glu Ile
130 135 140

Ser Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His
145 150 155 160

Asp Pro Asp Leu Gly Ser Asn Ser Leu Gln Thr Tyr Glu Leu Ser Arg
165 170 175

Asn Glu Tyr Phe Ala Leu Arg Val Gln Thr Arg Glu Asp Ser Thr Lys
180 185 190

Tyr Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro
195 200 205

Ser Leu Gln Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu
210 215 220

Ser Ala Ser Leu Pro Ile His Ile Lys Val Leu Asp Ala Asn Asp Asn
225 230 235 240

Ala Pro Val Phe Asn Gln Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly
245 250 255

Cys Thr Ser Gly Thr Arg Val Val Gln Val Leu Ala Thr Asp Leu Asp
260 265 270

Glu Gly Pro Asn Gly Glu Ile Ile Tyr Ser Phe Gly Ser His Asn Arg
275 280 285

Ala Gly Val Arg Gln Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu
290 295 300

Thr Ile Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu Ile
305 310 315 320

Tyr Ile Gln Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys
325 330 335

Lys Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu Ile
340 345 350

Thr Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr
355 360 365

Val Ile Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly
370 375 380

- 86 -

Leu Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser
385 390 395 400
Ser Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg
405 410 415
Glu Thr Val Pro Glu Tyr Asn Leu Ser Ile Thr Ala Arg Asp Ala Gly
420 425 430
Thr Pro Ser Leu Ser Ala Leu Thr Ile Val Arg Val Gln Val Ser Asp
435 440 445
Ile Asn Asp Asn Pro Pro Gln Ser Ser Gln Ser Ser Tyr Asp Val Tyr
450 455 460
Ile Glu Glu Asn Asn Leu Pro Gly Ala Pro Ile Leu Asn Leu Ser Val
465 470 475 480
Trp Asp Pro Asp Ala Pro Gln Asn Ala Arg Leu Ser Phe Phe Leu Leu
485 490 495
Glu Gln Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr Ile Asn
500 505 510
Arg Asp Asn Gly Ile Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp
515 520 525
Arg Arg Glu Phe Glu Leu Thr Ala His Ile Ser Asp Gly Gly Thr Pro
530 535 540
Val Leu Ala Thr Asn Ile Ser Val Asn Ile Phe Val Thr Asp Arg Asn
545 550 555 560
Asp Asn Ala Pro Gln Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val
565 570 575
Glu Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val
580 585 590
Val Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser
595 600 605
Leu Phe Gly Ser Pro Asn Gln Ser Leu Phe Ala Ile Gly Leu His Thr
610 615 620
Gly Gln Ile Ser Thr Ala Arg Pro Val Gln Asp Thr Asp Ser Pro Arg
625 630 635 640
Gln Thr Leu Thr Val Leu Ile Lys Asp Asn Gly Glu Pro Ser Leu Ser
645 650 655
Thr Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala
660 665 670
Arg Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gln Lys Lys Asn
675 680 685
Leu Thr Phe Tyr Leu Leu Ser Leu Ile Leu Val Ser Val Gly Phe
690 695 700

- 87 -

Val	Val	Thr	Val	Phe	Gly	Val	Ile	Ile	Phe	Lys	Val	Tyr	Lys	Trp	Lys
705															720
Gln	Ser	Arg	Asp	Leu	Tyr	Arg	Ala	Pro	Val	Ser	Ser	Leu	Tyr	Arg	Thr
				725					730				735		
Pro	Gly	Pro	Ser	Leu	His	Ala	Asp	Ala	Val	Arg	Gly	Gly	Leu	Met	Ser
									745				750		
Pro	His	Leu	Tyr	His	Gln	Val	Tyr	Leu	Thr	Thr	Asp	Ser	Arg	Arg	Ser
	755					760						765			
Asp	Pro	Leu	Leu	Lys	Lys	Pro	Gly	Ala	Ala	Ser	Pro	Leu	Ala	Ser	Arg
	770					775					780				
Gln	Asn	Thr	Leu	Arg	Ser	Cys	Asp	Pro	Val	Phe	Tyr	Arg	Gln	Val	Leu
	785				790					795			800		
Gly	Ala	Glu	Ser	Ala	Pro	Pro	Gly	Gln	Gln	Ala	Pro	Pro	Asn	Thr	Asp
					805				810				815		
Trp	Arg	Phe	Ser	Gln	Ala	Gln	Arg	Pro	Gly	Thr	Ser	Gly	Ser	Gln	Asn
					820			825			830				
Gly	Asp	Asp	Thr	Gly	Thr	Trp	Pro	Asn	Asn	Gln	Phe	Asp	Thr	Glu	Met
					835			840			845				
Leu	Gln	Ala	Met	Ile	Leu	Ala	Ser	Ala	Ser	Glu	Ala	Ala	Asp	Gly	Ser
					850			855			860				
Ser	Thr	Leu	Gly	Gly	Gly	Ala	Gly	Thr	Met	Gly	Leu	Ser	Ala	Arg	Tyr
						865			870		875			880	
Gly	Pro	Gln	Phe	Thr	Leu	Gln	His	Val	Pro	Asp	Tyr	Arg	Gln	Asn	Val
					885			890			895				
Tyr	Ile	Pro	Gly	Ser	Asn	Ala	His								
				900											

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 441 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Asp	Trp	Val	Ile	Pro	Pro	Ile	Asn	Leu	Pro	Glu	Asn	Ser	Arg	Gly	Pro
1						5					10				15
Phe	Pro	Gln	Glu	Leu	Val	Arg	Ile	Arg	Ser	Asp	Arg	Asp	Lys	Asn	Leu
					20			25			30				

- 88 -

Ser	Leu	Arg	Tyr	Thr	Val	Thr	Gly	Pro	Gly	Ala	Asp	Gln	Pro	Pro	Thr
35							40					45			
Gly	Ile	Phe	Ile	Ile	Asn	Pro	Ile	Ser	Gly	Gln	Leu	Ser	Val	Thr	Lys
50							55				60				
Pro	Leu	Asp	Arg	Glu	Gln	Ile	Ala	Arg	Phe	His	Leu	Arg	Ala	His	Ala
65						70				75			80		
Val	Asp	Ile	Asn	Gly	Asn	Gln	Val	Glu	Asn	Pro	Ile	Asp	Ile	Val	Ile
85							90					95			
Asn	Val	Ile	Asp	Met	Asn	Asp	Asn	Arg	Pro	Glu	Phe	Thr	Ala	Met	Thr
100							105					110			
Phe	Tyr	Gly	Glu	Val	Pro	Glu	Asn	Arg	Val	Asp	Ile	Ile	Val	Ala	Asn
115							120					125			
Leu	Thr	Val	Thr	Asp	Lys	Asp	Gln	Pro	His	Thr	Pro	Ala	Trp	Asn	Ala
130						135				140					
Val	Thr	Arg	Ile	Ser	Gly	Gly	Asp	Pro	Thr	Gly	Arg	Phe	Ala	Ile	Gln
145						150				155			160		
Thr	Asp	Pro	Asn	Ser	Asn	Asp	Gly	Leu	Val	Thr	Val	Val	Lys	Pro	Ile
165						170						175			
Asp	Phe	Glu	Thr	Asn	Arg	Met	Phe	Val	Leu	Thr	Val	Ala	Ala	Glu	Asn
180						185						190			
Gln	Val	Pro	Leu	Ala	Lys	Gly	Ile	Gln	His	Pro	Pro	Gln	Ser	Thr	Ala
195						200						205			
Thr	Val	Ser	Val	Thr	Val	Ile	Asp	Val	Asn	Glu	Asn	Pro	Tyr	Phe	Ala
210						215				220					
Pro	Asn	Pro	Lys	Ile	Ile	Arg	Gln	Glu	Glu	Gly	Leu	His	Ala	Gly	Thr
225						230				235			240		
Met	Leu	Thr	Thr	Phe	Thr	Ala	Gly	Asp	Pro	Asp	Arg	Tyr	Met	Gln	Gln
245						250						255			
Asn	Ile	Arg	Tyr	Thr	Lys	Leu	Ser	Asp	Pro	Ala	Asn	Trp	Leu	Lys	Ile
260						265						270			
Asp	Pro	Val	Asn	Gly	Gln	Ile	Thr	Thr	Ile	Ala	Val	Leu	Asp	Arg	Glu
275						280						285			
Ser	Pro	Asn	Val	Lys	Asn	Asn	Ile	Tyr	Asn	Ala	Thr	Phe	Leu	Ala	Ser
290						295						300			
Asp	Asn	Gly	Ile	Pro	Pro	Met	Ser	Gly	Thr	Gly	Thr	Leu	Gln	Ile	Tyr
305						310				315			320		
Leu	Leu	Asp	Ile	Asn	Asp	Asn	Ala	Pro	Gln	Val	Leu	Pro	Gln	Glu	Ala
325							330						335		
Glu	Thr	Cys	Glu	Thr	Pro	Asp	Pro	Asn	Ser	Ile	Asn	Ile	Thr	Thr	Ala
340						345						350			

- 89 -

Leu	Asp	Tyr	Asp	Ile	Asp	Pro	Asn	Ala	Gly	Pro	Phe	Ala	Tyr	Asp	Leu
355															365
Pro	Leu	Ser	Pro	Val	Thr	Ile	Lys	Arg	Asn	Trp	Thr	Ile	Thr	Arg	Leu
370															380
Asn	Gly	Asp	Phe	Ala	Gln	Leu	Asn	Leu	Lys	Ile	Lys	Phe	Leu	Glu	Ala
385															400
Gly	Ile	Tyr	Glu	Val	Pro	Ile	Ile	Ile	Thr	Asp	Ser	Gly	Asn	Pro	Pro
															415
405															
Lys	Ser	Asn	Lys	Ser	Ile	Leu	Arg	Val	Arg	Val	Cys	Gln	Cys	Asp	Phe
420															430
Asn	Gly	Asp	Cys	Thr	Asp	Val	Asp	Arg							
435															
440															

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 105 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Glu	Asp	Thr	Val	Tyr	Ser	Phe	Asp	Ile	Pro	Glu	Asn	Ala	Gln	Arg	Gly
1															15
Tyr	Gln	Val	Gly	Gln	Ile	Val	Ala	Arg	Asp	Ala	Asp	Leu	Gly	Gln	Asn
20															30
Ala	Gln	Leu	Ser	Tyr	Gly	Val	Val	Ser	Asp	Trp	Ala	Asn	Asp	Val	Phe
35															45
Ser	Leu	Asn	Pro	Gln	Thr	Gly	Met	Leu	Thr	Leu	Thr	Ala	Arg	Leu	Asp
50															
Tyr	Glu	Glu	Val	Gln	His	Tyr	Ile	Leu	Ile	Val	Gln	Ala	Gln	Asp	Asn
65															80
Gly	Gln	Pro	Ser	Leu	Ser	Thr	Thr	Ile	Thr	Val	Tyr	Cys	Asn	Val	Leu
85															95
Asp	Leu	Asn	Asp	Asn	Ala	Pro	Ile	Phe							
100															

(2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 90 -

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Asp Xaa Asp Xaa Gly Xaa Asn
1 5

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Ala Xaa Asp Xaa Gly Xaa Pro
1 5

(2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 4650 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 495..4103

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

CCTCTATTCTG ACATTCTCTT TGGATTGTT TGCTATACT TGAAATTTGG GATGTCACAA	60
ACGAAACTGT CATCTGTTTC CGCCAAACTG TGGTTCTGCT AATCTCCCAG GCTGGCAGCA	120
TTGGAGACTT GCTGACTTCT TTCATCCCC ACTCTTTCA CCTGAAATTC CTTCCTTGG	180
TTTGCTCTA AGTCCTATGC TTCAGTCAGG GGCCAACCAA ATCTCACTGC CTCCTTTTA	240
TCATGAAGCC TTTGATCACT GATAGTTCTT TTTATATCTT GAAAAATCAC CCTTCCCAGT	300
ACAGTTAATA TTTAGTATCT CTACTCATCT TGGCACTTAC TCACAGCTCC ATAATTCACT	360
CGTTTTCGTA CCTCTTCATG GTGATGGGA GCCCTTGGA GGTGGTGACT GTGCTTTATA	420
CTCCTCATGA TGCTTCACAT GTGGCAGGCC TGGAGTGCC GGAGGCGGCC CTCCTGATTG	480

- 91 -

TGGGGCCTCC CAGG ATG GAG CCC CTG AGG CAC AGC CCA GGC CCT GGG GGG Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly	530
1 5 10	
CAA CGG CTA CTG CTG CCC TCC ATG CTG CTA GCA CTG CTG CTC CTG CTG Gln Arg Leu Leu Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Leu	578
15 20 25	
GCT CCA TCC CCA GGC CAC GCC ACT CGG GTA GTG TAC AAG GTG CCG GAG Ala Pro Ser Pro Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu	626
30 35 40	
GAA CAG CCA CCC AAC ACC CTC ATT GGG AGC CTC GCA GCC GAC TAT GGT Glu Gln Pro Pro Asn Thr Leu Ile Gly Ser Leu Ala Ala Asp Tyr Gly	674
45 50 55 60	
TTT CCA GAT GTG GGG CAC CTG TAC AAG CTA GAG GTG GGT GCC CCG TAC Phe Pro Asp Val Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr	722
65 70 75	
CTT CGC GTG GAT GGC AAG ACA GGT GAC ATT TTC ACC ACC GAG ACC TCC Leu Arg Val Asp Gly Lys Thr Gly Asp Ile Phe Thr Thr Glu Thr Ser	770
80 85 90	
ATC GAC CGT GAG GGG CTC CGT GAA TGC CAG AAC CAG CTC CCT GGT GAT Ile Asp Arg Glu Gly Leu Arg Glu Cys Gln Asn Gln Leu Pro Gly Asp	818
95 100 105	
CCC TGC ATC CTG GAG TTT GAG GTA TCT ATC ACA GAC CTC GTG CAG AAT Pro Cys Ile Leu Glu Phe Glu Val Ser Ile Thr Asp Leu Val Gln Asn	866
110 115 120	
GCG AGC CCC CGG CTG CTA GAG GGC CAG ATA GAA GTA CAA GAC ATC AAT Ala Ser Pro Arg Leu Leu Glu Gly Gln Ile Glu Val Gln Asp Ile Asn	914
125 130 135 140	
GAC AAC ACA CCC AAC TTC GCC TCA CCA GTC ATC ACT CTG GCC ATC CCT Asp Asn Thr Pro Asn Phe Ala Ser Pro Val Ile Thr Leu Ala Ile Pro	962
145 150 155	
GAG AAC ACC AAC ATC GGC TCA CTC TTC CCC ATC CCG CTG GCT TCA GAC Glu Asn Thr Asn Ile Gly Ser Leu Phe Pro Ile Pro Leu Ala Ser Asp	1010
160 165 170	
CGT GAT GCT GGT CCC AAC GGT GTG GCA TCC TAT GAG CTG CAG GTG GCA Arg Asp Ala Gly Pro Asn Gly Val Ala Ser Tyr Glu Leu Gln Val Ala	1058
175 180 185	
GAG GAC CAG GAG GAG AAG CAA CCA CAG CTC ATT GTG ATG GGC AAC CTG Glu Asp Gln Glu Glu Lys Gln Pro Gln Leu Ile Val Met Gly Asn Leu	1106
190 195 200	
GAC CGT GAG CGC TGG GAC TCC TAT GAC CTC ACC ATC AAG GTG CAG GAT Asp Arg Glu Arg Trp Asp Ser Tyr Asp Leu Thr Ile Lys Val Gln Asp	1154
205 210 215 220	
GGC GGC AGC CCC CCA CGC GCC ACG AGT GCC CTG CTG CGT GTC ACC GTG Gly Gly Ser Pro Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val	1202
225 230 235	

- 92 -

CTT GAC ACC AAT GAC AAC GCC CCC AAG TTT GAG CGG CCC TCC TAT GAG Leu Asp Thr Asn Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu 240 245 250	1250
GCC GAA CTA TCT GAG AAT AGC CCC ATA GGC CAC TCG GTC ATC CAG GTG Ala Glu Leu Ser Glu Asn Ser Pro Ile Gly His Ser Val Ile Gln Val 255 260 265	1298
AAG GCC AAT GAC TCA GAC CAA GGT GCC AAT GCA GAA ATC GAA TAC ACA Lys Ala Asn Asp Ser Asp Gln Gly Ala Asn Ala Glu Ile Glu Tyr Thr 270 275 280	1346
TTC CAC CAG GCG CCC GAA GTT GTG AGG CGT CTT CTT CGA CTG GAC AGG Phe His Gln Ala Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg 285 290 295 300	1394
AAC ACT GGA CTT ATC ACT GTT CAG GGC CCG GTG GAC CGT GAG GAC CTA Asn Thr Gly Leu Ile Thr Val Gln Gly Pro Val Asp Arg Glu Asp Leu 305 310 315	1442
AGC ACC CTG CGC TTC TCA GTG CTT GCT AAG GAC CGA GGC ACC AAC CCC Ser Thr Leu Arg Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro 320 325 330	1490
AAG AGT GCC CGT GCC CAG GTG GTT GTG ACC GTG AAG GAC ATG AAT GAC Lys Ser Ala Arg Ala Gln Val Val Val Thr Val Lys Asp Met Asn Asp 335 340 345	1538
AAT GCC CCC ACC ATT GAG ATC CGG GGC ATA GGG CTA GTG ACT CAT CAA Asn Ala Pro Thr Ile Glu Ile Arg Gly Ile Gly Leu Val Thr His Gln 350 355 360	1586
GAT GGG ATG GCT AAC ATC TCA GAG GAT GTG GCA GAG GAG ACA GCT GTG Asp Gly Met Ala Asn Ile Ser Glu Asp Val Ala Glu Glu Thr Ala Val 365 370 375 380	1634
GCC CTG GTG CAG GTG TCT GAC CGA GAT GAG GGA GAG AAT GCA GCT GTC Ala Leu Val Gln Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val 385 390 395	1682
ACC TGT GTG GTG GCA GGT GAT GTG CCC TTC CAG CTG CGC CAG GCC AGT Thr Cys Val Val Ala Gly Asp Val Pro Phe Gln Leu Arg Gln Ala Ser 400 405 410	1730
GAG ACA GGC AGT GAC AGC AAG AAG AAG TAT TTC CTG CAG ACT ACC ACC Glu Thr Gly Ser Asp Ser Lys Lys Lys Tyr Phe Leu Gln Thr Thr Thr 415 420 425	1778
CCG CTA GAC TAC GAG AAG GTC AAA GAC TAC ACC ATT GAG ATT GTG GCT Pro Leu Asp Tyr Glu Lys Val Lys Asp Tyr Thr Ile Glu Ile Val Ala 430 435 440	1826
GTG GAC TCT GGC AAC CCC CCA CTC TCC AGC ACT AAC TCC CTC AAG GTG Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val 445 450 455 460	1874
CAG GTG GTG GAC GTC AAT GAC AAC GCA CCT GTC TTC ACT CAG AGT GTC Gln Val Val Asp Val Asn Asp Asn Ala Pro Val Phe Thr Gln Ser Val 465 470 475	1922

- 93 -

ACT GAG GTC GCC TTC CCG GAA AAC AAC AAG CCT GGT GAA GTG ATT GCT Thr Glu Val Ala Phe Pro Glu Asn Asn Lys Pro Gly Glu Val Ile Ala 480 485 490	1970
GAG ATC ACT GCC AGT GAT GCT GAC TCT GGC TCT AAT GCT GAG CTG GTT Glu Ile Thr Ala Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val 495 500 505	2018
TAC TCT CTG GAG CCT GAG CCG GCT GCT AAG GGC CTC TTC ACC ATC TCA Tyr Ser Leu Glu Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr Ile Ser 510 515 520	2066
CCC GAG ACT GGA GAG ATC CAG GTG AAG ACA TCT CTG GAT CGG GAA CAG Pro Glu Thr Gly Glu Ile Gln Val Lys Thr Ser Leu Asp Arg Glu Gln 525 530 535 540	2114
CGG GAG AGC TAT GAG TTG AAG GTG GTG GCA GCT GAC CGG GGC AGT CCT Arg Glu Ser Tyr Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro 545 550 555	2162
AGC CTC CAG GGC ACA GCC ACT GTC CTT GTC AAT GTG CTG GAC TGC AAT Ser Leu Gln Gly Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn 560 565 570	2210
GAC AAT GAC CCC AAA TTT ATG CTG AGT GGC TAC AAC TTC TCA GTG ATG Asp Asn Asp Pro Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met 575 580 585	2258
GAG AAC ATG CCA GCA CTG AGT CCA GTG GGC ATG GTG ACT GTC ATT GAT Glu Asn Met Pro Ala Leu Ser Pro Val Gly Met Val Thr Val Ile Asp 590 595 600	2306
GGA GAC AAG GGG GAG AAT GCC CAG GTG CAG CTC TCA GTG GAG CAG GAC Gly Asp Lys Gly Glu Asn Ala Gln Val Gln Leu Ser Val Glu Gln Asp 605 610 615 620	2354
AAC GGT GAC TTT GTT ATC CAG AAT GGC ACA GGC ACC ATC CTA TCC AGC Asn Gly Asp Phe Val Ile Gln Asn Gly Thr Gly Thr Ile Leu Ser Ser 625 630 635	2402
CTG AGC TTT GAT CGA GAG CAA CAA AGC ACC TAC ACC TTC CAG CTG AAG Leu Ser Phe Asp Arg Glu Gln Gln Ser Thr Tyr Thr Phe Gln Leu Lys 640 645 650	2450
GCA GTG GAT GGT GGC GTC CCA CCT CGC TCA GCT TAC GTT GGT GTC ACC Ala Val Asp Gly Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr 655 660 665	2498
ATC AAT GTG CTG GAC GAG AAT GAC AAC GCA CCC TAT ATC ACT GCC CCT Ile Asn Val Leu Asp Glu Asn Asp Asn Ala Pro Tyr Ile Thr Ala Pro 670 675 680	2546
TCT AAC ACC TCT CAC AAG CTG CTG ACC CCC CAG ACA CGT CTT GGT GAG Ser Asn Thr Ser His Lys Leu Leu Thr Pro Gln Thr Arg Leu Gly Glu 685 690 695 700	2594
ACG GTC AGC CAG GTG GCA GCC GAG GAC TTT GAC TCT GGT GTC AAT GCC Thr Val Ser Gln Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala 705 710 715	2642

- 94 -

GAG CTG ATC TAC AGC ATT GCA GGT GGC AAC CCT TAT GGA CTC TTC CAG Glu Leu Ile Tyr Ser Ile Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gln 720 725 730	2690
ATT GGG TCA CAT TCA GGT GCC ATC ACC CTG GAG AAG GAG ATT GAG CGG Ile Gly Ser His Ser Gly Ala Ile Thr Leu Glu Lys Glu Ile Glu Arg 735 740 745	2738
CGC CAC CAT GGG CTA CAC CGC CTG GTG GTG AAG GTC AGT GAC CGC GGC Arg His His Gly Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly 750 755 760	2786
AAG CCC CCA CGC TAT GGC ACA GCC TTG GTC CAT CTT TAT GTC AAT GAG Lys Pro Pro Arg Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu 765 770 775 780	2834
ACT CTG GCC AAC CGC ACG CTG CTG GAG ACC CTC CTG GGC CAC AGC CTG Thr Leu Ala Asn Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu 785 790 795	2882
GAC ACG CCG CTG GAT ATT GAC ATT GCT GGG GAT CCA GAA TAT GAG CGC Asp Thr Pro Leu Asp Ile Asp Ile Ala Gly Asp Pro Glu Tyr Glu Arg 800 805 810	2930
TCC AAG CAG CGT GGC AAC ATT CTC TTT GGT GTG GTG GCT GGT GTG GTG Ser Lys Gln Arg Gly Asn Ile Leu Phe Gly Val Val Ala Gly Val Val 815 820 825	2978
GCC GTG GCC TTG CTC ATC GCC CTG GCG GTT CTT GTG CGC TAC TGC AGA Ala Val Ala Leu Ile Ala Leu Ala Val Leu Val Arg Tyr Cys Arg 830 835 840	3026
CAG CGG GAG GCC AAA AGT GGT TAC CAG GCT GGT AAG AAG GAG ACC AAG Gln Arg Glu Ala Lys Ser Gly Tyr Gln Ala Gly Lys Glu Thr Lys 845 850 855 860	3074
GAC CTG TAT GCC CCC AAG CCC AGT GGC AAG GCC TCC AAG GGA AAC AAA Asp Leu Tyr Ala Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys 865 870 875	3122
AGC AAA GGC AAG AAG AGC AAG TCC CCA AAG CCC GTG AAG CCA GTG GAG Ser Lys Gly Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu 880 885 890	3170
GAC GAG GAT GAG GCC GGG CTG CAG AAG TCC CTC AAG TTC AAC CTG ATG Asp Glu Asp Glu Ala Gly Leu Gln Lys Ser Leu Lys Phe Asn Leu Met 895 900 905	3218
AGC GAT GCC CCT GGG GAC AGT CCC CGC ATC CAC CTG CCC CTC AAC TAC Ser Asp Ala Pro Gly Asp Ser Pro Arg Ile His Leu Pro Leu Asn Tyr 910 915 920	3266
CCA CCA GGC AGC CCT GAC CTG GGC CGC CAC TAT CGC TCT AAC TCC CCA Pro Pro Gly Ser Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro 925 930 935 940	3314
CTG CCT TCC ATC CAG CTG CAG CCC CAG TCA CCC TCA GCC TCC AAG AAG Leu Pro Ser Ile Gln Leu Gln Pro Gln Ser Pro Ser Ala Ser Lys Lys 945 950 955	3362

- 95 -

CAC CAG GTG GTA CAG GAC CTG CCA CCT GCA AAC ACA TTC GTG GGC ACC His Gln Val Val Gln Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr 960 965 970	3410
GGG GAC ACC ACG TCC ACG GGC TCT GAG CAG TAC TCC GAC TAC AGC TAC Gly Asp Thr Thr Ser Thr Gly Ser Glu Gln Tyr Ser Asp Tyr Ser Tyr 975 980 985	3458
CGC ACC AAC CCC CCC AAA TAC CCC AGC AAG CAG TTA CCT CAC CGC CGC Arg Thr Asn Pro Pro Lys Tyr Pro Ser Lys Gln Leu Pro His Arg Arg 990 995 1000	3506
GTC ACC TTC TCG GCC ACC AGC CAG GCC CAG GAG CTG CAG GAC CCA TCC Val Thr Phe Ser Ala Thr Ser Gln Ala Gln Glu Leu Gln Asp Pro Ser 1005 1010 1015 1020	3554
CAG CAC AGT TAC TAT GAC AGT GGC CTG GAG GAG TCT GAG ACG CCG TCC Gln His Ser Tyr Tyr Asp Ser Gly Leu Glu Glu Ser Glu Thr Pro Ser 1025 1030 1035	3602
AGC AAG TCA TCC TCA GGG CCT CGA CTC GGT CCC CTG GCC CTG CCT GAG Ser Lys Ser Ser Gly Pro Arg Leu Gly Pro Leu Ala Leu Pro Glu 1040 1045 1050	3650
GAT CAC TAT GAG CGC ACC ACC CCT GAT GGC AGC ATA GGA GAG ATG GAG Asp His Tyr Glu Arg Thr Thr Pro Asp Gly Ser Ile Gly Glu Met Glu 1055 1060 1065	3698
CAC CCC GAG AAT GAC CTT CGC CCT TTG CCT GAT GTC GCC ATG ACA GGC His Pro Glu Asn Asp Leu Arg Pro Leu Pro Asp Val Ala Met Thr Gly 1070 1075 1080	3746
ACA TGT ACC CGG GAG TGC AGT GAG TTT GGC CAC TCT GAC ACA TGC TGG Thr Cys Thr Arg Glu Cys Ser Glu Phe Gly His Ser Asp Thr Cys Trp 1085 1090 1095 1100	3794
ATG CCT GGC CAG TCA TCT CCC AGC CGC CGG ACC AAG AGC AGC GCC CTC Met Pro Gly Gln Ser Ser Pro Ser Arg Arg Thr Lys Ser Ser Ala Leu 1105 1110 1115	3842
AAA CTC TCC ACC TTC ATG CCT TAC CAG GAC CGA GGA GGG CAG GAG CCT Lys Leu Ser Thr Phe Met Pro Tyr Gln Asp Arg Gly Gln Glu Pro 1120 1125 1130	3890
GCG GGC GCC GGC AGC CCC AGC CCC CCG GAA GAC CGG AAC ACC AAA ACG Ala Gly Ala Gly Ser Pro Ser Pro Pro Glu Asp Arg Asn Thr Lys Thr 1135 1140 1145	3938
GCC CCC GTG CGC CTC CTG CCC TCC TAC AGT GCC TTC TCC CAC AGT AGC Ala Pro Val Arg Leu Leu Pro Ser Tyr Ser Ala Phe Ser His Ser Ser 1150 1155 1160	3986
CAT GAT TCC TGC AAG GAC TCG GCC ACC TTG GAG GAA ATC CCC CTG ACC His Asp Ser Cys Lys Asp Ser Ala Thr Leu Glu Glu Ile Pro Leu Thr 1165 1170 1175 1180	4034
CAG ACC TCG GAC TTC CCA CCC GCA GCC ACA CCG GCA TCT GCC CAG ACG Gln Thr Ser Asp Phe Pro Pro Ala Ala Thr Pro Ala Ser Ala Gln Thr 1185 1190 1195	4082

- 96 -

GCC AAG CGC GAG ATC TAC CTG TGAGCCCCCT ACTGGCCGGC CCCCCCTCCCC	4133
Ala Lys Arg Glu Ile Tyr Leu	
1200	
 CAGCGCCGGC CAGCTCCCAA ATGCCATTCA CAGGGCCTCA CTCTCCACCC CTTCAGCGTG	4193
GACTTCCTGC CAGGGCCCAA GTGGGGGTAT CACTGACCTC ATGACCACGC TGGCCCTTCT	4253
CCCATGCAGG GTCCAGGTCC TCTCCCTCA TTTCCATCTC CCAGCCCAGG GGCCCCTTCC	4313
CCTTTATGGG GCTTCCCCCA GCTGATGCCA AAGAGGGCTC CTCTGCAATG ACTGGGCTCC	4373
TTCCCTTGAC TTCCAGGGAG CACCCCTCG ATTGGGCAG ATGGTGGAGT CAAGGGTGGG	4433
CAGCGTACTT CTAACTCATT GTTCCCTCA TGGCCGACCA GGGCGGGGAT AGCATGCCA	4493
ATTTTAGCCC TGAAGCAGGG CTGAACTGGG GAGCCCTTT CCCTGGGAGC TCCCAGAGGA	4553
AACTCTTGAC CACCAGTGGC TCCCTGAAGG GCTTTGTTA CCAAAGGTGG GGTAGGGACG	4613
GGGGTGGGAG TGGAGCGGAG GCCTTGTGTT CCCGTGG	4650

(2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1203 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly Gln Arg Leu Leu	
1 5 10 15	
Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Ala Pro Ser Pro	
20 25 30	
Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu Glu Gln Pro Pro	
35 40 45	
Asn Thr Leu Ile Gly Ser Leu Ala Ala Asp Tyr Gly Phe Pro Asp Val	
50 55 60	
Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr Leu Arg Val Asp	
65 70 75 80	
Gly Lys Thr Gly Asp Ile Phe Thr Thr Glu Thr Ser Ile Asp Arg Glu	
85 90 95	
Gly Leu Arg Glu Cys Gln Asn Gln Leu Pro Gly Asp Pro Cys Ile Leu	
100 105 110	
Glu Phe Glu Val Ser Ile Thr Asp Leu Val Gln Asn Ala Ser Pro Arg	
115 120 125	

- 97 -

Leu Leu Glu Gly Gln Ile Glu Val Gln Asp Ile Asn Asp Asn Thr Pro
130 135 140

Asn Phe Ala Ser Pro Val Ile Thr Leu Ala Ile Pro Glu Asn Thr Asn
145 150 155 160

Ile Gly Ser Leu Phe Pro Ile Pro Leu Ala Ser Asp Arg Asp Ala Gly
165 170 175

Pro Asn Gly Val Ala Ser Tyr Glu Leu Gln Val Ala Glu Asp Gln Glu
180 185 190

Glu Lys Gln Pro Gln Leu Ile Val Met Gly Asn Leu Asp Arg Glu Arg
195 200 205

Trp Asp Ser Tyr Asp Leu Thr Ile Lys Val Gln Asp Gly Gly Ser Pro
210 215 220

Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val Leu Asp Thr Asn
225 230 235 240

Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu Ala Glu Leu Ser
245 250 255

Glu Asn Ser Pro Ile Gly His Ser Val Ile Gln Val Lys Ala Asn Asp
260 265 270

Ser Asp Gln Gly Ala Asn Ala Glu Ile Glu Tyr Thr Phe His Gln Ala
275 280 285

Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg Asn Thr Gly Leu
290 295 300

Ile Thr Val Gln Gly Pro Val Asp Arg Glu Asp Leu Ser Thr Leu Arg
305 310 315 320

Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro Lys Ser Ala Arg
325 330 335

Ala Gln Val Val Val Thr Val Lys Asp Met Asn Asp Asn Ala Pro Thr
340 345 350

Ile Glu Ile Arg Gly Ile Gly Leu Val Thr His Gln Asp Gly Met Ala
355 360 365

Asn Ile Ser Glu Asp Val Ala Glu Glu Thr Ala Val Ala Leu Val Gln
370 375 380

Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val Thr Cys Val Val
385 390 395 400

Ala Gly Asp Val Pro Phe Gln Leu Arg Gln Ala Ser Glu Thr Gly Ser
405 410 415

Asp Ser Lys Lys Lys Tyr Phe Leu Gln Thr Thr Pro Leu Asp Tyr
420 425 430

Glu Lys Val Lys Asp Tyr Thr Ile Glu Ile Val Ala Val Asp Ser Gly
435 440 445

- 98 -

Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val Gln Val Val Asp
450 455 460

Val Asn Asp Asn Ala Pro Val Phe Thr Gln Ser Val Thr Glu Val Ala
465 470 475 480

Phe Pro Glu Asn Asn Lys Pro Gly Glu Val Ile Ala Glu Ile Thr Ala
485 490 495

Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val Tyr Ser Leu Glu
500 505 510

Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr Ile Ser Pro Glu Thr Gly
515 520 525

Glu Ile Gln Val Lys Thr Ser Leu Asp Arg Glu Gln Arg Glu Ser Tyr
530 535 540

Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro Ser Leu Gln Gly
545 550 555 560

Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn Asp Asn Asp Pro
565 570 575

Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met Glu Asn Met Pro
580 585 590

Ala Leu Ser Pro Val Gly Met Val Thr Val Ile Asp Gly Asp Lys Gly
595 600 605

Glu Asn Ala Gln Val Gln Leu Ser Val Glu Gln Asp Asn Gly Asp Phe
610 615 620

Val Ile Gln Asn Gly Thr Gly Thr Ile Leu Ser Ser Leu Ser Phe Asp
625 630 635 640

Arg Glu Gln Gln Ser Thr Tyr Thr Phe Gln Leu Lys Ala Val Asp Gly
645 650 655

Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr Ile Asn Val Leu
660 665 670

Asp Glu Asn Asp Asn Ala Pro Tyr Ile Thr Ala Pro Ser Asn Thr Ser
675 680 685

His Lys Leu Leu Thr Pro Gln Thr Arg Leu Gly Glu Thr Val Ser Gln
690 695 700

Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala Glu Leu Ile Tyr
705 710 715 720

Ser Ile Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gln Ile Gly Ser His
725 730 735

Ser Gly Ala Ile Thr Leu Glu Lys Glu Ile Glu Arg Arg His His Gly
740 745 750

Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly Lys Pro Pro Arg
755 760 765

- 99 -

Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu Thr Leu Ala Asn
770 775 780

Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu Asp Thr Pro Leu
785 790 795 800

Asp Ile Asp Ile Ala Gly Asp Pro Glu Tyr Glu Arg Ser Lys Gln Arg
805 810 815

Gly Asn Ile Leu Phe Gly Val Val Ala Gly Val Val Ala Val Ala Leu
820 825 830

Leu Ile Ala Leu Ala Val Leu Val Arg Tyr Cys Arg Gln Arg Glu Ala
835 840 845

Lys Ser Gly Tyr Gln Ala Gly Lys Lys Glu Thr Lys Asp Leu Tyr Ala
850 855 860

Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys Ser Lys Gly Lys
865 870 875 880

Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu Asp Glu Asp Glu
885 890 895

Ala Gly Leu Gln Lys Ser Leu Lys Phe Asn Leu Met Ser Asp Ala Pro
900 905 910

Gly Asp Ser Pro Arg Ile His Leu Pro Leu Asn Tyr Pro Pro Gly Ser
915 920 925

Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro Leu Pro Ser Ile
930 935 940

Gln Leu Gln Pro Gln Ser Pro Ser Ala Ser Lys Lys His Gln Val Val
945 950 955 960

Gln Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr Gly Asp Thr Thr
965 970 975

Ser Thr Gly Ser Glu Gln Tyr Ser Asp Tyr Ser Tyr Arg Thr Asn Pro
980 985 990

Pro Lys Tyr Pro Ser Lys Gln Leu Pro His Arg Arg Val Thr Phe Ser
995 1000 1005

Ala Thr Ser Gln Ala Gln Glu Leu Gln Asp Pro Ser Gln His Ser Tyr
1010 1015 1020

Tyr Asp Ser Gly Leu Glu Glu Ser Glu Thr Pro Ser Ser Lys Ser Ser
1025 1030 1035 1040

Ser Gly Pro Arg Leu Gly Pro Leu Ala Leu Pro Glu Asp His Tyr Glu
1045 1050 1055

Arg Thr Thr Pro Asp Gly Ser Ile Gly Glu Met Glu His Pro Glu Asn
1060 1065 1070

Asp Leu Arg Pro Leu Pro Asp Val Ala Met Thr Gly Thr Cys Thr Arg
1075 1080 1085

- 100 -

Glu Cys Ser Glu Phe Gly His Ser Asp Thr Cys Trp Met Pro Gly Gln
 1090 1095 1100

Ser Ser Pro Ser Arg Arg Thr Lys Ser Ser Ala Leu Lys Leu Ser Thr
 1105 1110 1115 1120

Phe Met Pro Tyr Gln Asp Arg Gly Gly Gln Glu Pro Ala Gly Ala Gly
 1125 1130 1135

Ser Pro Ser Pro Pro Glu Asp Arg Asn Thr Lys Thr Ala Pro Val Arg
 1140 1145 1150

Leu Leu Pro Ser Tyr Ser Ala Phe Ser His Ser Ser His Asp Ser Cys
 1155 1160 1165

Lys Asp Ser Ala Thr Leu Glu Glu Ile Pro Leu Thr Gln Thr Ser Asp
 1170 1175 1180

Phe Pro Pro Ala Ala Thr Pro Ala Ser Ala Gln Thr Ala Lys Arg Glu
 1185 1190 1195 1200

Ile Tyr Leu

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2789 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 115..2622

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

CGAAAGCCAT GTCGGACTCG TCGCCCAGCG CCCAAGCGCT AACCCGCTGA AAGTTTCTCA	60
GCGAAATCTC AGGGACGATC TGGACCCCCGC TGAGAGGAAC TGCTTTGAG TGAG ATG	117
Met	
1	
GTC CCA GAG GCC TGG AGG AGC GGA CTG GTA AGC ACC GGG AGG GTA GTG	165
Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val Val	
5 10 15	
GGA GTT TTG CTT CTG CTT GGT GCC TTG AAC AAG GCT TCC ACG GTC ATT	213
Gly Val Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val Ile	
20 25 30	
CAC TAT GAG ATC CCG GAG GAA AGA GAG AAG GGT TTC GCT GTG GGC AAC	261
His Tyr Glu Ile Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly Asn	
35 40 45	

- 101 -

GTG GTC GCG AAC CTT GGT TTG GAT CTC GGT AGC CTC TCA GCC CGC AGG Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg Arg 50 55 60 65	309
TTC CCG GTG GTG TCT GGA GCT AGC CGA AGA TTC TTT GAG GTG AAC CGG Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn Arg 70 75 80	357
GAG ACC GGA GAG ATG TTT GTG AAC GAC CGT CTG GAT CGA GAG GAG CTG Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu Leu 85 90 95	405
TGT GGG ACA CTG CCC TCT TGC ACT GTA ACT CTG GAG TTG GTA GTG GAG Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val Glu 100 105 110	453
AAC CCG CTG GAG CTG TTC AGC GTG GAA GTG GTG ATC CAG GAC ATC AAC Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val Ile Gln Asp Ile Asn 115 120 125	501
GAC AAC AAT CCT GCT TTC CCT ACC CAG GAA ATG AAA TTG GAG ATT AGC Asp Asn Asn Pro Ala Phe Pro Thr Gln Glu Met Lys Leu Glu Ile Ser 130 135 140 145	549
GAG GCC GTG GCT CCG GGG ACG CGC TTT CCG CTC GAG AGC GCG CAC GAT Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His Asp 150 155 160	597
CCC GAT CTG GGA AGC AAC TCT TTA CAA ACC TAT GAG CTG AGC CGA AAT Pro Asp Leu Gly Ser Asn Ser Leu Gln Thr Tyr Glu Leu Ser Arg Asn 165 170 175	645
GAA TAC TTT GCG CTT CGC GTG CAG ACG CGG GAG GAC AGC ACC AAG TAC Glu Tyr Phe Ala Leu Arg Val Gln Thr Arg Glu Asp Ser Thr Lys Tyr 180 185 190	693
GCG GAG CTG GTG TTG GAG CGC GCC CTG GAC CGA GAA CGG GAG CCT AGT Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro Ser 195 200 205	741
CTC CAG TTA GTG CTG ACG GCG TTG GAC GGA GGG ACC CCA GCT CTC TCC Leu Gln Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu Ser 210 215 220 225	789
GCC AGC CTG CCT ATT CAC ATC AAG GTG CTG GAC GCG AAT GAC AAT GCG Ala Ser Leu Pro Ile His Ile Lys Val Leu Asp Ala Asn Asp Asn Ala 230 235 240	837
CCT GTC TTC AAC CAG TCC TTG TAC CGG GCG CGC GTT CCT GGA GGA TGC Pro Val Phe Asn Gln Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly Cys 245 250 255	885
ACC TCC GGC ACG CGC GTG GTA CAA GTC CTT GCA ACG GAT CTG GAT GAA Thr Ser Gly Thr Arg Val Val Gln Val Leu Ala Thr Asp Leu Asp Glu 260 265 270	933
GGC CCC AAC GGT GAA ATT ATT TAC TCC TTC GGC AGC CAC AAC CGC GCC Gly Pro Asn Gly Glu Ile Ile Tyr Ser Phe Gly Ser His Asn Arg Ala 275 280 285	981

- 102 -

GGC GTG CGG CAA CTA TTC GCC TTA GAC CTT GTA ACC GGG ATG CTG ACA Gly Val Arg Gln Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu Thr 290 295 300 305	1029
ATC AAG GGT CGG CTG GAC TTC GAG GAC ACC AAA CTC CAT GAG ATT TAC Ile Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu Ile Tyr 310 315 320	1077
ATC CAG GCC AAA GAC AAG GGC GCC AAT CCC GAA GGA GCA CAT TGC AAA Ile Gln Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys 325 330 335	1125
GTG TTG GTG GAG GTT GTG GAT GTG AAT GAC AAC GCC CCG GAG ATC ACA Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu Ile Thr 340 345 350	1173
GTC ACC TCC GTG TAC AGC CCA GTA CCC GAG GAT GCC TCT GGG ACT GTC Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr Val 355 360 365	1221
ATC GCT TTG CTC AGT GTG ACT GAC CTG GAT GCT GGC GAG AAC GGG CTG Ile Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly Leu 370 375 380 385	1269
GTG ACC TGC GAA GTT CCA CCG GGT CTC CCT TTC AGC CTT ACT TCT TCC Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser Ser 390 395 400	1317
CTC AAG AAT TAC TTC ACT TTG AAA ACC AGT GCA GAC CTG GAT CGG GAG Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg Glu 405 410 415	1365
ACT GTG CCA GAA TAC AAC CTC AGC ATC ACC GCC CGA GAC GCC GGA ACC Thr Val Pro Glu Tyr Asn Leu Ser Ile Thr Ala Arg Asp Ala Gly Thr 420 425 430	1413
CCT TCC CTC TCA GCC CTT ACA ATA GTG CGT GTT CAA GTG TCC GAC ATC Pro Ser Leu Ser Ala Leu Thr Ile Val Arg Val Gln Val Ser Asp Ile 435 440 445	1461
AAT GAC AAC CCT CCA CAA TCT TCT CAA TCT TCC TAC GAC GTT TAC ATT Asn Asp Asn Pro Pro Gln Ser Ser Gln Ser Ser Tyr Asp Val Tyr Ile 450 455 460 465	1509
GAA GAA AAC AAC CTC CCC GGG GCT CCA ATA CTA AAC CTA AGT GTC TGG Glu Glu Asn Asn Leu Pro Gly Ala Pro Ile Leu Asn Leu Ser Val Trp 470 475 480	1557
GAC CCC GAC GCC CCG CAG AAT GCT CGG CTT TCT TTC TTT CTC TTG GAG Asp Pro Asp Ala Pro Gln Asn Ala Arg Leu Ser Phe Phe Leu Leu Glu 485 490 495	1605
CAA GGA GCT GAA ACC GGG CTA GTG GGT CGC TAT TTC ACA ATA AAT CGT Gln Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr Ile Asn Arg 500 505 510	1653
GAC AAT GGC ATA GTG TCA TCC TTA GTG CCC CTA GAC TAT GAG GAT CGG Asp Asn Gly Ile Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp Arg 515 520 525	1701

- 103 -

CGG GAA TTT GAA TTA ACA GCT CAT ATC AGC GAT GGG GGC ACC CCG GTC Arg Glu Phe Glu Leu Thr Ala His Ile Ser Asp Gly Gly Thr Pro Val 530 535 540 545	1749
CTA GCC ACC AAC ATC AGC GTG AAC ATA TTT GTC ACT GAT CGC AAT GAC Leu Ala Thr Asn Ile Ser Val Asn Ile Phe Val Thr Asp Arg Asn Asp 550 555 560	1797
AAT GCC CCC CAG GTC CTA TAT CCT CGG CCA GGT GGG AGC TCG GTG GAG Asn Ala Pro Gln Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val Glu 565 570 575	1845
ATG CTG CCT CGA GGT ACC TCA GCT GGC CAC CTA GTG TCA CGG GTG GTA Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val Val 580 585 590	1893
GGC TGG GAC GCG GAT GCA GGG CAC AAT GCC TGG CTC TCC TAC AGT CTC Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser Leu 595 600 605	1941
TTT GGA TCC CCT AAC CAG AGC CTT TTT GCC ATA GGG CTG CAC ACT GGT Phe Gly Ser Pro Asn Gln Ser Leu Phe Ala Ile Gly Leu His Thr Gly 610 615 620 625	1989
CAA ATC AGT ACT GCC CGT CCA GTC CAA GAC ACA GAT TCA CCC AGG CAG Gln Ile Ser Thr Ala Arg Pro Val Gln Asp Thr Asp Ser Pro Arg Gln 630 635 640	2037
ACT CTC ACT GTC TTG ATC AAA GAC AAT GGG GAG CCT TCG CTC TCC ACC Thr Leu Thr Val Leu Ile Lys Asp Asn Gly Glu Pro Ser Leu Ser Thr 645 650 655	2085
ACT GCT ACC CTC ACT GTG TCA GTA ACC GAG GAC TCT CCT GAA GCC CGA Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala Arg 660 665 670	2133
GCC GAG TTC CCC TCT GGC TCT GCC CCC CGG GAG CAG AAA AAA AAT CTC Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gln Lys Lys Asn Leu 675 680 685	2181
ACC TTT TAT CTA CTT CTT TCT CTA ATC CTG GTT TCT GTG GGC TTC GTG Thr Phe Tyr Leu Leu Ser Leu Ile Leu Val Ser Val Gly Phe Val 690 695 700 705	2229
GTC ACA GTG TTC GGA GTA ATC ATA TTC AAA GTT TAC AAG TGG AAG CAG Val Thr Val Phe Gly Val Ile Ile Phe Lys Val Tyr Lys Trp Lys Gln 710 715 720	2277
TCT AGA GAC CTA TAC CGA GCC CCG GTG AGC TCA CTG TAC CGA ACA CCA Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr Pro 725 730 735	2325
GGG CCC TCC TTG CAC GCG GAC GCC GTG CGG GGA GGC CTG ATG TCG CCG Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser Pro 740 745 750	2373
CAC CTT TAC CAT CAG GTG TAT CTC ACC ACG GAC TCC CGC CGC AGC GAC His Leu Tyr His Gln Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser Asp 755 760 765	2421

- 104 -

CCG CTG CTG AAG AAA CCT GGT GCA GCC AGT CCA CTG GCC AGC CGC CAG Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg Gln 770 775 780 785	2469
AAC ACG CTG CGG AGC TGT GAT CCG GTG TTC TAT AGG CAG GTG TTG GGT Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gln Val Leu Gly 790 795 800	2517
GCA GAG AGC GCC CCT CCC GGA CAG GTA AGG TTT AGC AAG TCA TGC TTG Ala Glu Ser Ala Pro Pro Gly Gln Val Arg Phe Ser Lys Ser Cys Leu 805 810 815	2565
ACC CTG TTA GTG CCT TTT TAT TCC TAC ATC ATA TTG AGA AGG CTG GAG Thr Leu Leu Val Pro Phe Tyr Ser Tyr Ile Ile Leu Arg Arg Leu Glu 820 825 830	2613
CTG TTT TTT TAGTGATGAA GATGTTTCG TGGTGATGCA TTCACACTT Leu Phe Phe 835	2662
CAACTGGCTC TTCCTAGATC AAAGTTAGTG CCTTTGTGAG ATGGTGGCCT GCCAGAGTGT GGTTTGTGGT CCCATTCAG GGGGAAGATA CTTGACTCAT CTGTGGACCT AATTCACATC CTCAGCG	2722 2782 2789

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 836 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Met Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val 1 5 10 15
Val Gly Val Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val 20 25 30
Ile His Tyr Glu Ile Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly 35 40 45
Asn Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg 50 55 60
Arg Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn 65 70 75 80
Arg Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu 85 90 95
Leu Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val 100 105 110
Glu Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val Ile Gln Asp Ile 115 120 125

- 105 -

Asn Asp Asn Asn Pro Ala Phe Pro Thr Gln Glu Met Lys Leu Glu Ile
130 135 140

Ser Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His
145 150 155 160

Asp Pro Asp Leu Gly Ser Asn Ser Leu Gln Thr Tyr Glu Leu Ser Arg
165 170 175

Asn Glu Tyr Phe Ala Leu Arg Val Gln Thr Arg Glu Asp Ser Thr Lys
180 185 190

Tyr Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro
195 200 205

Ser Leu Gln Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu
210 215 220

Ser Ala Ser Leu Pro Ile His Ile Lys Val Leu Asp Ala Asn Asp Asn
225 230 235 240

Ala Pro Val Phe Asn Gln Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly
245 250 255

Cys Thr Ser Gly Thr Arg Val Val Gln Val Leu Ala Thr Asp Leu Asp
260 265 270

Glu Gly Pro Asn Gly Glu Ile Ile Tyr Ser Phe Gly Ser His Asn Arg
275 280 285

Ala Gly Val Arg Gln Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu
290 295 300

Thr Ile Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu Ile
305 310 315 320

Tyr Ile Gln Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys
325 330 335

Lys Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu Ile
340 345 350

Thr Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr
355 360 365

Val Ile Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly
370 375 380

Leu Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser
385 390 395 400

Ser Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg
405 410 415

Glu Thr Val Pro Glu Tyr Asn Leu Ser Ile Thr Ala Arg Asp Ala Gly
420 425 430

Thr Pro Ser Leu Ser Ala Leu Thr Ile Val Arg Val Gln Val Ser Asp
435 440 445

- 106 -

Ile Asn Asp Asn Pro Pro Gln Ser Ser Gln Ser Ser Tyr Asp Val Tyr
450 455 460

Ile Glu Glu Asn Asn Leu Pro Gly Ala Pro Ile Leu Asn Leu Ser Val
465 470 475 480

Trp Asp Pro Asp Ala Pro Gln Asn Ala Arg Leu Ser Phe Phe Leu Leu
485 490 495

Glu Gln Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr Ile Asn
500 505 510

Arg Asp Asn Gly Ile Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp
515 520 525

Arg Arg Glu Phe Glu Leu Thr Ala His Ile Ser Asp Gly Gly Thr Pro
530 535 540

Val Leu Ala Thr Asn Ile Ser Val Asn Ile Phe Val Thr Asp Arg Asn
545 550 555 560

Asp Asn Ala Pro Gln Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val
565 570 575

Glu Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val
580 585 590

Val Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser
595 600 605

Leu Phe Gly Ser Pro Asn Gln Ser Leu Phe Ala Ile Gly Leu His Thr
610 615 620

Gly Gln Ile Ser Thr Ala Arg Pro Val Gln Asp Thr Asp Ser Pro Arg
625 630 635 640

Gln Thr Leu Thr Val Leu Ile Lys Asp Asn Gly Glu Pro Ser Leu Ser
645 650 655

Thr Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala
660 665 670

Arg Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gln Lys Lys Asn
675 680 685

Leu Thr Phe Tyr Leu Leu Leu Ser Leu Ile Leu Val Ser Val Gly Phe
690 695 700

Val Val Thr Val Phe Gly Val Ile Ile Phe Lys Val Tyr Lys Trp Lys
705 710 715 720

Gln Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr
725 730 735

Pro Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser
740 745 750

Pro His Leu Tyr His Gln Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser
755 760 765

- 107 -

Asp Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg			
770	775		
Gln Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gln Val Leu			
785	790	795	800
Gly Ala Glu Ser Ala Pro Pro Gly Gln Val Arg Phe Ser Lys Ser Cys			
805	810	815	
Leu Thr Leu Leu Val Pro Phe Tyr Ser Tyr Ile Ile Leu Arg Arg Leu			
820	825	830	
Glu Leu Phe Phe			
835			

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2751 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 115..2160

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

CGAAAGCCAT GTCGGACTCG TCGCCCAGCG CCCAAGCGCT AACCCGCTGA AAGTTTCTCA	60
CGCAAATCTC AGGGACGATC TGGACCCCGC TGAGAGGAAC TGCTTTGAG TGAG ATG	117
Met 1	
GTC CCA GAG GCC TGG AGG AGC GGA CTG GTA AGC ACC GGG AGG GTA GTG	165
Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val Val	
5 10 15	
GGA GTT TTG CTT CTG CTT GGT GCC TTG AAC AAG GCT TCC ACG GTC ATT	213
Gly Val Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val Ile	
20 25 30	
CAC TAT GAG ATC CCG GAG GAA AGA GAG AAG GGT TTC GCT GTG GGC AAC	261
His Tyr Glu Ile Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly Asn	
35 40 45	
GTG GTC GCG AAC CTT GGT TTG GAT CTC GGT AGC CTC TCA GCC CGC AGG	309
Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg Arg	
50 55 60 65	
TTC CCG GTG GTG TCT GGA GCT AGC CGA AGA TTC TTT GAG GTG AAC CGG	357
Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn Arg	
70 75 80	

- 108 -

GAG ACC GGA GAG ATG TTT GTG AAC GAC CGT CTG GAT CGA GAG GAG CTG Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu Leu 85 90 95	405
TGT GGG ACA CTG CCC TCT TGC ACT GTC ACT CTG GAG TTG GTA GTG GAG Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val Glu 100 105 110	453
AAC CCG CTG GAG CTG TTC AGC GTG GAA GTG GTG ATC CAG GAC ATC AAC Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val Ile Gln Asp Ile Asn 115 120 125	501
GAC AAC AAT CCT GCT TTC CCT ACC CAG GAA ATG AAA TTG GAG ATT AGC Asp Asn Asn Pro Ala Phe Pro Thr Gln Glu Met Lys Leu Glu Ile Ser 130 135 140 145	549
GAG GCC GTG GCT CCG GGG ACG CGC TTT CCG CTC GAG AGC GCG CAC GAT Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His Asp 150 155 160	597
CCC GAT CTG GGA AGC AAC TCT TTA CAA ACC TAT GAG CTG AGC CGA AAT Pro Asp Leu Gly Ser Asn Ser Leu Gln Thr Tyr Glu Leu Ser Arg Asn 165 170 175	645
GAA TAC TTT GCG CTT CGC GTG CAG ACG CGG GAG GAC AGC ACC AAG TAC Glu Tyr Phe Ala Leu Arg Val Gln Thr Arg Glu Asp Ser Thr Lys Tyr 180 185 190	693
GCG GAG CTG GTG TTG GAG CGC GCC CTG GAC CGA GAA CGG GAG CCT AGT Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro Ser 195 200 205	741
CTC CAG TTA GTG CTG ACG GCG TTG GAC GGA GGG ACC CCA GCT CTC TCC Leu Gln Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu Ser 210 215 220 225	789
GCC AGC CTG CCT ATT CAC ATC AAG GTG CTG GAC GCG AAT GAC AAT GCG Ala Ser Leu Pro Ile His Ile Lys Val Leu Asp Ala Asn Asp Asn Ala 230 235 240	837
CCT GTC TTC AAC CAG TCC TTG TAC CGG GCG CGC GTT CCT GGA GGA TGC Pro Val Phe Asn Gln Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly Cys 245 250 255	885
ACC TCC GGC ACG CGC GTG GTA CAA GTC CTT GCA ACG GAT CTG GAT GAA Thr Ser Gly Thr Arg Val Val Gln Val Leu Ala Thr Asp Leu Asp Glu 260 265 270	933
GGC CCC AAC GGT GAA ATT ATT TAC TCC TTC GGC AGC CAC AAC CGC GCC Gly Pro Asn Gly Glu Ile Ile Tyr Ser Phe Gly Ser His Asn Arg Ala 275 280 285	981
GGC GTG CGG CAA CTA TTC GCC TTA GAC CTT GTA ACC GGG ATG CTG ACA Gly Val Arg Gln Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu Thr 290 295 300 305	1029
ATC AAG GGT CGG CTG GAC TTC GAG GAC ACC AAA CTC CAT GAG ATT TAC Ile Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu Ile Tyr 310 315 320	1077

- 109 -

ATC CAG GCC AAA GAC AAG GGC GCC AAT CCC GAA GGA GCA CAT TGC AAA Ile Gln Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys 325 330 335	1125
GTG TTG GTG GAG GTT GTG GAT GTG AAT GAC AAC GCC CCG GAG ATC ACA Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu Ile Thr 340 345 350	1173
GTC ACC TCC GTG TAC AGC CCA GTA CCC GAG GAT GCC TCT GGG ACT GTC Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr Val 355 360 365	1221
ATC GCT TTG CTC AGT GTG ACT GAC CTG GAT GCT GGC GAG AAC GGG CTG Ile Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly Leu 370 375 380 385	1269
GTG ACC TGC GAA GTT CCA CCG GGT CTC CCT TTC AGC CTT ACT TCT TCC Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser Ser 390 395 400	1317
CTC AAG AAT TAC TTC ACT TTG AAA ACC AGT GCA GAC CTG GAT CGG GAG Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg Glu 405 410 415	1365
ACT GTG CCA GAA TAC AAC CTC AGC ATC ACC GCC CGA GAC CTG GAT CGG GAG Thr Val Pro Glu Tyr Asn Leu Ser Ile Thr Ala Arg Asp Ala Gly Thr 420 425 430	1413
CCT TCC CTC TCA GCC CTT ACA ATA GTG CGT GTT CAA GTG TCC GAC ATC Pro Ser Leu Ser Ala Leu Thr Ile Val Arg Val Gln Val Ser Asp Ile 435 440 445	1461
AAT GAC AAC CCT CCA CAA TCT TCT CAA TCT TCC TAC GAC GTT TAC ATT Asn Asp Asn Pro Pro Gln Ser Ser Gln Ser Ser Tyr Asp Val Tyr Ile 450 455 460 465	1509
GAA GAA AAC AAC CTC CCC GGG GCT CCA ATA CTA AAC CTA AGT GTC TGG Glu Glu Asn Asn Leu Pro Gly Ala Pro Ile Leu Asn Leu Ser Val Trp 470 475 480	1557
GAC CCC GAC GCC CCG CAG AAT GCT CGG CTT TCT TTC TTT CTC TTG GAG Asp Pro Asp Ala Pro Gln Asn Ala Arg Leu Ser Phe Phe Leu Leu Glu 485 490 495	1605
CAA GGA GCT GAA ACC GGG CTA GTG GGT CGC TAT TTC ACA ATA AAT CGT Gln Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr Ile Asn Arg 500 505 510	1653
GAC AAT GGC ATA GTG TCA TCC TTA GTG CCC CTA GAC TAT GAG GAT CGG Asp Asn Gly Ile Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp Arg 515 520 525	1701
CGG GAA TTT GAA TTA ACA GCT CAT ATC AGC GAT GGG GGC ACC CCG GTC Arg Glu Phe Glu Leu Thr Ala His Ile Ser Asp Gly Gly Thr Pro Val 530 535 540 545	1749
CTA GCC ACC AAC ATC AGC GTG AAC ATA TTT GTC ACT GAT CGC AAT GAC Leu Ala Thr Asn Ile Ser Val Asn Ile Phe Val Thr Asp Arg Asn Asp 550 555 560	1797

- 110 -

AAT GCC CCC CAG GTC CTA TAT CCT CGG CCA GGT GGG AGC TCG GTG GAG Asn Ala Pro Gln Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val Glu 565 570 575	1845
ATG CTG CCT CGA GGT ACC TCA GCT GGC CAC CTA GTG TCA CGG GTG GTA Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val Val 580 585 590	1893
GGC TGG GAC GCG GAT GCA GGG CAC AAT GCC TGG CTC TCC TAC AGT CTC Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser Leu 595 600 605	1941
TTT GGA TCC CCT AAC CAG AGC CTT TTT GCC ATA GGG CTG CAC ACT GGT Phe Gly Ser Pro Asn Gln Ser Leu Phe Ala Ile Gly Leu His Thr Gly 610 615 620 625	1989
CAA ATC AGT ACT GCC CGT CCA GTC CAA GAC ACA GAT TCA CCC AGG CAG Gln Ile Ser Thr Ala Arg Pro Val Gln Asp Thr Asp Ser Pro Arg Gln 630 635 640	2037
ACT CTC ACT GTC TTG ATC AAA GAC AAT GGG GAG CCT TCG CTC TCC ACC Thr Leu Thr Val Leu Ile Lys Asp Asn Gly Glu Pro Ser Leu Ser Thr 645 650 655	2085
ACT GCT ACC CTC ACT GTG TCA GTA ACC GAG GAC TCT CCT GAA GCC CGA Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala Arg 660 665 670	2133
GCC GAG TTC CCC TCT GGC TCT GCC AGT TAAACCTTCT TTAATTATGG Ala Glu Phe Pro Ser Gly Ser Ala Ser 675 680	2180
ATTAGCCATT AACATTTTG AAACGTGGAC CATTAAACCT CGGCCTACCC CCTCCAAGTG TCCTGGTGAT GAGTCATTA GCTAAGTTAA ATTAAATTGAA CTTTGATCTA AACCAAAACA AATCAGGAAA ATAAAGCTGT AAAGGAACCTT ATCAAGCATT CCAAAACCAA CTAGAAATTAA CTTGAAGTTT CGAGTGAGCA TTGCCTGTGC CAGTATTCTT CATTATAGGA TTATAAACTC GTTTTTTCC CAAAGCGCAT GTCTACGCCA GGCAGAGGAG TAATTATTCA GCCAATTCA TGGATGTAAC GATGGATATA AATAATTGAT AGCACCTAGA GGCTTCCAGT TTGGGTGGAA GGCTAAAAGT AGAGGGAAC TCACTCACCT GAGAAATGAT ATTTAAGTGA ATAAATAGTT CTCTTCTATG AAACTATTAC TATTTAGTTC TCTGGAAAAC TTAAGTGTAT TAATGATTAG AACATCAAAT CCTAAGTAAA GAAATGACAT TTTAAATATA AAAAGCCAAA CTTTAAATAA ATCATAGAGA CCTCAGACAT AATATAGGAA A	2240 2300 2360 2420 2480 2540 2600 2660 2720 2751

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 682 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

- 111 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Met Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val
1 5 10 15

Val Gly Val Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val
20 25 30

Ile His Tyr Glu Ile Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly
35 40 45

Asn Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg
50 55 60

Arg Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn
65 70 75 80

Arg Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu
85 90 95

Leu Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val
100 105 110

Glu Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val Ile Gln Asp Ile
115 120 125

Asn Asp Asn Asn Pro Ala Phe Pro Thr Gln Glu Met Lys Leu Glu Ile
130 135 140

Ser Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His
145 150 155 160

Asp Pro Asp Leu Gly Ser Asn Ser Leu Gln Thr Tyr Glu Leu Ser Arg
165 170 175

Asn Glu Tyr Phe Ala Leu Arg Val Gln Thr Arg Glu Asp Ser Thr Lys
180 185 190

Tyr Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro
195 200 205

Ser Leu Gln Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu
210 215 220

Ser Ala Ser Leu Pro Ile His Ile Lys Val Leu Asp Ala Asn Asp Asn
225 230 235 240

Ala Pro Val Phe Asn Gln Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly
245 250 255

Cys Thr Ser Gly Thr Arg Val Val Gln Val Leu Ala Thr Asp Leu Asp
260 265 270

Glu Gly Pro Asn Gly Glu Ile Ile Tyr Ser Phe Gly Ser His Asn Arg
275 280 285

Ala Gly Val Arg Gln Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu
290 295 300

Thr Ile Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu Ile
305 310 315 320

- 112 -

Tyr Ile Gln Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys
325 330 335

Lys Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu Ile
340 345 350

Thr Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr
355 360 365

Val Ile Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly
370 375 380

Leu Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser
385 390 395 400

Ser Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg
405 410 415

Glu Thr Val Pro Glu Tyr Asn Leu Ser Ile Thr Ala Arg Asp Ala Gly
420 425 430

Thr Pro Ser Leu Ser Ala Leu Thr Ile Val Arg Val Gln Val Ser Asp
435 440 445

Ile Asn Asp Asn Pro Pro Gln Ser Ser Gln Ser Ser Tyr Asp Val Tyr
450 455 460

Ile Glu Glu Asn Asn Leu Pro Gly Ala Pro Ile Leu Asn Leu Ser Val
465 470 475 480

Trp Asp Pro Asp Ala Pro Gln Asn Ala Arg Leu Ser Phe Phe Leu Leu
485 490 495

Glu Gln Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr Ile Asn
500 505 510

Arg Asp Asn Gly Ile Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp
515 520 525

Arg Arg Glu Phe Glu Leu Thr Ala His Ile Ser Asp Gly Gly Thr Pro
530 535 540

Val Leu Ala Thr Asn Ile Ser Val Asn Ile Phe Val Thr Asp Arg Asn
545 550 555 560

Asp Asn Ala Pro Gln Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val
565 570 575

Glu Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val
580 585 590

Val Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser
595 600 605

Leu Phe Gly Ser Pro Asn Gln Ser Leu Phe Ala Ile Gly Leu His Thr
610 615 620

Gly Gln Ile Ser Thr Ala Arg Pro Val Gln Asp Thr Asp Ser Pro Arg
625 630 635 640

- 113 -

Gln Thr Leu Thr Val Leu Ile Lys Asp Asn Gly Glu Pro Ser Leu Ser
645 650 655

Thr Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala
660 665 670

Arg Ala Glu Phe Pro Ser Gly Ser Ala Ser
675 680

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2831 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

GAATTCGGCA CGAGGCTGAA CTGAGGGTGA CGGCACATAAA CGACTATTCT CCAGTGTCA	60
GTGAAAGAGA AATGATACTG AGGATACCAAG AAAACAGTGC TCGGGGAAAT ACATTCCCTT	120
TAAACAATGC TCTGGACTCA GACGTAGATA TCAACAATAT CCAGACCTAT AGGCTCAGCT	180
CAAAATCTCA TTTCCCTGGTT GTAACCCGCA ACCGCAGTGA TGGCAGGAAG TACCCAGAGC	240
TGGTGCTGGA GAAAGAACTG GATCGAGAGG AGGAACCTGA GCTGAGGTTA ACGCTGACAG	300
CTTTGGATGG TGGCTCTCCT CCCCGGTCTG GGACGACACA GGTCTCATT GAAGTAGTGG	360
ACACCAAACGA TAATGCACCC GAGTTTCAGC AGCCAACATA CCAAGTGCAA ACTCCGAGA	420
ACAGTCCCAC CGGCTCTCTG GTACTCACAG TCTCAGCCAA TGACTTAGAC AGTGGAGACT	480
ATGGGAAAGT CTTGTACGCA CTTTCGCAAC CCTCAGAAGA TATTAGCAAA ACATTGAGG	540
TAAACCCCTGT AACCGGGGAA ATTGCCTAC GAAAAGAGGT GAATTTGAA ACTATTCCCTT	600
CGTATGAAGT GGTTATCAAG GGGACGGACG GGGGAGGTCT CTCAGGAAAA TGCACTCTGT	660
TACTGCAGGT GGTGGACGTG AATGACAATG CCCCAGAAAGT GATGCTATCT GCGCTAACCA	720
ACCCAGTCCC AGAAAATTCC CCCGATGAGG TAGTGGCTGT TTTCAGTGT AGAGATCCTG	780
ACTCTGGGAA CAACGGAAAA GTGATTGCAT CCATCGAGGA AGACCTGCC 840	840
AATCTTCAGG AAAGAACTTT TACACTTTAG TAACCAAGGG AGCACTTGAC AGGGAAGAAA	900
GAGAGCAATT GAACATCACC ATCACAGTCA CTGACCTGGG CATAACCCAGG CTCACCCACCC	960
AACACACCAC AACAGTGCAG GTGGCAGACA TCAACGACAA TGCCCCCTCC TTCACCCAAA	1020
CCTCCTACAC CATGTTGTC CGCGAGAACCA ACAGCCCCGC CCTGCACATA GGCACCATCA	1080
GCGCCACAGA CTCAGACTCA GGATCCAATG CCCACATCAC CTACTCGCTG CTACCGCCCC	1140

- 114 -

AAGACCCACA	GCTGCCCTC	GACTCGCTCA	TCTCCATCAA	TGTAGACAAC	GGGCAGCTGT	1200
TCGCGCTCAG	GGCGCTAGAC	TATGAGGCTC	TGCAGGGCTT	CGAGTTCCAT	GTGGCGCCA	1260
CAGACCAAGG	CTCGCCCGCG	CTCAGCAGCC	AGGCTCTGGT	GCACGTGGTG	GTGTTGGACG	1320
ACAATGACAA	TGCGCCCTTC	GTGCTCTACC	CGCTGCAAAA	CCGCTCTGCA	CCCTTCACTG	1380
AGCTGCTGCC	CAGGGCGGCA	GAGCCTGGAT	ACCTGGTTAC	CAAGGTGGTA	GCTGTGGACC	1440
GCGACTCTGG	CCAGAATGCC	TGGCTGTCAT	TCCAGCTGCT	CAAGGCCACG	GAGCCCGGGC	1500
TGTTCAACGT	ATGGCGCAC	AATGGCGAGG	TACGCACCTC	CAGGCTGCTG	AGCGAGCGCG	1560
ACGCACCCAA	GCACAAGCTG	CTGCTGTTGG	TCAAGGACAA	TGGAGATCCT	CCACGCTCTG	1620
CCAGTGTAC	TCTGCACGTG	CTAGTGGTGG	ATGCCCTCTC	TCAGCCCTAC	CTGCCCTCTGC	1680
CAGAGGTGGC	GCACGACCCCT	GCACAAGAAC	AAGATGCGCT	AAACACTCTAC	CTGGTCATAG	1740
CTTTGGCATC	TGTGTCTTCT	CTCTTCCTCT	TGTCTGTGCT	GCTGTTCGTG	GGGGTGAGGC	1800
TCTGCAGGAG	GGCCAGGGCA	GCCTCTCTGA	GTGCCTATTTC	TGTGCCTGAA	GGCCACTTTC	1860
CTGGCCAGCT	GGTGGATGTC	AGAGGTATGG	GGACCCTGTC	CCAGAGCTAC	CAGTATGATG	1920
TATGTCTGAT	GGGGGATTCT	TCTGGGACCA	GCGAATTAA	CTTCTTAAAG	CCAGTTCTGC	1980
CTAGCTCTCT	GCACCAAGTGC	TCTGGGAAAG	AAATAGAGGA	AAATTCCACA	CTCCAGAATA	2040
GTCCCCATCT	TTTTTCAGGG	TCATGTCTAA	AGCTACAAGT	TTGNCTTTAC	TTATACTTGT	2100
TTGTTGATTA	ACTAAAGTCT	GTTCACATGT	AGCTAGCTAG	CAACGATTTT	AATGTTCACT	2160
TTACCCATCT	TTTTTCAGGG	TCATGTCTAA	AGCTACAAGT	TTGNCTTTAC	TTATACTTGT	2220
CGCACAGAAT	NNNNNNNNNN	TGGTGTATAA	GTCACAGTCA	TGGGATACTG	GCACAAGATG	2280
GCAGCTTGAT	TGCTCAGTTA	TGGCTGAAA	GGGGNGCTTG	AGTTTAGGGA	ATGTGTTAGA	2340
GCTGGAATAA	GTGTTCTGAG	AAATGTGTAA	GACAAATTTC	TTTGACACAT	TCCCTGTGTT	2400
CCTGTACCCC	TGTTTCCAGA	ACTACGAAAT	GTGTCATCAG	AAGGCATGCT	CACATTTCC	2460
CCTTTGTTG	CGTGACCCGG	GTGCCAGAAA	TTAAATAAAA	TTAGCATGGA	GTTCAATGCA	2520
GCATTAAAAAC	AAAGTTACTT	CTACAAACCT	TTTATTGAC	GGTTAAAATT	GTAACCTCCC	2580
CACCCATGAG	GCTGGCTGTA	AGAACCGAGA	TGAATGGGTG	TCTATCGCAA	CCTTATTTTC	2640
AAAAATCAA	CAAAAGGAGA	AATGAGAGAC	CAAACAAACAC	GCTACAGGAA	AGATTCATA	2700
AGGATGTATG	TATGGACACA	AAAACGGGA	TACAGACATT	TTAAATCTGT	TGGTACCAACA	2760
TGGTGGCGCT	GCAGGCTAAA	GAAATGCAAG	GGAAATTAAA	AAGAGGCTGA	GCTAGAAGTC	2820
AAAAAAAAAA A						2831

- 115 -

(2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3353 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 763..3123

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

GTATTTTCC ACAGTTAAA ATTTCATAA AATCATAACT CTCTGACTTT ATGTAGAAAG	60
GATACCACAC TGGAAATTAAC GTGTAGCTTT TTCTTGATGT AATCCAACCA ATGGGAGCAC	120
AATTCTGGTA CATAAGGCTGT CTAGAATTG AAAGAAATTA AAGAATTCAT TTTGTTTGCG	180
TGATAAAATT TTAAGAAATC ACCTGGCTTT ATGTTATTAT TATTACAAGA TGACTGATCA	240
CTATTATGTC TTCTTCACT TCTCAATTTC CCTCAGAACCA CTACACCCAG ACTACAGGCT	300
CTGGAGGGGTG GGGACCATGT CTGGGTTGTT TACTGATGTA TTTCATAATT TGGCACATAG	360
AGACCAATAA TACTCCTTTA AATGAAGAAA TTAATAATT CCATTGCGTG ATATTGTGAT	420
TACATCATT CCTCCCAATT TCCAAACTCC TAATAGAATA GAGAATAGAT CAATTGTAGC	480
AATTCTTTC GAAGCAAAGA CAACGCATGG TGGCGCTGCA GGCTAAGGCT TCAAAAAAAAG	540
GAAAAGGAAA AAGCCCATGA AATGCTACTA GCTACTTCAG ACCTCTTCA GCCTAAGAGG	600
AAAGCCTGTT AGCAGAGCAC GGACCAGTGT CTCCGGAGAA TGCTATTCTC CTACATTTC	660
GAACAGGTTA TCAACGCACA GATCGATCAC TGCCTCTGTC CCATCGCTCC CTGAAGTAGC	720
TCTGACTCCG GTTCCTTGAA AGGGGCGTGT ACAGAAGTAA AG ATG GAG CCT GCA Met Glu Pro Ala	774
1	
GGG GAG CGC TTT CCC GAA CAA AGG CAA GTC CTG ATT CTC CTT CTT TTA Gly Glu Arg Phe Pro Glu Gln Arg Gln Val Leu Ile Leu Leu Leu	822
5 10 15 20	
CTG GAA GTG ACT CTG GCA GGC TGG GAA CCC CGT CGC TAT TCT GTG ATG Leu Glu Val Thr Leu Ala Gly Trp Glu Pro Arg Arg Tyr Ser Val Met	870
25 30 35	
GAG GAA ACA GAG AGA GGT TCT TTT GTA GCC AAC CTG GCC AAT GAC CTA Glu Glu Thr Glu Arg Gly Ser Phe Val Ala Asn Leu Ala Asn Asp Leu	918
40 45 50	
GGG CTG GGA GTG GGG GAG CTA GCC GAG CGG GGA GCC CGG GTA GTT TCT Gly Leu Gly Val Gly Glu Leu Ala Glu Arg Gly Ala Arg Val Val Ser	966
55 60 65	

- 116 -

GAG GAT AAC GAA CAA GGC TTG CAG CTT GAT CTG CAG ACC GGG CAG TTG Glu Asp Asn Glu Gln Gly Leu Gln Leu Asp Leu Gln Thr Gly Gln Leu 70 75 80	1014
ATA TTA AAT GAG AAG CTG GAC CGG GAG AAG CTG TGT GGC CCT ACT GAG Ile Leu Asn Glu Lys Leu Asp Arg Glu Lys Leu Cys Gly Pro Thr Glu 85 90 95 100	1062
CCC TGT ATA ATG CAT TTC CAA GTG TTA CTG AAA AAA CCT TTG GAA GTA Pro Cys Ile Met His Phe Gln Val Leu Leu Lys Lys Pro Leu Glu Val 105 110 115	1110
TTT CGA GCT GAA CTA CTA GTG ACA GAC ATA AAC GAT CAT TCT CCT GAG Phe Arg Ala Glu Leu Leu Val Thr Asp Ile Asn Asp His Ser Pro Glu 120 125 130	1158
TTT CCT GAA AGA GAA ATG ACC CTG AAA ATC CCA GAA ACT AGC TCC CTT Phe Pro Glu Arg Glu Met Thr Leu Lys Ile Pro Glu Thr Ser Ser Leu 135 140 145	1206
GGG ACT GTG TTT CCT CTG AAA AAA GCT CGG GAC TTG GAC GTG GGC AGC Gly Thr Val Phe Pro Leu Lys Ala Arg Asp Leu Asp Val Gly Ser 150 155 160	1254
AAT AAT GTT CAA AAC TAC AAT ATT TCT CCC AAT TCT CAT TTC CAT GTT Asn Asn Val Gln Asn Tyr Asn Ile Ser Pro Asn Ser His Phe His Val 165 170 175 180	1302
TCC ACT CGC ACC CGA GGG GAT GGC AGG AAA TAC CCA GAG CTG GTG CTG Ser Thr Arg Thr Arg Gly Asp Gly Arg Lys Tyr Pro Glu Leu Val Leu 185 190 195	1350
GAC ACA GAA CTG GAT CGC GAG GAG CAG GCC GAG CTC AGA TTA ACC TTG Asp Thr Glu Leu Asp Arg Glu Glu Gln Ala Glu Leu Arg Leu Thr Leu 200 205 210	1398
ACA GCG GTG GAC GGT GGC TCT CCA CCC CGA TCT GGC ACC GTC CAG ATC Thr Ala Val Asp Gly Gly Ser Pro Pro Arg Ser Gly Thr Val Gln Ile 215 220 225	1446
CTC ATC TTG GTC TTG GAC GCC AAT GAC AAT GCC CCG GAG TTT GTG CAG Leu Ile Leu Val Leu Asp Ala Asn Asp Asn Ala Pro Glu Phe Val Gln 230 235 240	1494
GCG CTC TAC GAG GTG CAG GTC CCA GAG AAC AGC CCA GTA GGC TCC CTA Ala Leu Tyr Glu Val Gln Val Pro Glu Asn Ser Pro Val Gly Ser Leu 245 250 255 260	1542
GTT GTC AAG GTC TCT GCT AGG GAT TTA GAC ACT GGG ACA AAT GGA GAG Val Val Lys Val Ser Ala Arg Asp Leu Asp Thr Gly Thr Asn Gly Glu 265 270 275	1590
ATA TCA TAC TCC CTT TAT TAC AGC TCT CAG GAG ATA GAC AAA CCT TTT Ile Ser Tyr Ser Leu Tyr Tyr Ser Ser Gln Glu Ile Asp Lys Pro Phe 280 285 290	1638
GAG CTA AGC AGC CTT TCA GGA GAA ATT CGA CTA ATT AAA AAA CTA GAT Glu Leu Ser Ser Leu Ser Gly Glu Ile Arg Leu Ile Lys Lys Leu Asp 295 300 305	1686

- 117 -

TTT GAG ACA ATG TCT TCA TAT GAT CTA GAT ATA GAG GCA TCT GAT GGC Phe Glu Thr Met Ser Ser Tyr Asp Leu Asp Ile Glu Ala Ser Asp Gly 310 315 320	1734
GGG GGA CTT TCT GGA AAA TGC TCT GTC TCT GTT AAG GTG CTG GAT GTT Gly Gly Leu Ser Gly Lys Cys Ser Val Ser Val Lys Val Leu Asp Val 325 330 335 340	1782
AAC GAT AAC TTC CCG GAA CTA AGT ATT TCA TCA CTT ACC AGC CCT ATT Asn Asp Asn Phe Pro Glu Leu Ser Ile Ser Ser Leu Thr Ser Pro Ile 345 350 355	1830
CCC GAG AAT TCT CCA GAG ACA GAA GTG GCC CTG TTT AGG ATT AGA GAC Pro Glu Asn Ser Pro Glu Thr Glu Val Ala Leu Phe Arg Ile Arg Asp 360 365 370	1878
CGA GAC TCT GGA GAA AAT GGA AAA ATG ATT TGC TCA ATT CAG GAT GAT Arg Asp Ser Gly Glu Asn Gly Lys Met Ile Cys Ser Ile Gln Asp Asp 375 380 385	1926
GTT CCT TTT AAG CTA AAA CCT TCT GTT GAG AAT TTC TAC AGG CTG GTC Val Pro Phe Lys Leu Lys Pro Ser Val Glu Asn Phe Tyr Arg Leu Val 390 395 400	1974
ACA GAA GGG GCG CTG GAC AGA GAG ACC AGA GCC GAG TAC AAC ATC ACC Thr Glu Gly Ala Leu Asp Arg Glu Thr Arg Ala Glu Tyr Asn Ile Thr 405 410 415 420	2022
ATC ACC ATC ACA GAC TTG GGG ACT CCA AGG CTG AAA ACC GAG CAG AGC Ile Thr Ile Thr Asp Leu Gly Thr Pro Arg Leu Lys Thr Glu Gln Ser 425 430 435	2070
ATA ACC GTG CTG GTG TCG GAC GTC AAT GAC AAC GCC CCC GCC TTC ACC Ile Thr Val Leu Val Ser Asp Val Asn Asp Asn Ala Pro Ala Phe Thr 440 445 450	2118
CAA ACC TCC TAC ACC CTG TTC GTC CGC GAG AAC AAC AGC CCC GCC CTG Gln Thr Ser Tyr Thr Leu Phe Val Arg Glu Asn Asn Ser Pro Ala Leu 455 460 465	2166
CAC ATC GGC AGT GTC AGC GCC ACA GAC AGA GAC TCG GGC ACC AAC GCC His Ile Gly Ser Val Ser Ala Thr Asp Arg Asp Ser Gly Thr Asn Ala 470 475 480	2214
CAG GTC ACC TAC TCG CTG CTG CCG CCC CAG GAC CCG CAC CTG CCC CTA Gln Val Thr Tyr Ser Leu Leu Pro Pro Gln Asp Pro His Leu Pro Leu 485 490 495 500	2262
ACC TCC CTG GTC TCC ATT AAC ACG GAC AAC GGC CAC CTG TTC GCT CTC Thr Ser Leu Val Ser Ile Asn Thr Asp Asn Gly His Leu Phe Ala Leu 505 510 515	2310
CAG TCG CTG GAC TAC GAG GCC CTG CAG GCT TTC GAG TTC CGC GTG GGC Gln Ser Leu Asp Tyr Glu Ala Leu Gln Ala Phe Glu Phe Arg Val Gly 520 525 530	2358
GCC ACA GAC CGC GGC TTC CCG GCG CTG AGC AGC GAG GCG CTG GTG CGA Ala Thr Asp Arg Gly Phe Pro Ala Leu Ser Ser Glu Ala Leu Val Arg 535 540 545	2406

- 118 -

GTG CTG GTG CTG GAC GCC AAC GAC AAC TCG CCC TTC GTG CTG TAC CCG Val Leu Val Leu Asp Ala Asn Asp Asn Ser Pro Phe Val Leu Tyr Pro 550 555 560	2454
CTG CAG AAC GGC TCC GCG CCC TGC ACC GAG CTG GTG CCC CGG GCG GCC Leu Gln Asn Gly Ser Ala Pro Cys Thr Glu Leu Val Pro Arg Ala Ala 565 570 575 580	2502
GAG CCG GGC TAC CTG GTG ACC AAG GTG GTG GCG GTG GAC GGC GAC TCG Glu Pro Gly Tyr Leu Val Thr Lys Val Val Ala Val Asp Gly Asp Ser 585 590 595	2550
GGC CAG AAC GCC TGG CTG TCG TAC CAG CTG CTC AAG GCC ACG GAG CCC Gly Gln Asn Ala Trp Leu Ser Tyr Gln Leu Leu Lys Ala Thr Glu Pro 600 605 610	2598
GGG CTG TTC GGC GTG TGG GCG CAC AAT GGC GAG GTG CGC ACC GCC AGG Gly Leu Phe Gly Val Trp Ala His Asn Gly Glu Val Arg Thr Ala Arg 615 620 625	2646
CTG CTG AGC GAG CGC GAC GTG GCC AAG CAC AGG CTA GTG GTG CTG GTC Leu Leu Ser Glu Arg Asp Val Ala Lys His Arg Leu Val Val Leu Val 630 635 640	2694
AAG GAC AAT GGC GAG CCT CCG CGC TCG GCC ACA GCC ACG CTG CAA GTG Lys Asp Asn Gly Glu Pro Pro Arg Ser Ala Thr Ala Thr Leu Gln Val 645 650 655 660	2742
CTC CTG GTG GAC GGC TTC TCT CAG CCC TAC CTG CCG CTC CCA GAG GCG Leu Leu Val Asp Gly Phe Ser Gln Pro Tyr Leu Pro Leu Pro Glu Ala 665 670 675	2790
GCC CCG GCC CAA GCC CAG GCC GAC TCG CTT ACC GTC TAC CTG GTG GTG Ala Pro Ala Gln Ala Gln Ala Asp Ser Leu Thr Val Tyr Leu Val Val 680 685 690	2838
GCA TTG GCC TCG GTG TCT TCG CTC TTC CTC TTC TCG GTG TTC CTG TTC Ala Leu Ala Ser Val Ser Ser Leu Phe Leu Phe Ser Val Phe Leu Phe 695 700 705	2886
GTC GCA GTG CGG CTG TGC AGG AGG AGC AGG GCG GCC TCA GTG GGT CGC Val Ala Val Arg Leu Cys Arg Arg Ser Arg Ala Ala Ser Val Gly Arg 710 715 720	2934
TGC TCG GTG CCC GAG GGC CCC TTT CCA GGG CAT CTG GTG GAC GTG AGC Cys Ser Val Pro Glu Gly Pro Phe Pro Gly His Leu Val Asp Val Ser 725 730 735 740	2982
GGC ACC GGG ACC CTT TCC CAG AGC TAC CAG TAC GAG GTG TGT CTG ACG Gly Thr Gly Thr Leu Ser Gln Ser Tyr Gln Tyr Glu Val Cys Leu Thr 745 750 755	3030
GGA GGC TCT GAA ACT AAT GAT TTC AAG TTC TTG AAG CCT ATA TTC CCA Gly Gly Ser Glu Ser Asn Asp Phe Lys Phe Leu Lys Pro Ile Phe Pro 760 765 770	3078
AAT ATT GTA AGC CAG GAC TCT AGG AGG AAA TCA GAA TTT CTA GAA Asn Ile Val Ser Gln Asp Ser Arg Arg Lys Ser Glu Phe Leu Glu 775 780 785	3123
TAATGTAGGT ATCTGTAGCT TTCCGACCGT CTGTTAATTT TGTCTTCCTC ACTTTTCACC	3183

- 119 -

TTAGTTTTT TTAACCCTTT AGTAATCTTG AATTCTACTT TTTTTAAAT TTCTACTGTT	3243
GTCTTTAGTA ATGTTACTCA TTTCCTTGT CTGATTGTTA GTTTCAAAT TATTGTATTA	3303
TTATAAATAT TTTATATCAG GAAAGTTCAT ATTTCTGAAT AAATTAATAG	3353

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 787 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Met Glu Pro Ala Gly Glu Arg Phe Pro Glu Gln Arg Gln Val Leu Ile	
1 5 10 15	
Leu Leu Leu Leu Glu Val Thr Leu Ala Gly Trp Glu Pro Arg Arg	
20 25 30	
Tyr Ser Val Met Glu Glu Thr Glu Arg Gly Ser Phe Val Ala Asn Leu	
35 40 45	
Ala Asn Asp Leu Gly Leu Gly Val Gly Glu Leu Ala Glu Arg Gly Ala	
50 55 60	
Arg Val Val Ser Glu Asp Asn Glu Gln Gly Leu Gln Leu Asp Leu Gln	
65 70 75 80	
Thr Gly Gln Leu Ile Leu Asn Glu Lys Leu Asp Arg Glu Lys Leu Cys	
85 90 95	
Gly Pro Thr Glu Pro Cys Ile Met His Phe Gln Val Leu Leu Lys Lys	
100 105 110	
Pro Leu Glu Val Phe Arg Ala Glu Leu Leu Val Thr Asp Ile Asn Asp	
115 120 125	
His Ser Pro Glu Phe Pro Glu Arg Glu Met Thr Leu Lys Ile Pro Glu	
130 135 140	
Thr Ser Ser Leu Gly Thr Val Phe Pro Leu Lys Lys Ala Arg Asp Leu	
145 150 155 160	
Asp Val Gly Ser Asn Asn Val Gln Asn Tyr Asn Ile Ser Pro Asn Ser	
165 170 175	
His Phe His Val Ser Thr Arg Thr Arg Gly Asp Gly Arg Lys Tyr Pro	
180 185 190	
Glu Leu Val Leu Asp Thr Glu Leu Asp Arg Glu Glu Gln Ala Glu Leu	
195 200 205	
Arg Leu Thr Leu Thr Ala Val Asp Gly Gly Ser Pro Pro Arg Ser Gly	
210 215 220	

- 120 -

Thr Val Gln Ile Leu Ile Leu Val Leu Asp Ala Asn Asp Asn Ala Pro
225 230 235 240

Glu Phe Val Gln Ala Leu Tyr Glu Val Gln Val Pro Glu Asn Ser Pro
245 250 255

Val Gly Ser Leu Val Val Lys Val Ser Ala Arg Asp Leu Asp Thr Gly
260 265 270

Thr Asn Gly Glu Ile Ser Tyr Ser Leu Tyr Tyr Ser Ser Gln Glu Ile
275 280 285

Asp Lys Pro Phe Glu Leu Ser Ser Leu Ser Gly Glu Ile Arg Leu Ile
290 295 300

Lys Lys Leu Asp Phe Glu Thr Met Ser Ser Tyr Asp Leu Asp Ile Glu
305 310 315 320

Ala Ser Asp Gly Gly Leu Ser Gly Lys Cys Ser Val Ser Val Lys
325 330 335

Val Leu Asp Val Asn Asp Asn Phe Pro Glu Leu Ser Ile Ser Ser Leu
340 345 350

Thr Ser Pro Ile Pro Glu Asn Ser Pro Glu Thr Glu Val Ala Leu Phe
355 360 365

Arg Ile Arg Asp Arg Asp Ser Gly Glu Asn Gly Lys Met Ile Cys Ser
370 375 380

Ile Gln Asp Asp Val Pro Phe Lys Leu Lys Pro Ser Val Glu Asn Phe
385 390 395 400

Tyr Arg Leu Val Thr Glu Gly Ala Leu Asp Arg Glu Thr Arg Ala Glu
405 410 415

Tyr Asn Ile Thr Ile Thr Asp Leu Gly Thr Pro Arg Leu Lys
420 425 430

Thr Glu Gln Ser Ile Thr Val Leu Val Ser Asp Val Asn Asp Asn Ala
435 440 445

Pro Ala Phe Thr Gln Thr Ser Tyr Thr Leu Phe Val Arg Glu Asn Asn
450 455 460

Ser Pro Ala Leu His Ile Gly Ser Val Ser Ala Thr Asp Arg Asp Ser
465 470 475 480

Gly Thr Asn Ala Gln Val Thr Tyr Ser Leu Leu Pro Pro Gln Asp Pro
485 490 495

His Leu Pro Leu Thr Ser Leu Val Ser Ile Asn Thr Asp Asn Gly His
500 505 510

Leu Phe Ala Leu Gln Ser Leu Asp Tyr Glu Ala Leu Gln Ala Phe Glu
515 520 525

Phe Arg Val Gly Ala Thr Asp Arg Gly Phe Pro Ala Leu Ser Ser Glu
530 535 540

- 121 -

Ala Leu Val Arg Val Leu Val Leu Asp Ala Asn Asp Asn Ser Pro Phe
545 550 555 560

Val Leu Tyr Pro Leu Gln Asn Gly Ser Ala Pro Cys Thr Glu Leu Val
565 570 575

Pro Arg Ala Ala Glu Pro Gly Tyr Leu Val Thr Lys Val Val Ala Val
580 585 590

Asp Gly Asp Ser Gly Gln Asn Ala Trp Leu Ser Tyr Gln Leu Leu Lys
595 600 605

Ala Thr Glu Pro Gly Leu Phe Gly Val Trp Ala His Asn Gly Glu Val
610 615 620

Arg Thr Ala Arg Leu Leu Ser Glu Arg Asp Val Ala Lys His Arg Leu
625 630 635 640

Val Val Leu Val Lys Asp Asn Gly Glu Pro Pro Arg Ser Ala Thr Ala
645 650 655

Thr Leu Gln Val Leu Leu Val Asp Gly Phe Ser Gln Pro Tyr Leu Pro
660 665 670

Leu Pro Glu Ala Ala Pro Ala Gln Ala Asp Ser Leu Thr Val
675 680 685

Tyr Leu Val Val Ala Leu Ala Ser Val Ser Ser Leu Phe Leu Phe Ser
690 695 700

Val Phe Leu Phe Val Ala Val Arg Leu Cys Arg Arg Ser Arg Ala Ala
705 710 715 720

Ser Val Gly Arg Cys Ser Val Pro Glu Gly Pro Phe Pro Gly His Leu
725 730 735

Val Asp Val Ser Gly Thr Gly Thr Leu Ser Gln Ser Tyr Gln Tyr Glu
740 745 750

Val Cys Leu Thr Gly Gly Ser Glu Ser Asn Asp Phe Lys Phe Leu Lys
755 760 765

Pro Ile Phe Pro Asn Ile Val Ser Gln Asp Ser Arg Arg Lys Ser Glu
770 775 780

Phe Leu Glu
785

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3033 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 122 -

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 138..2528

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

GTGATTGGAC GTGTTTTGT GACTATTGG GAAGAAGACA CCTTCCTAAC CAGATTTACT	60
CCAATATCTT CCCGGACCCCT CATGAGTGGG TTGCAATTGA CTTGAAGAAG CAGCACCCCTC	120
AGGACTGAAT CTGAACA ATG GAG ACA GCA CTA GCA AAA ATA CCA CAG CAA Met Glu Thr Ala Leu Ala Lys Ile Pro Gln Gln	170
1 5 10	
AGG CAA GTC TTT TTT CTT ACT ATA TTG TCG TTA TTG TGG AAG TCT AGC Arg Gln Val Phe Leu Thr Ile Leu Ser Leu Leu Trp Lys Ser Ser	218
15 20 25	
TCT GAG GCC ATT AGA TAT TCC ATG CCA GAA ACA GAG AGT GGC TAT Ser Glu Ala Ile Arg Tyr Ser Met Pro Glu Glu Thr Ser Gly Tyr	266
30 35 40	
ATG GTG GCT AAC CTG GCG AAA GAT CTG GGG ATC AGG GTT GGA GAA CTG Met Val Ala Asn Leu Ala Lys Asp Leu Gly Ile Arg Val Gly Glu Leu	314
45 50 55	
TCC TCT AGA GGA GCT CAA ATC CAT TAC AAA GGA AAC AAA GAA CTT TTG Ser Ser Arg Gly Ala Gln Ile His Tyr Lys Gly Asn Lys Glu Leu Leu	362
60 65 70 75	
CAG CTG GAT GCA GAG ACT GGG AAT TTG TTC TTA AAG GAA AAA CTA GAC Gln Leu Asp Ala Glu Thr Gly Asn Leu Phe Leu Lys Glu Lys Leu Asp	410
80 85 90	
AGA GAA CTG CTG TGT GGA GAG ACA GAA CCC TGT GTG CTG AAC TTC CAG Arg Glu Leu Leu Cys Gly Glu Thr Glu Pro Cys Val Leu Asn Phe Gln	458
95 100 105	
ATC ATA CTG GAA AAC CCT ATG CAG TTC TTC CAA ACT GAA CTG CAG CTC Ile Ile Leu Glu Asn Pro Met Gln Phe Phe Gln Thr Glu Leu Gln Leu	506
110 115 120	
ACA GAT ATA AAC GAC CAT TCT CCA GAG TTC CCC AAC AAG AAA ATG CTT Thr Asp Ile Asn Asp His Ser Pro Glu Phe Pro Asn Lys Lys Met Leu	554
125 130 135	
CTA ACA ATT CCT GAG AGT GCC CAT CCA GGG ACT GTG TTT CCT CTG AAG Leu Thr Ile Pro Glu Ser Ala His Pro Gly Thr Val Phe Pro Leu Lys	602
140 145 150 155	
GCA GCT CGG GAC TCT GAC ATA GGG AGC AAC GCT GTT CAG AAC TAC ACA Ala Ala Arg Asp Ser Asp Ile Gly Ser Asn Ala Val Gln Asn Tyr Thr	650
160 165 170	
GTC AAT CCC AAC CTC CAT TTC CAC GTC GTT ACT CAC AGT CGC ACA GAT Val Asn Pro Asn Leu His Phe His Val Val Thr His Ser Arg Thr Asp	698
175 180 185	

- 123 -

GGC AGG AAA TAC CCA GAG CTG GTG CTG GAC AGA GCC CTG GAT AGG GAG Gly Arg Lys Tyr Pro Glu Leu Val Leu Asp Arg Ala Leu Asp Arg Glu 190 195 200	746
GAG CAG CCT GAG CTC ACT TTA ATC CTC ACT GCT CTG GAT GGT GGA GCT Glu Gln Pro Glu Leu Thr Leu Ile Leu Thr Ala Leu Asp Gly Gly Ala 205 210 215	794
CCT TCC AGG TCA GGA ACC ACC ACA GTT CAC ATA GAA GTT GTG GAC ATC Pro Ser Arg Ser Gly Thr Thr Val His Ile Glu Val Val Asp Ile 220 225 230 235	842
AAT GAT AAC TCC CCC CAG TTT GTA CAG TCA CTC TAT AAG GTG CAA GTT Asn Asp Asn Ser Pro Gln Phe Val Gln Ser Leu Tyr Lys Val Gln Val 240 245 250	890
CCT GAG AAT AAT CCC CTC AAT GCC TTT GTT GTC ACG GTC TCT GCC ACG Pro Glu Asn Asn Pro Leu Asn Ala Phe Val Val Thr Val Ser Ala Thr 255 260 265	938
GAT TTA GAT GCT GGG GTA TAT GGC AAT GTG ACC TAT TCT CTG TTT CAA Asp Leu Asp Ala Gly Val Tyr Gly Asn Val Thr Tyr Ser Leu Phe Gln 270 275 280	986
GGG TAT GGG GTA TTT CAA CCA TTT GTA ATA GAC GAA ATC ACT GGA GAA Gly Tyr Gly Val Phe Gln Pro Phe Val Ile Asp Glu Ile Thr Gly Glu 285 290 295	1034
ATC CAT CTG AGC AAA GAG CTG GAT TTT GAG GAA ATT AGC AAT CAT AAC Ile His Leu Ser Lys Glu Leu Asp Phe Glu Glu Ile Ser Asn His Asn 300 305 310 315	1082
ATA GAA ATC GCA GCC ACA GAT GGA GGA GGC CTT TCA GGA AAA TGC ACT Ile Glu Ile Ala Ala Thr Asp Gly Gly Leu Ser Gly Lys Cys Thr 320 325 330	1130
G TG GCT GTA CAG GTG TTG GAT GTG AAT GAC AAC GCC CCA GAG TTG ACA Val Ala Val Gln Val Leu Asp Val Asn Asp Asn Ala Pro Glu Leu Thr 335 340 345	1178
ATT AGG AAG CTC ACA GTC CTG GTC CCA GAA AAT TCC GCA GAG ACT GTA Ile Arg Lys Leu Thr Val Leu Val Pro Glu Asn Ser Ala Glu Thr Val 350 355 360	1226
GTT GCT GTT TTT AGT GTT TCT GAT TCT GAT TCG GGG GAC AAT GGA AGG Val Ala Val Phe Ser Val Asp Ser Asp Ser Gly Asp Asn Gly Arg 365 370 375	1274
ATG GTG TGT TCT ATT CCG AAC AAT ATC CCA TTT CTC CTG AAA CCC ACA Met Val Cys Ser Ile Pro Asn Asn Ile Pro Phe Leu Leu Lys Pro Thr 380 385 390 395	1322
TTT GAG AAT TAT TAC ACG TTA GTG ACT GAG GGG CCA CTT GAT AGA GAG Phe Glu Asn Tyr Tyr Thr Leu Val Thr Glu Gly Pro Leu Asp Arg Glu 400 405 410	1370
AAC AGA GCT GAG TAC AAC ATC ACC ATC ACG GTC TCA GAT CTG GGC ACA Asn Arg Ala Glu Tyr Asn Ile Thr Ile Thr Val Ser Asp Leu Gly Thr 415 420 425	1418

- 124 -

CCC AGG CTC ACA ACC CAG CAC ACC ATA ACA GTG CAA GTG TCC GAC ATC Pro Arg Leu Thr Thr Gln His Thr Ile Thr Val Gln Val Ser Asp Ile 430 435 440	1466
AAC GAC AAC GCC CCT GCC TTC ACC CAA ACC TCC TAC ACC ATG TTT GTC Asn Asp Asn Ala Pro Ala Phe Thr Gln Thr Ser Tyr Thr Met Phe Val 445 450 455	1514
CAC GAG AAC AAC AGC CCC GCC CTG CAC ATA GCC ACC ATC AGT GCC ACA His Glu Asn Asn Ser Pro Ala Leu His Ile Gly Thr Ile Ser Ala Thr 460 465 470 475	1562
GAC TCA GAC TCA GGC TCC AAT GCC CAC ATC ACC TAC TCG CTG CTG CCG Asp Ser Asp Ser Gly Ser Asn Ala His Ile Thr Tyr Ser Leu Leu Pro 480 485 490	1610
CCT GAT GAC CCG CAG CTG GCC CTC GAC TCA CTC ATC TCC ATC AAT GTT Pro Asp Asp Pro Gln Leu Ala Leu Asp Ser Leu Ile Ser Ile Asn Val 495 500 505	1658
GAC AAT GGG CAG CTG TTC GCG CTC AGA GCT CTA GAC TAT GAG GCA CTG Asp Asn Gly Gln Leu Phe Ala Leu Arg Ala Leu Asp Tyr Glu Ala Leu 510 515 520	1706
CAG TCC TTC GAG TTC TAC GTG GGC GCT ACA GAT GGA GGC TCA CCC GCG Gln Ser Phe Glu Phe Tyr Val Gly Ala Thr Asp Gly Ser Pro Ala 525 530 535	1754
CTC AGC AGC CAG ACT CTG GTG CGG ATG GTG GTG CTG GAT GAC AAT GAC Leu Ser Ser Gln Thr Leu Val Arg Met Val Val Leu Asp Asp Asn Asp 540 545 550 555	1802
AAT GCC CCC TTC GTG CTC TAC CCA CTG CAG AAT GCC TCA GCA CCC TGT Asn Ala Pro Phe Val Leu Tyr Pro Leu Gln Asn Ala Ser Ala Pro Cys 560 565 570	1850
ACT GAG CTA CTG CCT AGG GCA GCA GAG CCC GGC TAC CTG ATC ACC AAA Thr Glu Leu Leu Pro Arg Ala Ala Glu Pro Gly Tyr Leu Ile Thr Lys 575 580 585	1898
G TG GCT GTG GAT CGC GAC TCT GGA CAG AAT GCT TGG CTG TCG TTC Val Val Ala Val Asp Arg Asp Ser Gly Gln Asn Ala Trp Leu Ser Phe 590 595 600	1946
CAG CTA CTT AAA GCT ACA GAG CCA GGG CTG TTC AGT GTA TGG GCA CAC Gln Leu Leu Lys Ala Thr Glu Pro Gly Leu Phe Ser Val Trp Ala His 605 610 615	1994
AAT GGT GAA GTG CGC ACC ACT AGG CTG CTG AGT GAG CGA GAT GCT CAG Asn Gly Glu Val Arg Thr Thr Arg Leu Leu Ser Glu Arg Asp Ala Gln 620 625 630 635	2042
AAG CAC AAG CTA CTG CTG GTC AAG GAC AAT GGC GAT CCT CTG CGC Lys His Lys Leu Leu Leu Val Lys Asp Asn Gly Asp Pro Leu Arg 640 645 650	2090
TCT GCC AAT GTC ACT CTT CAC GTG CTA GTG GTG GAT GGC TTC TCG CAG Ser Ala Asn Val Thr Leu His Val Leu Val Val Asp Gly Phe Ser Gln 655 660 665	2138

- 125 -

CCT TAC CTA CCA TTG GCT GAG GTG GCA CAG GAT TCC ATG CAA GAT AAT Pro Tyr Leu Pro Leu Ala Glu Val Ala Gln Asp Ser Met Gln Asp Asn 670 675 680	2186
TAC GAC GTT CTC ACA CTG TAC CTA GTC ATT GCC TTG GCA TCT GTA TCT Tyr Asp Val Leu Thr Leu Tyr Leu Val Ile Ala Leu Ala Ser Val Ser 685 690 695	2234
TCT CTC TTC CTC TTG TCT GTA GTG CTG TTT GTG GGG GTG AGG CTG TGC Ser Leu Phe Leu Leu Ser Val Val Leu Phe Val Gly Val Arg Leu Cys 700 705 710 715	2282
AGG AGG GCC AGG GAG GCC TCC TTG GGT GAC TAC TCT GTG CCT GAG GGA Arg Arg Ala Arg Glu Ala Ser Leu Gly Asp Tyr Ser Val Pro Glu Gly 720 725 730	2330
CAC TTT CCT AGC CAC TTG GTG GAT GTC AGC GGT GCC GGG ACC CTG TCC His Phe Pro Ser His Leu Val Asp Val Ser Gly Ala Gly Thr Leu Ser 735 740 745	2378
CAG AGT TAT CAA TAT GAG GTG TGT CTT AAT GGA GGT ACT AGA ACA AAT Gln Ser Tyr Gln Tyr Glu Val Cys Leu Asn Gly Gly Thr Arg Thr Asn 750 755 760	2426
GAG TTT AAC TTT CTT AAA CCA TTG TTT CCT ATC CTT CCG ACC CAG GCT Glu Phe Asn Phe Leu Lys Pro Leu Phe Pro Ile Leu Pro Thr Gln Ala 765 770 775	2474
GCT GCT GCT GAA GAA AGA GAA AAC GCT GTT GTG CAC AAT AGC GTT GGA Ala Ala Ala Glu Arg Glu Asn Ala Val Val His Asn Ser Val Gly 780 785 790 795	2522
TTC TAT TAGAGCACTG ATTTTGAAGT GGTGGTTACC TCATTTTCC TTAACTATCC Phe Tyr	2578
CTGATGTAGA ATGGTGTAGT GCCGTGAATC AACTCCTGAG ATATATGTTA ATTTTATCCT	2638
TTGTTTGAA TCAAACATT CAGATGTGAT CCTACTCTAG AGAATTGGT TCTACTCCAT	2698
TGTGTTGTT TAGATTTCTA CGCCATACCA GTGCATGCTG GGTTGTTTT TTTTTTACAA	2758
TTATTATAAC TTTGCTTGG AGGGAACTC ATATTCGCTG TAACGAATTG GAACCACTTT	2818
CATTGTTAGA GATGCCCTGC TTTGTTGTGT TATTCAGAC AGGGTCTTAA ATTGTAGCCC	2878
TGGGTGACCT GAAATGACTA TGTACAGACT GACTTTGAAT TTGTGGCAGT CCATCTGCCT	2938
CTGTTGTCCT ATGTTGGGAT TGTGAGCATG CATGAGTAGG CTCAGCTGTG GTGAGCGACC	2998
TTAATAAAAA TCAAATACTA AAAAAAAAAA AAAAAA	3033

(2) INFORMATION FOR SEQ ID NO:112:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 797 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

- 126 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Met Glu Thr Ala Leu Ala Lys Ile Pro Gln Gln Arg Gln Val Phe Phe
1 5 10 15

Leu Thr Ile Leu Ser Leu Leu Trp Lys Ser Ser Ser Glu Ala Ile Arg
20 25 30

Tyr Ser Met Pro Glu Glu Thr Glu Ser Gly Tyr Met Val Ala Asn Leu
35 40 45

Ala Lys Asp Leu Gly Ile Arg Val Gly Glu Leu Ser Ser Arg Gly Ala
50 55 60

Gln Ile His Tyr Lys Gly Asn Lys Glu Leu Leu Gln Leu Asp Ala Glu
65 70 75 80

Thr Gly Asn Leu Phe Leu Lys Glu Lys Leu Asp Arg Glu Leu Leu Cys
85 90 95

Gly Glu Thr Glu Pro Cys Val Leu Asn Phe Gln Ile Ile Leu Glu Asn
100 105 110

Pro Met Gln Phe Phe Gln Thr Glu Leu Gln Leu Thr Asp Ile Asn Asp
115 120 125

His Ser Pro Glu Phe Pro Asn Lys Lys Met Leu Leu Thr Ile Pro Glu
130 135 140

Ser Ala His Pro Gly Thr Val Phe Pro Leu Lys Ala Ala Arg Asp Ser
145 150 155 160

Asp Ile Gly Ser Asn Ala Val Gln Asn Tyr Thr Val Asn Pro Asn Leu
165 170 175

His Phe His Val Val Thr His Ser Arg Thr Asp Gly Arg Lys Tyr Pro
180 185 190

Glu Leu Val Leu Asp Arg Ala Leu Asp Arg Glu Glu Gln Pro Glu Leu
195 200 205

Thr Leu Ile Leu Thr Ala Leu Asp Gly Gly Ala Pro Ser Arg Ser Gly
210 215 220

Thr Thr Thr Val His Ile Glu Val Val Asp Ile Asn Asp Asn Ser Pro
225 230 235 240

Gln Phe Val Gln Ser Leu Tyr Lys Val Gln Val Pro Glu Asn Asn Pro
245 250 255

Leu Asn Ala Phe Val Val Thr Val Ser Ala Thr Asp Leu Asp Ala Gly
260 265 270

Val Tyr Gly Asn Val Thr Tyr Ser Leu Phe Gln Gly Tyr Gly Val Phe
275 280 285

Gln Pro Phe Val Ile Asp Glu Ile Thr Gly Glu Ile His Leu Ser Lys
290 295 300

- 127 -

Glu	Leu	Asp	Phe	Glu	Glu	Ile	Ser	Asn	His	Asn	Ile	Glu	Ile	Ala	Ala
305				310						315					320
Thr	Asp	Gly	Gly	Gly	Leu	Ser	Gly	Lys	Cys	Thr	Val	Ala	Val	Gln	Val
	325							330						335	
Leu	Asp	Val	Asn	Asp	Asn	Ala	Pro	Glu	Leu	Thr	Ile	Arg	Lys	Leu	Thr
		340						345				350			
Val	Leu	Val	Pro	Glu	Asn	Ser	Ala	Glu	Thr	Val	Val	Ala	Val	Phe	Ser
				355				360				365			
Val	Ser	Asp	Ser	Asp	Ser	Gly	Asp	Asn	Gly	Arg	Met	Val	Cys	Ser	Ile
		370				375				380					
Pro	Asn	Asn	Ile	Pro	Phe	Leu	Leu	Lys	Pro	Thr	Phe	Glu	Asn	Tyr	Tyr
		385				390				395				400	
Thr	Leu	Val	Thr	Glu	Gly	Pro	Leu	Asp	Arg	Glu	Asn	Arg	Ala	Glu	Tyr
				405				410				415			
Asn	Ile	Thr	Ile	Thr	Val	Ser	Asp	Leu	Gly	Thr	Pro	Arg	Leu	Thr	Thr
				420				425				430			
Gln	His	Thr	Ile	Thr	Val	Gln	Val	Ser	Asp	Ile	Asn	Asp	Asn	Ala	Pro
				435				440				445			
Ala	Phe	Thr	Gln	Thr	Ser	Tyr	Thr	Met	Phe	Val	His	Glu	Asn	Asn	Ser
				450				455				460			
Pro	Ala	Leu	His	Ile	Gly	Thr	Ile	Ser	Ala	Thr	Asp	Ser	Asp	Ser	Gly
				465				470				475			480
Ser	Asn	Ala	His	Ile	Thr	Tyr	Ser	Leu	Leu	Pro	Pro	Asp	Asp	Pro	Gln
				485				490				495			
Leu	Ala	Leu	Asp	Ser	Leu	Ile	Ser	Ile	Asn	Val	Asp	Asn	Gly	Gln	Leu
				500				505				510			
Phe	Ala	Leu	Arg	Ala	Leu	Asp	Tyr	Glu	Ala	Leu	Gln	Ser	Phe	Glu	Phe
				515				520				525			
Tyr	Val	Gly	Ala	Thr	Asp	Gly	Gly	Ser	Pro	Ala	Leu	Ser	Ser	Gln	Thr
				530				535				540			
Leu	Val	Arg	Met	Val	Val	Leu	Asp	Asp	Asn	Asp	Asn	Ala	Pro	Phe	Val
				545				550				555			560
Leu	Tyr	Pro	Leu	Gln	Asn	Ala	Ser	Ala	Pro	Cys	Thr	Glu	Leu	Leu	Pro
				565				570				575			
Arg	Ala	Ala	Glu	Pro	Gly	Tyr	Leu	Ile	Thr	Lys	Val	Val	Ala	Val	Asp
				580				585				590			
Arg	Asp	Ser	Gly	Gln	Asn	Ala	Trp	Leu	Ser	Phe	Gln	Leu	Leu	Lys	Ala
				595				600				605			
Thr	Glu	Pro	Gly	Leu	Phe	Ser	Val	Trp	Ala	His	Asn	Gly	Glu	Val	Arg
				610				615				620			

- 128 -

Thr Thr Arg Leu Leu Ser Glu Arg Asp Ala Gln Lys His Lys Leu Leu
 625 630 635 640

Leu Leu Val Lys Asp Asn Gly Asp Pro Leu Arg Ser Ala Asn Val Thr
 645 650 655

Leu His Val Leu Val Val Asp Gly Phe Ser Gln Pro Tyr Leu Pro Leu
 660 665 670

Ala Glu Val Ala Gln Asp Ser Met Gln Asp Asn Tyr Asp Val Leu Thr
 675 680 685

Leu Tyr Leu Val Ile Ala Leu Ala Ser Val Ser Ser Leu Phe Leu Leu
 690 695 700

Ser Val Val Leu Phe Val Gly Val Arg Leu Cys Arg Arg Ala Arg Glu
 705 710 715 720

Ala Ser Leu Gly Asp Tyr Ser Val Pro Glu Gly His Phe Pro Ser His
 725 730 735

Leu Val Asp Val Ser Gly Ala Gly Thr Leu Ser Gln Ser Tyr Gln Tyr
 740 745 750

Glu Val Cys Leu Asn Gly Gly Thr Arg Thr Asn Glu Phe Asn Phe Leu
 755 760 765

Lys Pro Leu Phe Pro Ile Leu Pro Thr Gln Ala Ala Ala Glu Glu
 770 775 780

Arg Glu Asn Ala Val Val His Asn Ser Val Gly Phe Tyr
 785 790 795

(2) INFORMATION FOR SEQ ID NO:113:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2347 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

AAAACACGGG GGAAATGACA GTAGCAAAGA ATCTGGACTA TGAAGAATGC TCATTGTATG	60
AAATGGAAAT ACAGGCTGAA GATGTGGGGG CGCTTCTGGG GAGGAGCAA GTGGTAATTAA	120
TGGTAGAAGA TGTAAATGAC AATCGGCCAG AAGTGACCAT TACATCCTTG TTTAACCCGG	180
TATTGGAAAA TTCTCTTCCC GGGACAGTAA TTGCCTTCTT GAATGTGCAT GACCGAGACT	240
CTGGAAAGAA CGGCCAAGTT GTCTGTTACA CGCATGATAA CTTACCTTT AAATTAGAAA	300
AGTCAATAGA TAATTATTAT AGATTGGTGA CATGGAAATA TTTGGACCGA GAAAAAGTCT	360
CCATCTACAA TATCACAGTG ATAGCCTCAG ATCTAGGAGC CCACTCTGTC ACTGAAACTT	420

- 129 -

ACATTGCCCT	GATTGTGGCA	GACACTAATG	ACAACCCTCC	TCGTTTCCCT	CACACCTCCT	480
ACACAGCCTA	TATTCCAGAG	AACAACCTGA	GGGGCGCCTC	CATCTTCTCA	CTGACTGCAC	540
ATGATCCTGA	CAGTCAGGAA	AATGCACAGG	TCACTTACTC	TGTGTCTGAG	GACACCATAAC	600
AGGGAGTGCC	TTTGTCCCTCT	TATATCTCCA	TCAACTCAGA	TACTGGTGTGTC	CTGTATGCAC	660
TGCACTCTTT	TGACTTCGAG	AAGATACAAG	ACTTGCAGCT	ACTGGTTGTT	GCCACTGACA	720
GTGGAAGCCC	ACCTCTCAGC	AGCAATGTGT	CATTGAGCTT	GTTTGTGTTG	GACCAGAACG	780
ACAACGCACC	TGAGATTCTA	TATCCTAGCT	TCCCCACAGA	TGGCTCCACT	GGTGTGGAAC	840
TAGCACCCCCG	CTCTGCAGAG	CCTGGATACC	TAGTGACCAA	AGTGGTGGCA	GTGGACAAAG	900
ACTCAGGACA	GAATGCTTGG	CTGTCCTACC	GTCTGCTGAA	GGCCAGCGAA	CCTGGGCTCT	960
TCTCTGTAGG	ACTTCACACG	GGTGAGGTGC	GTACAGCGAG	GGCCCTGCTG	GACAGAGATG	1020
CTCTCAAACA	GAATCTGGTG	ATGGCCGTGC	AGGACCATGG	CCAACCCCCCT	CTCTCGGCCA	1080
CTGTAACCTCT	CACTGTGGCA	GTGGCTAACAA	GCATCCCTGA	GGTGTGGCT	GACTTGAGCA	1140
GCATTAGGAC	CCCTGGGGTA	CCAGAGGATT	CTGATATCAC	GCTCCACCTG	GTGGTGGCAG	1200
TGGCTGTGGT	CTCCTGTGTC	TTCTTGTCT	TTGTCATTGT	CCTCCTAGCT	CTCAGGCTTC	1260
AGCGCTGGCA	GAAGTCTCGC	CAGCTCCAGG	GCTCCAAAGG	TGGATTGGCT	CCTGCACCTC	1320
CATCACATTT	TGTGGGCATC	GACGGGGTAC	AGGCTTTCT	ACAAACCTAT	TCTCATGAAG	1380
TCTCGCTCAC	TTCAGGCTCC	CAGACAAGCC	ACATTATCTT	TCCTCAGCCC	AACTATGCAG	1440
ACATGCTCAT	TAACCAAGAA	GGCTGTGAGA	AAAATGATTC	CTTATTAACA	TCCATAGATT	1500
TTCATGAGAG	TAACCGTGAA	GATGCTTGCG	CCCCGCAAGC	CCCGCCCAAC	ACTGACTGGC	1560
GTTCCTCTCA	AGCCCAGAGA	CCCGGCACGA	GCGGATCCCA	AAATGGGGAT	GAAACCGGCA	1620
CCTGGCCCAA	CAACCAGTTC	GATACAGAGA	TGCTGCAAGC	CATGATCTTG	GCCTCTGCCA	1680
GTGAAGCCGC	TGATGGGAGC	TCCACTCTGG	GAGGGGGCAC	TGGCACTATG	GGTTTGAGCG	1740
CTCGATATGG	ACCCCAGTTT	ACCTGCAGC	ACGTGCCTGA	CTACCGCCAG	AACGTGTACA	1800
TCCCTGGCAG	CAATGCCACA	CTGACCAACG	CAGCTGGCAA	ACGAGATGGC	AAGGCTCCGG	1860
CAGGCGGCAA	TGGCAACAAC	AACAAGTCGG	GCAAGAAAGA	GAAGAAGTAA	TATGGAGGCC	1920
AGGCCTTGAG	CCACAGGGCA	GCCTCCCTCC	CCAGCCAGTC	CAGCTTGTC	TTACTTGTAC	1980
CCAGGCCTCA	GAATTTCAAGG	GCTCACCCCA	GGATTCTGGT	AGGAGCCACA	GCCAGGCCAT	2040
GCTCCCCGTT	GGGAAACAGA	AACAAGTGC	CAAGCCAACA	CCCCCTCTTT	GTACCCCTAGG	2100
GGGGTTGAAT	ATGCAAAGAG	AGTTCTGCTG	GGACCCCCCTA	TCCAATCAGT	GATTGTACCC	2160
ACATAGGTAG	CAGGGTTAGT	GTGGATAACAC	ACACACACAC	ACACACACAC	ACACACACAA	2220
CCCTTGTCCCT	CCGCAGTGCC	TGCCACTTTC	TGGGACTTTC	TCATCCCCCT	ACGCCCTTCC	2280

- 130 -

TTTATCCTCT CCCACCCAGA CACAGCTGCT GGAGAATAAA TTTGGGGATG CTGATGCTAA 2340
AAAAAAA 2347

(2) INFORMATION FOR SEQ ID NO:114:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 2972 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 2..1849

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

A GAG GCT GCT CAC CAC CTG GTC CTC ACG GCC TCG GAT GGC GGC AAG Glu Ala Ala His His Leu Val Leu Thr Ala Ser Asp Gly Gly Lys	1 5 10 15	46
CCG CCT CGC TCT AGC ACA GTG CGC ATC CAC GTG ACA GTG TTG GAT ACA Pro Pro Arg Ser Ser Thr Val Arg Ile His Val Thr Val Leu Asp Thr	20 25 30	94
AAT GAC AAT GCC CCG GTT TTT CCT CAC CCG ATT TAC CGA GTG AAA GTC Asn Asp Asn Ala Pro Val Phe Pro His Pro Ile Tyr Arg Val Lys Val	35 40 45	142
CTT GAG AAC ATG CCC CCA GGC ACG CGG CTG CTT ACT GTA ACA GCC AGC Leu Glu Asn Met Pro Pro Gly Thr Arg Leu Leu Thr Val Thr Ala Ser	50 55 60	190
GAC CCG GAT GAG GGA ATC AAC GGA AAA GTG GCA TAC AAA TTC CGG AAA Asp Pro Asp Glu Gly Ile Asn Gly Lys Val Ala Tyr Lys Phe Arg Lys	65 70 75	238
ATT AAT GAA AAA CAA ACT CCG TTA TTC CAG CTT AAT GAA AAT ACT GGG Ile Asn Glu Lys Gln Thr Pro Leu Phe Gln Leu Asn Glu Asn Thr Gly	80 85 90 95	286
GAA ATA TCA ATA GCA AAA AGT CTA GAT TAT GAA GAA TGT TCA TTT TAT Glu Ile Ser Ile Ala Lys Ser Leu Asp Tyr Glu Glu Cys Ser Phe Tyr	100 105 110	334
GAA ATG GAA ATA CAA GCC GAA GAT GTG GGG GCA CTT CTG GGG AGG ACC Glu Met Glu Ile Gln Ala Glu Asp Val Gly Ala Leu Leu Gly Arg Thr	115 120 125	382
AAA TTG CTC ATT TCT GTG GAA GAT GTA AAT GAC AAT AGA CCA GAA GTG Lys Leu Leu Ile Ser Val Glu Asp Val Asn Asp Asn Arg Pro Glu Val	130 135 140	430
ATC ATT ACG TCT TTG TTT AGC CCA GTG TTA GAA AAT TCT CTT CCC GGG Ile Ile Thr Ser Leu Phe Ser Pro Val Leu Glu Asn Ser Leu Pro Gly	145 150 155	478

- 131 -

ACA GTA ATT GCC TTC TTG AGT GTG CAT GAC CAA GAC TCT GGA AAG AAT Thr Val Ile Ala Phe Leu Ser Val His Asp Gln Asp Ser Gly Lys Asn 160 165 170 175	526
GGT CAA GTT GTC TGT TAC ACA CGT GAT AAT TTA CCT TTT AAA TTA GAA Gly Gln Val Val Cys Tyr Thr Arg Asp Asn Leu Pro Phe Lys Leu Glu 180 185 190	574
AAG TCA ATA GGT AAT TAT TAT AGA TTA GTG ACA AGG AAA TAT TTG GAC Lys Ser Ile Gly Asn Tyr Tyr Arg Leu Val Thr Arg Lys Tyr Leu Asp 195 200 205	622
CGA GAA AAT GTC TCT ATC TAC AAT ATC ACA GTG ATG GCC TCA GAT CTA Arg Glu Asn Val Ser Ile Tyr Asn Ile Thr Val Met Ala Ser Asp Leu 210 215 220	670
GGA ACA CCA CCT CTG TCC ACT GAA ACT CAA ATC GCT CTG CAC GTG GCA Gly Thr Pro Pro Leu Ser Thr Glu Thr Gln Ile Ala Leu His Val Ala 225 230 235	718
GAC ATT AAC GAC AAC CCT CCT ACT TTC CCT CAT GCC TCC TAC TCA GCG Asp Ile Asn Asp Asn Pro Pro Thr Phe Pro His Ala Ser Tyr Ser Ala 240 245 250 255	766
TAT ATC CTA GAG AAC AAC CTG AGA GGA GCC TCC ATC TTT TCC TTG ACT Tyr Ile Leu Glu Asn Asn Leu Arg Gly Ala Ser Ile Phe Ser Leu Thr 260 265 270	814
GCA CAC GAC CCC GAC AGC CAG GAG AAT GCC CAG GTC ACT TAC TCT GTG Ala His Asp Pro Asp Ser Gln Glu Asn Ala Gln Val Thr Tyr Ser Val 275 280 285	862
ACC GAG GAC ACG CTG CAG GGG GCG CCC CTG TCC TCG TAT ATC TCC ATC Thr Glu Asp Thr Leu Gln Gly Ala Pro Leu Ser Ser Tyr Ile Ser Ile 290 295 300	910
AAC TCT GAC ACC GGT GTC CTG TAT GCG CTG CAA TCT TTC GAC TAT GAG Asn Ser Asp Thr Gly Val Leu Tyr Ala Leu Gln Ser Phe Asp Tyr Glu 305 310 315	958
CAG ATC CGA GAC CTG CAG CTA CTG GTA ACA GCC AGC GAC AGC GGG GAC Gln Ile Arg Asp Leu Gln Leu Val Thr Ala Ser Asp Ser Gly Asp 320 325 330 335	1006
CCG CCC CTC AGC AGC AAC ATG TCA CTG AGC CTG TTC GTG CTG GAC CAG Pro Pro Leu Ser Ser Asn Met Ser Leu Ser Leu Phe Val Leu Asp Gln 340 345 350	1054
AAT GAC AAC GCG CCC GAG ATC CTG TAC CCC GCC CTC CCC ACA GAC GGT Asn Asp Asn Ala Pro Glu Ile Leu Tyr Pro Ala Leu Pro Thr Asp Gly 355 360 365	1102
TCC ACT GGC GTG GAG CTG GCG CCC CGC TCC GCA GAG CGT GGC TAC CTG Ser Thr Gly Val Glu Leu Ala Pro Arg Ser Ala Glu Arg Gly Tyr Leu 370 375 380	1150
GTG ACC AAG GTG GTG GCG GTG GAC AGA GAC TCG GGC CAG AAC GCC TGG Val Thr Lys Val Val Ala Val Asp Arg Asp Ser Gly Gln Asn Ala Trp 385 390 395	1198

- 132 -

CTG TCC TAC CGC CTG CTC AAG GCC AGC GAG CCG GGA CTC TTC TCG GTG Leu Ser Tyr Arg Leu Leu Lys Ala Ser Glu Pro Gly Leu Phe Ser Val 400 405 410 415	1246
GGT CTG CAC ACG GGC GAG GTG CGC ACG GCG CGA GCC CTG CTG GAC AGA Gly Leu His Thr Gly Glu Val Arg Thr Ala Arg Ala Leu Leu Asp Arg 420 425 430	1294
GAC GCG CTC AAG CAG AGC CTC GTG GTG GCC GTC CAG GAC CAT GCC CAG Asp Ala Leu Lys Gln Ser Leu Val Val Ala Val Gln Asp His Gly Gln 435 440 445	1342
CCC CCT CTC TCC GCC ACT GTC ACG CTC ACC GTA GCC GTG GCT GAC AGC Pro Pro Leu Ser Ala Thr Val Thr Leu Thr Val Ala Val Ala Asp Ser 450 455 460	1390
ATC CCC GAA GTC CTG ACC GAG TTG GGC AGT CTG AAG CCT TCG GTC GAC Ile Pro Glu Val Leu Thr Glu Leu Gly Ser Leu Lys Pro Ser Val Asp 465 470 475	1438
CCG AAC GAT TCG AGC CTT ACA CTC TAT CTC GTG GTG GCA GTG GCT GCC Pro Asn Asp Ser Ser Leu Thr Leu Tyr Leu Val Val Ala Val Ala Ala 480 485 490 495	1486
ATC TCC TGT GTC TTC CTC GCC TTT GTC GCT GTG CTT CTG GGG CTC AGG Ile Ser Cys Val Phe Leu Ala Phe Val Ala Val Leu Leu Gly Leu Arg 500 505 510	1534
CTG AGG CGC TGG CAC AAG TCA CGC CTG CTC CAG GAT TCC GGT GGC AGA Leu Arg Arg Trp His Lys Ser Arg Leu Leu Gln Asp Ser Gly Gly Arg 515 520 525	1582
TTG GTA GGC GTG CCT GCC TCA CAT TTT GTG GGT GTT GAG GAG GTA CAG Leu Val Gly Val Pro Ala Ser His Phe Val Gly Val Glu Glu Val Gln 530 535 540	1630
GCT TTC CTG CAG ACC TAT TCC CAG GAA GTC TCC CTC ACC GCC GAC TCG Ala Phe Leu Gln Thr Tyr Ser Gln Glu Val Ser Leu Thr Ala Asp Ser 545 550 555	1678
CGG AAG AGT CAC CTG ATC TTT CCC CAG CCC AAC TAC GCA GAC ATG CTC Arg Lys Ser His Leu Ile Phe Pro Gln Pro Asn Tyr Ala Asp Met Leu 560 565 570 575	1726
ATC AGT CAG GAG GGC TGT GAG AAA AAT GAT TCT TTG TTA ACA TCC GTA Ile Ser Gln Glu Gly Cys Glu Lys Asn Asp Ser Leu Leu Thr Ser Val 580 585 590	1774
GAT TTT CAT GAA TAT AAG AAT GAA GCT GAT CAT GGT CAG GTG AGT TTA Asp Phe His Glu Tyr Lys Asn Glu Ala Asp His Gly Gln Val Ser Leu 595 600 605	1822
GTT CTT TGC TTG CTT TTA ATT TCC AGA TGAATTTAT TTGGCATAAAA Val Leu Cys Leu Leu Ile Ser Arg 610 615	1869
TTATGTTTG AAAAACATTG TGAAGATAGT TGAAAATAAT TTTTAAGGTG TATCACAGAG	1929
TTTTGGGTTT ATTTGGTGG TGTTACCAAA AAATTGAACT CTAATAGTCA TAGGTTATTG	1989
TTTCATTTGC TTTAACCGA CTTGGAAAAG ATTGTTCCAC CATTAAAC CTTCCAGTAT	2049

- 133 -

TTTATTCCCTA TTATCACTCA TTCACCTAAC AAGTAGCTAC CCGTCCATAC TGGTAATT	2109
GCTATTGTTT GTTTGTGTGT GTGTGTGTGT GTGTGTGTAT CCCAAACTAG	2169
AACTTCAGAA AATTATCAAG AAGTCTAACG CCTTGTTATT AGCTTAGCAA AAGTAAAATA	2229
TATCTCAGAA TTTTAGGGT TATGTTAGC ATTTGAACCT GTAACCTAGGC TCTTGTATAT	2289
TTCTTCACCT TAAACCTCTT TTCTGAGCCC TGTTCTGTA CCAGTGCCTC TCAAAACTTT	2349
AATACTTCTT ACCATCCTTC AAAACATGAA CAAACTTAA AGATGGATCT TGGTGGGAGA	2409
TGAGACTGGT TACTAAATAT TAAGTATGTG AGTCAGTGGT CACCTGGGCT CCATCCCCAT	2469
GGAGACATGA AATCTAAAGC CTAGAATGTC CATTGCTCCC CCAAACAAAA AACAAAAGCA	2529
AAAACATTAG ATCTGAATTA AAATGTAATT TTAAACTGTT GAAAGTGAAT TTTGTAAT	2589
ATGTAAGAAC ATATTCAAT ACAATTCAA TTAGCTGTT CGGTTGTGCA TTGATGTGAA	2649
GTGGTGAGAA TGTTGATATT AAGAACCAAT GTTTCAGGTA CACAAGTTCT AAATAAGCTG	2709
ATCAATTCAA TTAAAGTTAT TCAGTCTTGG CTGGACACAG TGCCTCATGT CTGAAATCCC	2769
AGCACTTGG GAGGCTGGGG CAGGAGGACC GCTTGAGCCC CGGGGGTTTG AAACATGCAGT	2829
GAGCTATGAT CATGCCACTG CACTCCAGCC TAGGTGGCAG AACTAGACCC TGTCTCTAAA	2889
AAAACATTAA TTAGGCCGCG TGCGGTGGCT CACGCCGTAA ATCCCAGCAC TTTGGGAGAC	2949
TGAGGTGGGT GGATCACCTG AGC	2972

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 616 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Glu Ala Ala His His Leu Val Leu Thr Ala Ser Asp Gly Gly Lys Pro	
1 5 10 15	
Pro Arg Ser Ser Thr Val Arg Ile His Val Thr Val Leu Asp Thr Asn	
20 25 30	
Asp Asn Ala Pro Val Phe Pro His Pro Ile Tyr Arg Val Lys Val Leu	
35 40 45	
Glu Asn Met Pro Pro Gly Thr Arg Leu Leu Thr Val Thr Ala Ser Asp	
50 55 60	
Pro Asp Glu Gly Ile Asn Gly Lys Val Ala Tyr Lys Phe Arg Lys Ile	
65 70 75 80	

- 134 -

Asn Glu Lys Gln Thr Pro Leu Phe Gln Leu Asn Glu Asn Thr Gly Glu
85 90 95

Ile Ser Ile Ala Lys Ser Leu Asp Tyr Glu Glu Cys Ser Phe Tyr Glu
100 105 110

Met Glu Ile Gln Ala Glu Asp Val Gly Ala Leu Leu Gly Arg Thr Lys
115 120 125

Leu Leu Ile Ser Val Glu Asp Val Asn Asp Asn Arg Pro Glu Val Ile
130 135 140

Ile Thr Ser Leu Phe Ser Pro Val Leu Glu Asn Ser Leu Pro Gly Thr
145 150 155 160

Val Ile Ala Phe Leu Ser Val His Asp Gln Asp Ser Gly Lys Asn Gly
165 170 175

Gln Val Val Cys Tyr Thr Arg Asp Asn Leu Pro Phe Lys Leu Glu Lys
180 185 190

Ser Ile Gly Asn Tyr Tyr Arg Leu Val Thr Arg Lys Tyr Leu Asp Arg
195 200 205

Glu Asn Val Ser Ile Tyr Asn Ile Thr Val Met Ala Ser Asp Leu Gly
210 215 220

Thr Pro Pro Leu Ser Thr Glu Thr Gln Ile Ala Leu His Val Ala Asp
225 230 235 240

Ile Asn Asp Asn Pro Pro Thr Phe Pro His Ala Ser Tyr Ser Ala Tyr
245 250 255

Ile Leu Glu Asn Asn Leu Arg Gly Ala Ser Ile Phe Ser Leu Thr Ala
260 265 270

His Asp Pro Asp Ser Gln Glu Asn Ala Gln Val Thr Tyr Ser Val Thr
275 280 285

Glu Asp Thr Leu Gln Gly Ala Pro Leu Ser Ser Tyr Ile Ser Ile Asn
290 295 300

Ser Asp Thr Gly Val Leu Tyr Ala Leu Gln Ser Phe Asp Tyr Glu Gln
305 310 315 320

Ile Arg Asp Leu Gln Leu Leu Val Thr Ala Ser Asp Ser Gly Asp Pro
325 330 335

Pro Leu Ser Ser Asn Met Ser Leu Ser Leu Phe Val Leu Asp Gln Asn
340 345 350

Asp Asn Ala Pro Glu Ile Leu Tyr Pro Ala Leu Pro Thr Asp Gly Ser
355 360 365

Thr Gly Val Glu Leu Ala Pro Arg Ser Ala Glu Arg Gly Tyr Leu Val
370 375 380

Thr Lys Val Val Ala Val Asp Arg Asp Ser Gly Gln Asn Ala Trp Leu
385 390 395 400

- 135 -

Ser Tyr Arg Leu Leu Lys Ala Ser Glu Pro Gly Leu Phe Ser Val Gly
405 410 415

Leu His Thr Gly Glu Val Arg Thr Ala Arg Ala Leu Leu Asp Arg Asp
420 425 430

Ala Leu Lys Gln Ser Leu Val Val Ala Val Gln Asp His Gly Gln Pro
435 440 445

Pro Leu Ser Ala Thr Val Thr Leu Thr Val Ala Val Ala Asp Ser Ile
450 455 460

Pro Glu Val Leu Thr Glu Leu Gly Ser Leu Lys Pro Ser Val Asp Pro
465 470 475 480

Asn Asp Ser Ser Leu Thr Leu Tyr Leu Val Val Ala Val Ala Ala Ile
485 490 495

Ser Cys Val Phe Leu Ala Phe Val Ala Val Leu Leu Gly Leu Arg Leu
500 505 510

Arg Arg Trp His Lys Ser Arg Leu Leu Gln Asp Ser Gly Gly Arg Leu
515 520 525

Val Gly Val Pro Ala Ser His Phe Val Gly Val Glu Glu Val Gln Ala
530 535 540

Phe Leu Gln Thr Tyr Ser Gln Glu Val Ser Leu Thr Ala Asp Ser Arg
545 550 555 560

Lys Ser His Leu Ile Phe Pro Gln Pro Asn Tyr Ala Asp Met Leu Ile
565 570 575

Ser Gln Glu Gly Cys Glu Lys Asn Asp Ser Leu Leu Thr Ser Val Asp
580 585 590

Phe His Glu Tyr Lys Asn Glu Ala Asp His Gly Gln Val Ser Leu Val
595 600 605

Leu Cys Leu Leu Leu Ile Ser Arg
610 615

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>5</u> lines <u>19-20</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (<i>including postal code and country</i>) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 16 December 1992	Accession Number ATCC 69162
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>) This information is continued on an additional sheet <input type="checkbox"/>	
<p>"In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 23(4) EPC)."</p>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>) EP	
E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>) The indications listed below will be submitted to the International Bureau later (<i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i>)	
<p>For receiving Office use only</p> <input type="checkbox"/> This sheet was received with the international application Authorized officer	
<p>For International Bureau use only</p> <input type="checkbox"/> This sheet was received by the International Bureau on Authorized officer	

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description
on page 5 lines 19-20

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution

American Type Culture Collection

Address of depositary institution (*including postal code and country*)

12301 Parklawn Drive
Rockville, Maryland 20852
United States of America

Date of deposit

Accession Number

16 December 1992

ATCC 69163

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet

"In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 23(4) EPC)."

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

EP

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only

 This sheet was received with the international application

For International Bureau use only

 This sheet was received by the International Bureau on

Authorized officer

Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>7</u> lines <u>6-8</u>	
B. IDENTIFICATION OF DEPOSIT	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (<i>including postal code and country</i>) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 2 December 1992	Accession Number ATCC HB11207
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>) This information is continued on an additional sheet <input type="checkbox"/>	
"In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 23(4) EPC)."	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>) EP	
E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	
<input type="checkbox"/> This sheet was received with the international application	For International Bureau use only
Authorized officer	
Authorized officer	

CLAIMS

What is claimed is:

1. A purified and isolated polynucleotide sequence encoding human protocadherin pc3.
2. A purified and isolated polynucleotide sequence encoding human protocadherin pc4.
3. A purified and isolated polynucleotide sequence encoding rat protocadherin pc5.
4. The polynucleotide sequence of claim 1, 2 or 3 which is a DNA sequence.
5. The DNA sequence of claim 4 which is a cDNA sequence.
6. The DNA sequence of claim 4 which is a genomic DNA sequence.
7. The DNA sequence of claim 4 which is wholly or partially chemically synthesized.
8. A polynucleotide sequence according to claim 1 comprising the human protocadherin pc3 encoding sequence of SEQ ID NO: 109.
9. A polynucleotide sequence according to claim 2 comprising the human protocadherin pc4 encoding sequence of SEQ ID NO: 111.

10. A polynucleotide sequence according to claim 3 comprising the rat protocadherin pc5 encoding sequence of SEQ ID NO: 114.
11. A biologically functional DNA vector comprising a DNA sequence according to claim 4.
12. The vector of claim 11 wherein said DNA sequence is operatively linked to an expression control DNA sequence.
13. A host cell transformed or transfected with a DNA sequence according to claim 4 in a manner allowing the expression in said host cell of a protocadherin polypeptide.
14. A method for producing a protocadherin polypeptide comprising the steps of growing a host cell according to claim 13 in a suitable nutrient medium and isolating protocadherin polypeptide from said cell or from the medium of its growth.
15. Purified and isolated human protocadherin pc3 polypeptide.
16. Purified and isolated human protocadherin pc4 polypeptide.
17. Purified and isolated rat protocadherin pc5 polypeptide.
18. An antibody substance specific for human protocadherin pc3.
19. An antibody substance specific for human protocadherin pc4.
20. An antibody substance specific for rat protocadherin pc5.

21. The antibody substance of claim 18, 19 or 20 which is a monoclonal antibody.

22. A hybridoma cell line producing a monoclonal antibody according to claim 21.

23. A method for modulating the binding activity of human protocadherin pc3 comprising contacting said protocadherin with an antibody substance according to claim 18 specific for said protocadherin.

24. A method for modulating the binding activity of human protocadherin pc3 comprising contacting said protocadherin with a peptide ligand of said protocadherin.

25. A method for modulating the binding activity of human protocadherin pc4 comprising contacting said protocadherin with an antibody substance according to claim 19 specific for said protocadherin.

26. A method for modulating the binding activity of human protocadherin pc4 comprising contacting said protocadherin with a peptide ligand of said protocadherin.

27. A method for modulating the binding activity of rat protocadherin pc5 comprising contacting said protocadherin with an antibody substance according to claim 20 specific for said protocadherin.

28. A method for modulating the binding activity of rat protocadherin pc5 comprising contacting said protocadherin with a peptide ligand of said protocadherin.

PC43	EC 1	ASTVIIHYEIPEEREK-----GFAVGNNVVANL--GLDLGSLSA--
	EC 2	PTQEMKLEISEAVAP-----GTRFPLESAH---DPDLGSNSL--
	EC 3	NOSLYRARVPGGCTS----GTRVVQVLAT---DLDEGPNGE--
	EC 4	TVTSVYSPVPEDAS----GTVIALLSVT---DLDAGENGL--
	EC 5	SQSSYDVYIEENNLP---GAPILNLSWV---DPDAPONAR--
	EC 6	LYPRPGGSSVEMPLRGTSAGHLVSRVVGW---DADAGHNAW--
PC42	EC 1	VPEEQPPNTLI-----GSL-----AADYGFPDVG--
	EC 2	ASPVTILAIPENTNI----GSLFPIPLAS---DRDAGPNGV--
	EC 3	ERPSYEAEILSENNSPI---GHSV1QVKAN---DSDDQGANAE--
	EC 4	EIRGIGLVTHQDGMANISEDVAEETAVALVQVSDRDEGENAA--
	EC 5	TOSVTEVAFPENNKP----GEVIAEITAS---DADSGSNAE--
	EC 6	MLSGYNFSVMMENMPA---LSPVGMVTVI---DGDKGENAQ--
	EC 7	TAPSNTSHKLTPQTRL---GETVSQVAEE---DFDSGVNAE--
FAT	EC18	EDTVYSFDIPENAQR----GYQVQGOIVAR---DADLGQNAQ--
N-CAD	EC 1	DWVIPPINLPENSRG----PFPQELVRIRS--DRDKNLSLRYT
	EC 2	LHQVWNGTYPESKP----GTYVMTVTAI---DADDPNALNGM
	EC 3	TAMTFYGEVPENRVD---IIVANLTVT---DKDOPHTPAWN
	EC 4	APNPKIIROEEGLHA----GTMLTTFTAG---DPDRYMQQN--
	EC 5	LPQEAETCETPDPNINITIAL---DYDIDPNAGP--
MOTIF		*-*-*O**V*EN*-*----GT*v**v*A*----D*D*G*N*-*--

FIGURE 1A

PC43	EC 1	RRFPVVSGASRR-----FFEVNRET-----GEMFVNDR-----
	EC 2	QTYELSRNEY-----FALRVQTREDSTKYAELVLERA-----
	EC 3	IIYSGFGSHNRAGYRQL--FALDLVT-----GMLTIKGR-----
	EC 4	VTCEVPGPGLP-----FSLTSSLKNYFTLKTSD-----
	EC 5	LSFFLLEQGAETGLVGRYFTINRDN-----GIVSSLVP-----
	EC 6	LSYSLFGSPNQSL-----FAIGLHT-----GQISTARPV-----
PC42	EC 1	HLYKLEVGYAP-----YLRVDGKTT-----GDIFFTETS-----
	EC 2	ASYELOVAED-----QEEKOPQLIVMGN-----
	EC 3	IEYTFHQAPEVVRRL-----LRLDRNT-----GLITVQGP-----
	EC 4	VTCWVAGDVP-----FOLROASETGSDSKKKYFLQTTTP-----
	EC 5	LVYSLEPEPAAKGL-----FTISPET-----GEIQVKTS-----
	EC 6	VQLSVEQDNNGD-----FVIONGT-----GTILSSLS-----
	EC 7	LIYSIAGGGNPYGL-----FOIGSHS-----GAITLEKE-----
FAT	EC18	LSYGVVSDWANDV-----FSLNPQT-----GMLTLTAR-----
N-CAD	EC 1	VTGPAGADQPPPTGI-----FIINPIS-----GOLSVTKP-----
	EC 2	LRYRIVSOAPSTPSPNM-----FTINNET-----GDIITVAAG-----
	EC 3	AVYRISGGDPTGR-----FAIQTDPNNSND-----GLVTVVKP-----
	EC 4	TRYTKLSDPAN-----WLKIDPVN-----GOITTIAV-----
	EC 5	FAFDLPLSPVTIKRN-----WTITRLN-----GDFAQNLK-----

MOTIF
I*0*I*****0*I***T-----G*I*T***T-----

FIGURE 1B

PC43	EC 1	LDRL ELC GTL PSCT VTL ELV VENP-----	-LELF SVE VVI ODI DND NNP AF
	EC 2	LD RER EPS LQ LVL TAL DGGTPAL-----	-SASLP IHI KVILD AND NAP VF
	EC 3	LD FED TKL HEI YIOAK DKG ANPE-----	-GAHCK VL VE VD VND NAP E J
	EC 4	LD RET VPE YNL SIT A RDAG TPS L-----	-SALT IV RV QVS DIND NPP Q S
	EC 5	LD YED RREFELTA HIS DGGTPV L-----	-ATN IS VN IF VT DRND NAP Q V
	EC 6	QD TD SPR QTL TV L -IKD NG E PSL ST A TL TV SV TED SPE A RE AF P SG SA PRE QK KN	
PC42	EC 1	ID REG L RECONOL PG DPC ILE FE VS IT DL V QN AS-----	-PR LL EG QIE V QD I ND NTP NF
	EC 2	LD RER WDS YDL LT K VQ DGG SPP R-----	-AT SALL RRV T VLD TND NAP K F
	EC 3	VD RED L S T L RFS VLA KDR GT NPK-----	-SARA QW VV T V KDM ND NAP T I
	EC 4	LD YEK V KDY TIE I V A V D SGN PPL-----	-SST NSL KVQ V QV D VND NAP V F
	EC 5	LD RE QRE SY E LKV V A A D RGS PSL-----	-QGT AT VLV NV LD CND ND P K F
	EC 6	FD RE QOS TY TF QLK A V D G G V P PR-----	-SAY V GT IN V NL D END NAP Y I
	EC 7	IERR HH GL H RL VV KV SDR GK P PR Y GT AL V H L Y V NET TL LAN RT L LET LL GH S L D TPL D	IDI AGD PEY ER SK OR GN
FAT	EC18	LD YEE V QHY YI LIV QAO QD NG QPS L-----	-STT IT VY CN V LD LND NAP I F
N-CAD	EC 1	LD REQ IAR FHL RA H A V D IN G N Q V-----	-EN PID I V I N V ID M ND N R P EF
	EC 2	LD REN V Q Q YT L I I Q AT DME G I PT Y GL-----	-SNT AT AV I T V TD VND N P P EF
	EC 3	ID FET NRM FV LTV AA EN QV PLAK GI QH PP-----	-QSTA T V S V T V ID V NE -NP Y F
	EC 4	LD RE SPN V KNN I YN AT FLAS DNG I P PM-----	-SGT GT L QI Y LL D IND NAP Q V
	EC 5	IK FILE AGI YEV PI II IT DSG N PPK S N IS-----	-ILR VR V C Q CD FNG DC T DV DR

MOTIF

LDRE *** * O * L * V * A * D * G * P * * ----- * * T * TV * v * V * D * NDNAP * F

FIGURE 1C

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 95/08071

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C12N15/12	C12N15/85	C12N5/10	C07K14/705	C07K16/28
A61K39/395					

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EMBO (EUR MOL BIOL ORGAN) J 12 (6). 1993. 2249-2256. CODEN: EMJODG ISSN: 0261-4189, SANO K ET AL 'PROTOCOLADHERINS A LARGE FAMILY OF CADHERIN-RELATED MOLECULES IN CENTRAL NERVOUS SYSTEM.' cited in the application see abstract see page 2250, left column, paragraph 2 - page 2251, left column, paragraph 1; figure 2 see page 2252, left column, paragraph 3 - page 2253, left column, paragraph 1 see page 2253, right column, paragraph 2 - page 2254, right column, paragraph 1 see page 2255, left column, paragraph 4 - right column, paragraph 2 -----</p>	1-28

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 October 1995	05.12.95
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Montero Lopez, B